PedAM

Pediatric Disease Annotations & Medicines


	arteriosclerosis

Disease ID	535
Disease	arteriosclerosis
Definition	Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
Synonym	arterial sclerosis arterioscleroses arteriosclerosis (morphologic abnormality) arteriosclerosis [disease/finding] arteriosclerosis nos arteriosclerosis, nos arteriosclerotic vascular disease arteriosclerotic vascular disease (disorder) arteriosclerotic vascular disease nos arteriosclerotic vascular disease nos (disorder) arteriosclerotic vascular disease, nos atherosclerosis vascular sclerosis vascular sclerosis (morphologic abnormality)
DOID	DOID:2349 DOID:1936
UMLS	C0003850
MeSH	D001161 D050197
SNOMED-CT	SNOMEDCT_US_2016_09_01:72092001
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:281) C0011847 \| diabetes \| 200 C0042373 \| vascular disease \| 131 C0011860 \| type 2 diabetes \| 116 C0007222 \| cardiovascular disease \| 105 C0020538 \| hypertension \| 70 C0011849 \| diabetes mellitus \| 69 C0010068 \| coronary artery disease \| 68 C0003873 \| rheumatoid arthritis \| 54 C0018799 \| heart disease \| 50 C0948265 \| metabolic syndrome \| 44 C0024141 \| systemic lupus erythematosus \| 41 C0022661 \| chronic kidney disease \| 40 C0011860 \| type 2 diabetes mellitus \| 38 C0022658 \| kidney disease \| 38 C0028754 \| obesity \| 36 C0027051 \| myocardial infarct \| 36 C0027051 \| myocardial infarction \| 35 C0022116 \| ischemia \| 34 C0003864 \| arthritis \| 34 C0042373 \| vascular diseases \| 32 C0010068 \| coronary heart disease \| 30 C0409974 \| lupus erythematosus \| 30 C0007222 \| cardiovascular diseases \| 26 C0011854 \| type 1 diabetes \| 23 C0020443 \| hypercholesterolemia \| 21 C0027051 \| heart attack \| 18 C0022658 \| renal disease \| 17 C1561644 \| chronic kidney disease (ckd) \| 17 C0040053 \| thrombosis \| 15 C0032285 \| pneumoniae \| 13 C1704436 \| peripheral arterial disease \| 13 C0852949 \| arterial disease \| 13 C0022661 \| end-stage renal disease \| 13 C0023895 \| liver disease \| 12 C0035435 \| rheumatic disease \| 12 C0035435 \| rheumatic diseases \| 10 C0151744 \| myocardial ischemia \| 10 C0033860 \| psoriasis \| 9 C0020456 \| hyperglycemia \| 9 C0018801 \| heart failure \| 9 C0037315 \| sleep apnea \| 8 C0085580 \| essential hypertension \| 8 C0021053 \| immune disease \| 8 C0162429 \| malnutrition \| 8 C0007785 \| cerebral infarct \| 7 C0007785 \| cerebral infarction \| 7 C0028754 \| adiposity \| 7 C0029456 \| osteoporosis \| 7 C0520679 \| obstructive sleep apnea \| 6 C0022661 \| chronic renal failure \| 6 C0003507 \| aortic stenosis \| 6 C0020676 \| hypothyroidism \| 6 C0010054 \| coronary atherosclerosis \| 6 C0271650 \| prediabetes \| 6 C0035078 \| renal failure \| 6 C0038013 \| ankylosing spondylitis \| 6 C0035309 \| retinopathy \| 5 C0740394 \| hyperuricemia \| 5 C0020445 \| familial hypercholesterolemia \| 5 C0020443 \| hypercholesterolaemia \| 5 C0003872 \| psoriatic arthritis \| 5 C0031099 \| periodontitis \| 5 C0598608 \| hyperhomocysteinemia \| 5 C0085096 \| peripheral vascular disease \| 5 C0011570 \| depression \| 5 C0026691 \| kawasaki disease \| 4 C0021390 \| inflammatory bowel disease \| 4 C0027051 \| myocardial infarction (mi) \| 4 C0021831 \| bowel disease \| 4 C0242231 \| coronary stenosis \| 4 C0041948 \| uremia \| 4 C0002395 \| alzheimer's disease \| 4 C0021775 \| intermittent claudication \| 4 C0019158 \| hepatitis \| 4 C0031090 \| periodontal disease \| 4 C0007282 \| carotid stenosis \| 4 C1510471 \| hypovitaminosis \| 3 C0002965 \| unstable angina \| 3 C0027726 \| nephrotic syndrome \| 3 C0022661 \| end-stage kidney disease \| 3 C0008148 \| chlamydia \| 3 C0035579 \| hypovitaminosis d \| 3 C0520679 \| obstructive sleep apnea syndrome \| 3 C0040188 \| tic disorders \| 3 C0878544 \| cardiomyopathy \| 3 C0007785 \| cerebral ischemia \| 3 C0037315 \| sleep apnea syndrome \| 3 C0018099 \| gout \| 3 C0019196 \| hepatitis c \| 3 C0011854 \| type 1 diabetes mellitus \| 3 C0011860 \| type ii diabetes \| 3 C0520679 \| obstructive sleep apnoea \| 3 C0242231 \| coronary artery stenosis \| 3 C0442874 \| neuropathy \| 3 C0036421 \| systemic sclerosis \| 3 C0021053 \| immune disorders \| 3 C0242350 \| erectile dysfunction \| 3 C0021053 \| immune disorder \| 3 C0162871 \| abdominal aortic aneurysm \| 3 C0003486 \| aortic aneurysm \| 3 C0031069 \| familial mediterranean fever \| 3 C0011860 \| diabetes mellitus type 2 \| 2 C0271650 \| glucose intolerance \| 2 C0152021 \| congenital heart disease \| 2 C0007282 \| carotid artery stenosis \| 2 C0151744 \| ischaemic heart disease \| 2 C0149931 \| migraine \| 2 C0042384 \| vasculitis \| 2 C0007273 \| carotid artery disease \| 2 C0553662 \| juvenile idiopathic arthritis \| 2 C0020445 \| familial hypercholesteremia \| 2 C0006142 \| breast cancer \| 2 C0029408 \| osteoarthritis \| 2 C0009319 \| colitis \| 2 C0001206 \| acromegaly \| 2 C0039730 \| thalassemia \| 2 C0085278 \| antiphospholipid syndrome \| 2 C0022116 \| ischaemia \| 2 C0007787 \| transient ischemic attack \| 2 C0014544 \| epilepsy \| 2 C0497327 \| dementia \| 2 C0018799 \| cardiac disease \| 2 C0020459 \| hyperinsulinemia \| 2 C0037315 \| sleep apnoea \| 2 C0007286 \| carpal tunnel syndrome \| 2 C0003467 \| anxiety \| 2 C0155626 \| acute myocardial infarction \| 2 C0022661 \| end stage renal disease \| 2 C0024143 \| lupus nephritis \| 2 C0004623 \| bacterial infection \| 2 C0020443 \| hypercholesteremia \| 2 C0023787 \| lipodystrophy \| 2 C0009324 \| ulcerative colitis \| 2 C0155765 \| microangiopathy \| 2 C1956346 \| coronary artery diseases \| 2 C0040053 \| thrombus \| 2 C0027051 \| myocardial infarctions \| 2 C0011884 \| diabetic retinopathy \| 2 C0040021 \| thromboangiitis obliterans \| 1 C0175693 \| russell-silver syndrome \| 1 C0085207 \| gestational diabetes mellitus \| 1 C0002871 \| anemia \| 1 C0949690 \| spondyloarthritis \| 1 C0038012 \| spondylitis \| 1 C0264683 \| coronary atheroma \| 1 C0155502 \| benign paroxysmal positional vertigo \| 1 C0007193 \| dilated cardiomyopathy \| 1 C0271694 \| familial partial lipodystrophy \| 1 C0011860 \| type ii diabetes mellitus \| 1 C0020538 \| high blood pressure \| 1 C0020479 \| type iii hyperlipoproteinemia \| 1 C0008049 \| varicella \| 1 C0040261 \| onychomycosis \| 1 C0003493 \| aortic disease \| 1 C0010073 \| coronary vasospasm \| 1 C0004135 \| ataxia telangiectasia \| 1 C0011881 \| diabetic kidney disease \| 1 C0024117 \| chronic obstructive pulmonary disease \| 1 C0024437 \| age-related macular degeneration \| 1 C0042345 \| varicose veins \| 1 C0011880 \| diabetic ketosis \| 1 C0020619 \| hypogonadism \| 1 C0398623 \| hypercoagulability \| 1 C0751651 \| mitochondrial disorder \| 1 C0151650 \| renal fibrosis \| 1 C0085278 \| antiphospholipid antibody syndrome \| 1 C0019880 \| homocystinuria \| 1 C0009782 \| connective tissue disease \| 1 C0003504 \| aortic insufficiency \| 1 C0020514 \| hyperprolactinaemia \| 1 C0020443 \| elevated cholesterol \| 1 C0011882 \| diabetic neuropathy \| 1 C0282193 \| iron overload \| 1 C0020538 \| systemic hypertension \| 1 C0020456 \| hyperglycaemia \| 1 C0917996 \| cerebral aneurysm \| 1 C0038531 \| subclavian steal syndrome \| 1 C0751651 \| mitochondrial disorders \| 1 C0027697 \| nephritis \| 1 C0162871 \| abdominal aortic aneurysms \| 1 C0019360 \| zoster \| 1 C0027765 \| neurological disease \| 1 C0022661 \| chronic renal disease \| 1 C0001175 \| acquired immunodeficiency syndrome \| 1 C0020676 \| hypothyroid \| 1 C0042870 \| vitamin d deficiency \| 1 C0001627 \| congenital adrenal hyperplasia \| 1 C0003469 \| anxiety disorders \| 1 C0155626 \| acute mi \| 1 C0007789 \| cerebral palsy \| 1 C1527336 \| sjogren's syndrome \| 1 C0003864 \| inflammatory arthritis \| 1 C0162316 \| iron deficiency anemia \| 1 C0031036 \| polyarteritis nodosa \| 1 C0003851 \| arteriosclerosis obliterans \| 1 C0022408 \| arthropathies \| 1 C0019112 \| hemorrhoids \| 1 C0022408 \| arthropathy \| 1 C0043325 \| xanthomatosis \| 1 C0020542 \| pulmonary hypertension \| 1 C0086543 \| cataracts \| 1 C0042373 \| vascular problem \| 1 C0020550 \| hyperthyroidism \| 1 C0039483 \| giant cell arteritis \| 1 C0002895 \| sickle cell disease \| 1 C0009447 \| common variable immunodeficiency \| 1 C0018799 \| heart diseases \| 1 C0042075 \| urological diseases \| 1 C0010073 \| coronary spasm \| 1 C0018784 \| sensorineural hearing loss \| 1 C0023794 \| lipidosis \| 1 C1261473 \| sarcomas \| 1 C0020598 \| hypoglycemia \| 1 C0042769 \| virus infection \| 1 C0019829 \| hodgkin's lymphoma \| 1 C0011881 \| diabetic nephropathy \| 1 C0033300 \| progeria \| 1 C0024437 \| macular degeneration \| 1 C0035326 \| retinal vascular occlusion \| 1 C0035078 \| kidney failure \| 1 C0524851 \| neurodegenerative disease \| 1 C0085207 \| gestational diabetes \| 1 C0678222 \| breast carcinoma \| 1 C0006384 \| bundle branch block \| 1 C0026769 \| multiple sclerosis \| 1 C0043092 \| wegener's granulomatosis \| 1 C0042164 \| uveitis \| 1 C0006012 \| borderline personality disorder \| 1 C0271084 \| exudative age-related macular degeneration \| 1 C0013990 \| emphysema \| 1 C0085580 \| primary hypertension \| 1 C0040147 \| thyroiditis \| 1 C0035309 \| retinopathies \| 1 C0023195 \| lcat deficiency \| 1 C0002965 \| unstable angina pectoris \| 1 C0016052 \| fibromuscular dysplasia \| 1 C0042373 \| vascular disorder \| 1 C0019069 \| hemophilia \| 1 C0020544 \| renal hypertension \| 1 C0040021 \| buerger's disease \| 1 C0042373 \| vascular disorders \| 1 C0020445 \| familial hypercholesterolaemia \| 1 C0238052 \| cerebrotendinous xanthomatosis \| 1 C0031117 \| peripheral neuropathy \| 1 C0242666 \| protein s deficiency \| 1 C0022658 \| nephropathy \| 1 C0677607 \| hashimoto's thyroiditis \| 1 C0020474 \| familial combined hyperlipidemia \| 1 C0027051 \| cardiac infarction \| 1 C0019069 \| haemophilia \| 1 C0023890 \| liver cirrhosis \| 1 C0042870 \| vitamin d defic \| 1 C0311262 \| chronic mesenteric ischemia \| 1 C0025322 \| early menopause \| 1 C0033687 \| proteinuria \| 1 C0031039 \| pericardial effusion \| 1 C0003469 \| anxiety disorder \| 1 C0020514 \| hyperprolactinemia \| 1 C0003128 \| anovulation \| 1 C0004134 \| ataxia \| 1 C0740457 \| kidney cancer \| 1 C0027092 \| myopia \| 1 C0395887 \| tympanosclerosis \| 1 C0018203 \| chronic granulomatous disease \| 1 C0018802 \| congestive heart failure \| 1 C0010068 \| coronary disease \| 1 C0030920 \| peptic ulcer \| 1 C0019163 \| hepatitis b \| 1 C0030920 \| peptic ulcers \| 1 C0362046 \| prediabetic states \| 1 C0003972 \| atherosclerotic cardiovascular disease \| 1 C0023890 \| cirrhosis \| 1 C1621895 \| adrenal hyperplasia \| 1 C0007570 \| celiac disease \| 1 C0010481 \| cushing's syndrome \| 1 C0037998 \| splenic infarction \| 1 C0013080 \| trisomy 21 \| 1 C0009782 \| connective tissue diseases \| 1 C0003504 \| aortic regurgitation \| 1 C0042345 \| varicose vein \| 1 C0409818 \| cinca syndrome \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:13) NOS3 \| 4846 \| CTD_human ABCA1 \| 19 \| UniProtKB-KW APOE \| 348 \| CTD_human APOA1 \| 335 \| UniProtKB-KW APOB \| 338 \| UniProtKB-KW SERPINA1 \| 5265 \| CTD_human KL \| 9365 \| CTD_human LDLRAP1 \| 26119 \| UniProtKB-KW CETP \| 1071 \| UniProtKB-KW RSAD2 \| 91543 \| UniProtKB-KW APOBR \| 55911 \| UniProtKB-KW LPA \| 4018 \| UniProtKB-KW GSTA4 \| 2941 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:351) 348 \| APOE \| infer 2099 \| ESR1 \| infer 3569 \| IL6 \| infer 4049 \| LTA \| infer 4524 \| MTHFR \| infer 19 \| ABCA1 \| infer 24 \| ABCA4 \| infer 4363 \| ABCC1 \| infer 9619 \| ABCG1 \| infer 64137 \| ABCG4 \| infer 64240 \| ABCG5 \| infer 1636 \| ACE \| infer 58 \| ACTA1 \| infer 80332 \| ADAM33 \| infer 101 \| ADAM8 \| infer 126 \| ADH1C \| infer 9370 \| ADIPOQ \| infer 51094 \| ADIPOR1 \| infer 135 \| ADORA2A \| infer 136 \| ADORA2B \| infer 154 \| ADRB2 \| infer 177 \| AGER \| infer 183 \| AGT \| infer 185 \| AGTR1 \| infer 186 \| AGTR2 \| infer 207 \| AKT1 \| infer 217 \| ALDH2 \| infer 239 \| ALOX12 \| infer 246 \| ALOX15 \| infer 240 \| ALOX5 \| infer 241 \| ALOX5AP \| infer 270 \| AMPD1 \| infer 271 \| AMPD2 \| infer 325 \| APCS \| infer 335 \| APOA1 \| infer 336 \| APOA2 \| infer 337 \| APOA4 \| infer 116519 \| APOA5 \| infer 338 \| APOB \| infer 344 \| APOC2 \| infer 345 \| APOC3 \| infer 367 \| AR \| infer 285973 \| ATG9B \| infer 558 \| AXL \| infer 635 \| BHMT \| infer 23743 \| BHMT2 \| infer 644 \| BLVRA \| infer 717 \| C2 \| infer 718 \| C3 \| infer 727 \| C5 \| infer 8912 \| CACNA1H \| infer 819 \| CAMLG \| infer 124583 \| CANT1 \| infer 11132 \| CAPN10 \| infer 726 \| CAPN5 \| infer 834 \| CASP1 \| infer 847 \| CAT \| infer 857 \| CAV1 \| infer 858 \| CAV2 \| infer 875 \| CBS \| infer 6356 \| CCL11 \| infer 6347 \| CCL2 \| infer 929 \| CD14 \| infer 948 \| CD36 \| infer 958 \| CD40 \| infer 959 \| CD40LG \| infer 54901 \| CDKAL1 \| infer 1029 \| CDKN2A \| infer 1030 \| CDKN2B \| infer 1056 \| CEL \| infer 1071 \| CETP \| infer 3075 \| CFH \| infer 1147 \| CHUK \| infer 1215 \| CMA1 \| infer 1282 \| COL4A1 \| infer 1363 \| CPE \| infer 1374 \| CPT1A \| infer 1401 \| CRP \| infer 1435 \| CSF1 \| infer 1437 \| CSF2 \| infer 1440 \| CSF3 \| infer 1491 \| CTH \| infer 6376 \| CX3CL1 \| infer 1524 \| CX3CR1 \| infer 3627 \| CXCL10 \| infer 6387 \| CXCL12 \| infer 4283 \| CXCL9 \| infer 2833 \| CXCR3 \| infer 1535 \| CYBA \| infer 1585 \| CYP11B2 \| infer 1543 \| CYP1A1 \| infer 1559 \| CYP2C9 \| infer 1571 \| CYP2E1 \| infer 1760 \| DMPK \| infer 259234 \| DSCR10 \| infer 1889 \| ECE1 \| infer 1906 \| EDN1 \| infer 1909 \| EDNRA \| infer 2202 \| EFEMP1 \| infer 2006 \| ELN \| infer 55556 \| ENOSF1 \| infer 2053 \| EPHX2 \| infer 2074 \| ERCC6 \| infer 2100 \| ESR2 \| infer 2162 \| F13A1 \| infer 2165 \| F13B \| infer 2147 \| F2 \| infer 2153 \| F5 \| infer 2155 \| F7 \| infer 10516 \| FBLN5 \| infer 2212 \| FCGR2A \| infer 55527 \| FEM1A \| infer 10116 \| FEM1B \| infer 2243 \| FGA \| infer 2244 \| FGB \| infer 2266 \| FGG \| infer 79068 \| FTO \| infer 57818 \| G6PC2 \| infer 2621 \| GAS6 \| infer 2641 \| GCG \| infer 2645 \| GCK \| infer 2646 \| GCKR \| infer 2729 \| GCLC \| infer 2730 \| GCLM \| infer 2701 \| GJA4 \| infer 2778 \| GNAS \| infer 2784 \| GNB3 \| infer 2811 \| GP1BA \| infer 29933 \| GPR132 \| infer 2878 \| GPX3 \| infer 2879 \| GPX4 \| infer 2868 \| GRK4 \| infer 2936 \| GSR \| infer 2937 \| GSS \| infer 2941 \| GSTA4 \| infer 2944 \| GSTM1 \| infer 2946 \| GSTM2 \| infer 2947 \| GSTM3 \| infer 2948 \| GSTM4 \| infer 2949 \| GSTM5 \| infer 9446 \| GSTO1 \| infer 2950 \| GSTP1 \| infer 2952 \| GSTT1 \| infer 3077 \| HFE \| infer 3087 \| HHEX \| infer 3123 \| HLA-DRB1 \| infer 83872 \| HMCN1 \| infer 3156 \| HMGCR \| infer 3162 \| HMOX1 \| infer 3163 \| HMOX2 \| infer 3172 \| HNF4A \| infer 5654 \| HTRA1 \| infer 3383 \| ICAM1 \| infer 3399 \| ID3 \| infer 3455 \| IFNAR2 \| infer 3458 \| IFNG \| infer 3459 \| IFNGR1 \| infer 3460 \| IFNGR2 \| infer 3479 \| IGF1 \| infer 3481 \| IGF2 \| infer 10642 \| IGF2BP1 \| infer 10644 \| IGF2BP2 \| infer 3484 \| IGFBP1 \| infer 3485 \| IGFBP2 \| infer 3486 \| IGFBP3 \| infer 8517 \| IKBKG \| infer 3586 \| IL10 \| infer 3592 \| IL12A \| infer 3593 \| IL12B \| infer 3596 \| IL13 \| infer 3606 \| IL18 \| infer 3552 \| IL1A \| infer 3553 \| IL1B \| infer 3554 \| IL1R1 \| infer 7850 \| IL1R2 \| infer 3557 \| IL1RN \| infer 3558 \| IL2 \| infer 3565 \| IL4 \| infer 3630 \| INS \| infer 51141 \| INSIG2 \| infer 3643 \| INSR \| infer 3654 \| IRAK1 \| infer 3673 \| ITGA2 \| infer 3655 \| ITGA6 \| infer 3688 \| ITGB1 \| infer 3690 \| ITGB3 \| infer 3767 \| KCNJ11 \| infer 3775 \| KCNK1 \| infer 3776 \| KCNK2 \| infer 3910 \| LAMA4 \| infer 3931 \| LCAT \| infer 3938 \| LCT \| infer 3949 \| LDLR \| infer 3990 \| LIPC \| infer 9388 \| LIPG \| infer 4000 \| LMNA \| infer 4018 \| LPA \| infer 4023 \| LPL \| infer 4035 \| LRP1 \| infer 4041 \| LRP5 \| infer 4048 \| LTA4H \| infer 4050 \| LTB \| infer 10747 \| MASP2 \| infer 79648 \| MCPH1 \| infer 10461 \| MERTK \| infer 4311 \| MME \| infer 4312 \| MMP1 \| infer 4321 \| MMP12 \| infer 4322 \| MMP13 \| infer 4313 \| MMP2 \| infer 4314 \| MMP3 \| infer 4317 \| MMP8 \| infer 4318 \| MMP9 \| infer 4353 \| MPO \| infer 124995 \| MRPL10 \| infer 347704 \| MRPS36P3 \| infer 2206 \| MS4A2 \| infer 4437 \| MSH3 \| infer 4481 \| MSR1 \| infer 4522 \| MTHFD1 \| infer 4544 \| MTNR1B \| infer 4548 \| MTR \| infer 4552 \| MTRR \| infer 4647 \| MYO7A \| infer 10 \| NAT2 \| infer 4780 \| NFE2L2 \| infer 4790 \| NFKB1 \| infer 4791 \| NFKB2 \| infer 4792 \| NFKBIA \| infer 4793 \| NFKBIB \| infer 4794 \| NFKBIE \| infer 64127 \| NOD2 \| infer 9722 \| NOS1AP \| infer 4846 \| NOS3 \| infer 4878 \| NPPA \| infer 4852 \| NPY \| infer 7376 \| NR1H2 \| infer 9971 \| NR1H4 \| infer 2908 \| NR3C1 \| infer 3084 \| NRG1 \| infer 8650 \| NUMB \| infer 25903 \| OLFML2B \| infer 4973 \| OLR1 \| infer 5028 \| P2RY1 \| infer 5080 \| PAX6 \| infer 5105 \| PCK1 \| infer 255738 \| PCSK9 \| infer 5144 \| PDE4D \| infer 5154 \| PDGFA \| infer 5155 \| PDGFB \| infer 56034 \| PDGFC \| infer 5156 \| PDGFRA \| infer 5173 \| PDYN \| infer 5175 \| PECAM1 \| infer 54984 \| PINX1 \| infer 7941 \| PLA2G7 \| infer 5327 \| PLAT \| infer 59338 \| PLEKHA1 \| infer 5360 \| PLTP \| infer 5444 \| PON1 \| infer 5445 \| PON2 \| infer 5446 \| PON3 \| infer 5465 \| PPARA \| infer 5467 \| PPARD \| infer 5468 \| PPARG \| infer 10891 \| PPARGC1A \| infer 5478 \| PPIA \| infer 5562 \| PRKAA1 \| infer 5563 \| PRKAA2 \| infer 5564 \| PRKAB1 \| infer 5565 \| PRKAB2 \| infer 5571 \| PRKAG1 \| infer 51422 \| PRKAG2 \| infer 53632 \| PRKAG3 \| infer 5624 \| PROC \| infer 5742 \| PTGS1 \| infer 5743 \| PTGS2 \| infer 5770 \| PTPN1 \| infer 56729 \| RETN \| infer 5997 \| RGS2 \| infer 8787 \| RGS9 \| infer 388531 \| RGS9BP \| infer 100271159 \| RPL21P41 \| infer 100130537 \| RPL31P26 \| infer 1901 \| S1PR1 \| infer 9294 \| S1PR2 \| infer 22937 \| SCAP \| infer 51435 \| SCARA3 \| infer 949 \| SCARB1 \| infer 6337 \| SCNN1A \| infer 6338 \| SCNN1B \| infer 6340 \| SCNN1G \| infer 6383 \| SDC2 \| infer 6385 \| SDC4 \| infer 6401 \| SELE \| infer 6402 \| SELL \| infer 6403 \| SELP \| infer 6404 \| SELPLG \| infer 5265 \| SERPINA1 \| infer 1992 \| SERPINB1 \| infer 5054 \| SERPINE1 \| infer 10050 \| SLC17A4 \| infer 6513 \| SLC2A1 \| infer 6514 \| SLC2A2 \| infer 6517 \| SLC2A4 \| infer 169026 \| SLC30A8 \| infer 6647 \| SOD1 \| infer 6648 \| SOD2 \| infer 6649 \| SOD3 \| infer 114815 \| SORCS1 \| infer 6696 \| SPP1 \| infer 6720 \| SREBF1 \| infer 6721 \| SREBF2 \| infer 6934 \| TCF7L2 \| infer 6947 \| TCN1 \| infer 6948 \| TCN2 \| infer 7040 \| TGFB1 \| infer 7042 \| TGFB2 \| infer 7043 \| TGFB3 \| infer 7056 \| THBD \| infer 7057 \| THBS1 \| infer 7058 \| THBS2 \| infer 7060 \| THBS4 \| infer 7077 \| TIMP2 \| infer 7097 \| TLR2 \| infer 7099 \| TLR4 \| infer 51284 \| TLR7 \| infer 54106 \| TLR9 \| infer 7124 \| TNF \| infer 7128 \| TNFAIP3 \| infer 8797 \| TNFRSF10A \| infer 7132 \| TNFRSF1A \| infer 7133 \| TNFRSF1B \| infer 7293 \| TNFRSF4 \| infer 7157 \| TP53 \| infer 7173 \| TPO \| infer 7295 \| TXN \| infer 7301 \| TYRO3 \| infer 7350 \| UCP1 \| infer 7351 \| UCP2 \| infer 7352 \| UCP3 \| infer 54658 \| UGT1A1 \| infer 7391 \| USF1 \| infer 27340 \| UTP20 \| infer 7412 \| VCAM1 \| infer 7423 \| VEGFB \| infer 79001 \| VKORC1 \| infer 7450 \| VWF \| infer 7486 \| WRN \| infer 25937 \| WWTR1 \| infer 284695 \| ZNF326 \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:2394) 100048912 \| CDKN2B-AS1 \| DISEASES 100048912 \| CDKN2B-AS1 \| DISEASES 100874194 \| CLDN10-AS1 \| DISEASES 100874194 \| CLDN10-AS1 \| DISEASES 104940698 \| DALIR \| DISEASES 104940698 \| DALIR \| DISEASES 6376 \| CX3CL1 \| DISEASES 6376 \| CX3CL1 \| DISEASES 972 \| CD74 \| DISEASES 972 \| CD74 \| DISEASES 1015 \| CDH17 \| DISEASES 1015 \| CDH17 \| DISEASES 1634 \| DCN \| DISEASES 1634 \| DCN \| DISEASES 10911 \| UTS2 \| DISEASES 10911 \| UTS2 \| DISEASES 50508 \| NOX3 \| DISEASES 50508 \| NOX3 \| DISEASES 3385 \| ICAM3 \| DISEASES 3385 \| ICAM3 \| DISEASES 7132 \| TNFRSF1A \| DISEASES 7132 \| TNFRSF1A \| DISEASES 9817 \| KEAP1 \| DISEASES 9817 \| KEAP1 \| DISEASES 9423 \| NTN1 \| DISEASES 9423 \| NTN1 \| DISEASES 30009 \| TBX21 \| DISEASES 30009 \| TBX21 \| DISEASES 5607 \| MAP2K5 \| DISEASES 5607 \| MAP2K5 \| DISEASES 1361 \| CPB2 \| DISEASES 1361 \| CPB2 \| DISEASES 1071 \| CETP \| DISEASES 1071 \| CETP \| DISEASES 23409 \| SIRT4 \| DISEASES 23409 \| SIRT4 \| DISEASES 368 \| ABCC6 \| DISEASES 368 \| ABCC6 \| DISEASES 350 \| APOH \| DISEASES 350 \| APOH \| DISEASES 2099 \| ESR1 \| DISEASES 2099 \| ESR1 \| DISEASES 8086 \| AAAS \| DISEASES 8086 \| AAAS \| DISEASES 7414 \| VCL \| DISEASES 7414 \| VCL \| DISEASES 23411 \| SIRT1 \| DISEASES 23411 \| SIRT1 \| DISEASES 4616 \| GADD45B \| DISEASES 4616 \| GADD45B \| DISEASES 3053 \| SERPIND1 \| DISEASES 3053 \| SERPIND1 \| DISEASES 4282 \| MIF \| DISEASES 4282 \| MIF \| DISEASES 5008 \| OSM \| DISEASES 5008 \| OSM \| DISEASES 5594 \| MAPK1 \| DISEASES 5594 \| MAPK1 \| DISEASES 3957 \| LGALS2 \| DISEASES 3957 \| LGALS2 \| DISEASES 7494 \| XBP1 \| DISEASES 7494 \| XBP1 \| DISEASES 9567 \| GTPBP1 \| DISEASES 9567 \| GTPBP1 \| DISEASES 3162 \| HMOX1 \| DISEASES 3162 \| HMOX1 \| DISEASES 80339 \| PNPLA3 \| DISEASES 80339 \| PNPLA3 \| DISEASES 2287 \| FKBP3 \| DISEASES 1511 \| CTSG \| DISEASES 1511 \| CTSG \| DISEASES 3002 \| GZMB \| DISEASES 3002 \| GZMB \| DISEASES 9517 \| SPTLC2 \| DISEASES 9517 \| SPTLC2 \| DISEASES 4792 \| NFKBIA \| DISEASES 4792 \| NFKBIA \| DISEASES 10544 \| PROCR \| DISEASES 10544 \| PROCR \| DISEASES 57761 \| TRIB3 \| DISEASES 57761 \| TRIB3 \| DISEASES 3929 \| LBP \| DISEASES 3929 \| LBP \| DISEASES 140679 \| SLC32A1 \| DISEASES 140679 \| SLC32A1 \| DISEASES 191 \| AHCY \| DISEASES 191 \| AHCY \| DISEASES 9352 \| TXNL1 \| DISEASES 9352 \| TXNL1 \| DISEASES 2158 \| F9 \| DISEASES 2158 \| F9 \| DISEASES 7076 \| TIMP1 \| DISEASES 7076 \| TIMP1 \| DISEASES 54 \| ACP5 \| DISEASES 54 \| ACP5 \| DISEASES 4313 \| MMP2 \| DISEASES 4313 \| MMP2 \| DISEASES 6367 \| CCL22 \| DISEASES 23659 \| PLA2G15 \| DISEASES 23659 \| PLA2G15 \| DISEASES 4210 \| MEFV \| DISEASES 4210 \| MEFV \| DISEASES 3163 \| HMOX2 \| DISEASES 3163 \| HMOX2 \| DISEASES 4150 \| MAZ \| DISEASES 4150 \| MAZ \| DISEASES 23269 \| MGA \| DISEASES 23269 \| MGA \| DISEASES 1445 \| CSK \| DISEASES 1445 \| CSK \| DISEASES 51285 \| RASL12 \| DISEASES 9333 \| TGM5 \| DISEASES 9333 \| TGM5 \| DISEASES 2222 \| FDFT1 \| DISEASES 2222 \| FDFT1 \| DISEASES 8767 \| RIPK2 \| DISEASES 8767 \| RIPK2 \| DISEASES 1666 \| DECR1 \| DISEASES 1666 \| DECR1 \| DISEASES 5327 \| PLAT \| DISEASES 5327 \| PLAT \| DISEASES 8175 \| SF3A2 \| DISEASES 8175 \| SF3A2 \| DISEASES 56729 \| RETN \| DISEASES 56729 \| RETN \| DISEASES 2091 \| FBL \| DISEASES 7040 \| TGFB1 \| DISEASES 7040 \| TGFB1 \| DISEASES 10226 \| PLIN3 \| DISEASES 10226 \| PLIN3 \| DISEASES 973 \| CD79A \| DISEASES 973 \| CD79A \| DISEASES 6822 \| SULT2A1 \| DISEASES 6822 \| SULT2A1 \| DISEASES 3036 \| HAS1 \| DISEASES 3036 \| HAS1 \| DISEASES 26291 \| FGF21 \| DISEASES 26291 \| FGF21 \| DISEASES 1311 \| COMP \| DISEASES 1311 \| COMP \| DISEASES 57817 \| HAMP \| DISEASES 57817 \| HAMP \| DISEASES 5444 \| PON1 \| DISEASES 5444 \| PON1 \| DISEASES 3082 \| HGF \| DISEASES 3082 \| HGF \| DISEASES 7980 \| TFPI2 \| DISEASES 7980 \| TFPI2 \| DISEASES 10135 \| NAMPT \| DISEASES 10135 \| NAMPT \| DISEASES 5445 \| PON2 \| DISEASES 5445 \| PON2 \| DISEASES 10392 \| NOD1 \| DISEASES 10392 \| NOD1 \| DISEASES 5054 \| SERPINE1 \| DISEASES 5054 \| SERPINE1 \| DISEASES 5919 \| RARRES2 \| DISEASES 5919 \| RARRES2 \| DISEASES 165 \| AEBP1 \| DISEASES 165 \| AEBP1 \| DISEASES 10952 \| SEC61B \| DISEASES 10952 \| SEC61B \| DISEASES 59 \| ACTA2 \| DISEASES 59 \| ACTA2 \| DISEASES 6348 \| CCL3 \| DISEASES 6348 \| CCL3 \| DISEASES 4353 \| MPO \| DISEASES 4353 \| MPO \| DISEASES 1440 \| CSF3 \| DISEASES 1440 \| CSF3 \| DISEASES 5023 \| P2RX1 \| DISEASES 5023 \| P2RX1 \| DISEASES 6198 \| RPS6KB1 \| DISEASES 6198 \| RPS6KB1 \| DISEASES 708 \| C1QBP \| DISEASES 708 \| C1QBP \| DISEASES 6347 \| CCL2 \| DISEASES 6347 \| CCL2 \| DISEASES 6357 \| CCL13 \| DISEASES 6357 \| CCL13 \| DISEASES 4619 \| MYH1 \| DISEASES 4619 \| MYH1 \| DISEASES 7448 \| VTN \| DISEASES 7448 \| VTN \| DISEASES 952 \| CD38 \| DISEASES 952 \| CD38 \| DISEASES 3381 \| IBSP \| DISEASES 6783 \| SULT1E1 \| DISEASES 6783 \| SULT1E1 \| DISEASES 5197 \| PF4V1 \| DISEASES 5197 \| PF4V1 \| DISEASES 4790 \| NFKB1 \| DISEASES 4790 \| NFKB1 \| DISEASES 3558 \| IL2 \| DISEASES 3558 \| IL2 \| DISEASES 6688 \| SPI1 \| DISEASES 6688 \| SPI1 \| DISEASES 1075 \| CTSC \| DISEASES 1075 \| CTSC \| DISEASES 595 \| CCND1 \| DISEASES 595 \| CCND1 \| DISEASES 116519 \| APOA5 \| DISEASES 116519 \| APOA5 \| DISEASES 345 \| APOC3 \| DISEASES 345 \| APOC3 \| DISEASES 5829 \| PXN \| DISEASES 5829 \| PXN \| DISEASES 969 \| CD69 \| DISEASES 969 \| CD69 \| DISEASES 6404 \| SELPLG \| DISEASES 6404 \| SELPLG \| DISEASES 4048 \| LTA4H \| DISEASES 4048 \| LTA4H \| DISEASES 1027 \| CDKN1B \| DISEASES 1027 \| CDKN1B \| DISEASES 4055 \| LTBR \| DISEASES 4055 \| LTBR \| DISEASES 4256 \| MGP \| DISEASES 4256 \| MGP \| DISEASES 3458 \| IFNG \| DISEASES 3458 \| IFNG \| DISEASES 2597 \| GAPDH \| DISEASES 2597 \| GAPDH \| DISEASES 2784 \| GNB3 \| DISEASES 2784 \| GNB3 \| DISEASES 339 \| APOBEC1 \| DISEASES 339 \| APOBEC1 \| DISEASES 2729 \| GCLC \| DISEASES 2729 \| GCLC \| DISEASES 84830 \| ADTRP \| DISEASES 84830 \| ADTRP \| DISEASES 1432 \| MAPK14 \| DISEASES 1432 \| MAPK14 \| DISEASES 7942 \| TFEB \| DISEASES 7942 \| TFEB \| DISEASES 1839 \| HBEGF \| DISEASES 1839 \| HBEGF \| DISEASES 4015 \| LOX \| DISEASES 4015 \| LOX \| DISEASES 6678 \| SPARC \| DISEASES 6678 \| SPARC \| DISEASES 64902 \| AGXT2 \| DISEASES 64902 \| AGXT2 \| DISEASES 3565 \| IL4 \| DISEASES 3565 \| IL4 \| DISEASES 3567 \| IL5 \| DISEASES 3567 \| IL5 \| DISEASES 2908 \| NR3C1 \| DISEASES 2908 \| NR3C1 \| DISEASES 3273 \| HRG \| DISEASES 3273 \| HRG \| DISEASES 7035 \| TFPI \| DISEASES 7035 \| TFPI \| DISEASES 338 \| APOB \| DISEASES 338 \| APOB \| DISEASES 3554 \| IL1R1 \| DISEASES 3554 \| IL1R1 \| DISEASES 9173 \| IL1RL1 \| DISEASES 9173 \| IL1RL1 \| DISEASES 5997 \| RGS2 \| DISEASES 6402 \| SELL \| DISEASES 6402 \| SELL \| DISEASES 1509 \| CTSD \| DISEASES 1509 \| CTSD \| DISEASES 4317 \| MMP8 \| DISEASES 4317 \| MMP8 \| DISEASES 335 \| APOA1 \| DISEASES 335 \| APOA1 \| DISEASES 471 \| ATIC \| DISEASES 471 \| ATIC \| DISEASES 7276 \| TTR \| DISEASES 7276 \| TTR \| DISEASES 7128 \| TNFAIP3 \| DISEASES 7128 \| TNFAIP3 \| DISEASES 6943 \| TCF21 \| DISEASES 6943 \| TCF21 \| DISEASES 8074 \| FGF23 \| DISEASES 8074 \| FGF23 \| DISEASES 2745 \| GLRX \| DISEASES 2745 \| GLRX \| DISEASES 7043 \| TGFB3 \| DISEASES 1843 \| DUSP1 \| DISEASES 1843 \| DUSP1 \| DISEASES 4488 \| MSX2 \| DISEASES 4488 \| MSX2 \| DISEASES 4360 \| MRC1 \| DISEASES 4360 \| MRC1 \| DISEASES 8600 \| TNFSF11 \| DISEASES 8600 \| TNFSF11 \| DISEASES 1958 \| EGR1 \| DISEASES 1958 \| EGR1 \| DISEASES 27230 \| SERP1 \| DISEASES 27230 \| SERP1 \| DISEASES 847 \| CAT \| DISEASES 847 \| CAT \| DISEASES 2693 \| GHSR \| DISEASES 2693 \| GHSR \| DISEASES 8743 \| TNFSF10 \| DISEASES 8743 \| TNFSF10 \| DISEASES 4852 \| NPY \| DISEASES 4852 \| NPY \| DISEASES 10268 \| RAMP3 \| DISEASES 35 \| ACADS \| DISEASES 35 \| ACADS \| DISEASES 58158 \| NEUROD4 \| DISEASES 58158 \| NEUROD4 \| DISEASES 4035 \| LRP1 \| DISEASES 4035 \| LRP1 \| DISEASES 5335 \| PLCG1 \| DISEASES 5335 \| PLCG1 \| DISEASES 5740 \| PTGIS \| DISEASES 5740 \| PTGIS \| DISEASES 3991 \| LIPE \| DISEASES 3991 \| LIPE \| DISEASES 1088 \| CEACAM8 \| DISEASES 1088 \| CEACAM8 \| DISEASES 54210 \| TREM1 \| DISEASES 54210 \| TREM1 \| DISEASES 1026 \| CDKN1A \| DISEASES 1026 \| CDKN1A \| DISEASES 2806 \| GOT2 \| DISEASES 2806 \| GOT2 \| DISEASES 6555 \| SLC10A2 \| DISEASES 6555 \| SLC10A2 \| DISEASES 1948 \| EFNB2 \| DISEASES 3659 \| IRF1 \| DISEASES 3659 \| IRF1 \| DISEASES 652 \| BMP4 \| DISEASES 652 \| BMP4 \| DISEASES 140685 \| ZBTB46 \| DISEASES 140685 \| ZBTB46 \| DISEASES 51141 \| INSIG2 \| DISEASES 51141 \| INSIG2 \| DISEASES 8744 \| TNFSF9 \| DISEASES 8744 \| TNFSF9 \| DISEASES 718 \| C3 \| DISEASES 718 \| C3 \| DISEASES 7408 \| VASP \| DISEASES 7408 \| VASP \| DISEASES 1236 \| CCR7 \| DISEASES 1236 \| CCR7 \| DISEASES 6945 \| MLX \| DISEASES 29108 \| PYCARD \| DISEASES 29108 \| PYCARD \| DISEASES 391013 \| PLA2G2C \| DISEASES 391013 \| PLA2G2C \| DISEASES 10365 \| KLF2 \| DISEASES 10365 \| KLF2 \| DISEASES 14 \| AAMP \| DISEASES 14 \| AAMP \| DISEASES 3315 \| HSPB1 \| DISEASES 3315 \| HSPB1 \| DISEASES 7538 \| ZFP36 \| DISEASES 7538 \| ZFP36 \| DISEASES 2678 \| GGT1 \| DISEASES 2678 \| GGT1 \| DISEASES 2952 \| GSTT1 \| DISEASES 2952 \| GSTT1 \| DISEASES 80831 \| APOL5 \| DISEASES 80831 \| APOL5 \| DISEASES 5880 \| RAC2 \| DISEASES 5880 \| RAC2 \| DISEASES 22933 \| SIRT2 \| DISEASES 22933 \| SIRT2 \| DISEASES 54567 \| DLL4 \| DISEASES 54567 \| DLL4 \| DISEASES 968 \| CD68 \| DISEASES 968 \| CD68 \| DISEASES 6351 \| CCL4 \| DISEASES 6351 \| CCL4 \| DISEASES 1215 \| CMA1 \| DISEASES 1215 \| CMA1 \| DISEASES 3630 \| INS \| DISEASES 3630 \| INS \| DISEASES 239 \| ALOX12 \| DISEASES 239 \| ALOX12 \| DISEASES 3040 \| HBA2 \| DISEASES 3040 \| HBA2 \| DISEASES 2006 \| ELN \| DISEASES 2006 \| ELN \| DISEASES 1264 \| CNN1 \| DISEASES 1264 \| CNN1 \| DISEASES 348 \| APOE \| DISEASES 348 \| APOE \| DISEASES 341 \| APOC1 \| DISEASES 341 \| APOC1 \| DISEASES 59272 \| ACE2 \| DISEASES 59272 \| ACE2 \| DISEASES 2056 \| EPO \| DISEASES 2056 \| EPO \| DISEASES 9518 \| GDF15 \| DISEASES 9518 \| GDF15 \| DISEASES 10343 \| PKDREJ \| DISEASES 7376 \| NR1H2 \| DISEASES 7376 \| NR1H2 \| DISEASES 9945 \| GFPT2 \| DISEASES 9945 \| GFPT2 \| DISEASES 10266 \| RAMP2 \| DISEASES 314 \| AOC2 \| DISEASES 314 \| AOC2 \| DISEASES 2538 \| G6PC \| DISEASES 2538 \| G6PC \| DISEASES 8431 \| NR0B2 \| DISEASES 8431 \| NR0B2 \| DISEASES 3958 \| LGALS3 \| DISEASES 3958 \| LGALS3 \| DISEASES 6382 \| SDC1 \| DISEASES 6382 \| SDC1 \| DISEASES 1401 \| CRP \| DISEASES 1401 \| CRP \| DISEASES 325 \| APCS \| DISEASES 325 \| APCS \| DISEASES 10400 \| PEMT \| DISEASES 10400 \| PEMT \| DISEASES 1116 \| CHI3L1 \| DISEASES 1116 \| CHI3L1 \| DISEASES 2167 \| FABP4 \| DISEASES 2167 \| FABP4 \| DISEASES 10894 \| LYVE1 \| DISEASES 10894 \| LYVE1 \| DISEASES 10001 \| MED6 \| DISEASES 10001 \| MED6 \| DISEASES 6272 \| SORT1 \| DISEASES 6272 \| SORT1 \| DISEASES 377 \| ARF3 \| DISEASES 377 \| ARF3 \| DISEASES 10468 \| FST \| DISEASES 10468 \| FST \| DISEASES 187 \| APLNR \| DISEASES 187 \| APLNR \| DISEASES 301 \| ANXA1 \| DISEASES 301 \| ANXA1 \| DISEASES 6927 \| HNF1A \| DISEASES 4907 \| NT5E \| DISEASES 4907 \| NT5E \| DISEASES 55226 \| NAT10 \| DISEASES 55226 \| NAT10 \| DISEASES 967 \| CD63 \| DISEASES 967 \| CD63 \| DISEASES 1019 \| CDK4 \| DISEASES 1019 \| CDK4 \| DISEASES 6610 \| SMPD2 \| DISEASES 6610 \| SMPD2 \| DISEASES 1593 \| CYP27A1 \| DISEASES 1593 \| CYP27A1 \| DISEASES 3569 \| IL6 \| DISEASES 3569 \| IL6 \| DISEASES 3557 \| IL1RN \| DISEASES 3557 \| IL1RN \| DISEASES 5168 \| ENPP2 \| DISEASES 5168 \| ENPP2 \| DISEASES 6366 \| CCL21 \| DISEASES 6366 \| CCL21 \| DISEASES 8737 \| RIPK1 \| DISEASES 8737 \| RIPK1 \| DISEASES 1208 \| CLPS \| DISEASES 1208 \| CLPS \| DISEASES 7097 \| TLR2 \| DISEASES 7097 \| TLR2 \| DISEASES 10068 \| IL18BP \| DISEASES 7274 \| TTPA \| DISEASES 7274 \| TTPA \| DISEASES 6653 \| SORL1 \| DISEASES 6653 \| SORL1 \| DISEASES 4316 \| MMP7 \| DISEASES 4316 \| MMP7 \| DISEASES 25833 \| POU2F3 \| DISEASES 25833 \| POU2F3 \| DISEASES 4322 \| MMP13 \| DISEASES 4322 \| MMP13 \| DISEASES 7057 \| THBS1 \| DISEASES 7057 \| THBS1 \| DISEASES 102 \| ADAM10 \| DISEASES 102 \| ADAM10 \| DISEASES 2644 \| GCHFR \| DISEASES 2644 \| GCHFR \| DISEASES 64240 \| ABCG5 \| DISEASES 64240 \| ABCG5 \| DISEASES 1559 \| CYP2C9 \| DISEASES 1559 \| CYP2C9 \| DISEASES 9360 \| PPIG \| DISEASES 9360 \| PPIG \| DISEASES 114882 \| OSBPL8 \| DISEASES 114882 \| OSBPL8 \| DISEASES 10060 \| ABCC9 \| DISEASES 4659 \| PPP1R12A \| DISEASES 4659 \| PPP1R12A \| DISEASES 4069 \| LYZ \| DISEASES 4069 \| LYZ \| DISEASES 9388 \| LIPG \| DISEASES 9388 \| LIPG \| DISEASES 4040 \| LRP6 \| DISEASES 4040 \| LRP6 \| DISEASES 9627 \| SNCAIP \| DISEASES 9627 \| SNCAIP \| DISEASES 55567 \| DNAH3 \| DISEASES 55567 \| DNAH3 \| DISEASES 7450 \| VWF \| DISEASES 7450 \| VWF \| DISEASES 11019 \| LIAS \| DISEASES 11019 \| LIAS \| DISEASES 51274 \| KLF3 \| DISEASES 51274 \| KLF3 \| DISEASES 3290 \| HSD11B1 \| DISEASES 3290 \| HSD11B1 \| DISEASES 1535 \| CYBA \| DISEASES 1535 \| CYBA \| DISEASES 949 \| SCARB1 \| DISEASES 949 \| SCARB1 \| DISEASES 217 \| ALDH2 \| DISEASES 217 \| ALDH2 \| DISEASES 384 \| ARG2 \| DISEASES 384 \| ARG2 \| DISEASES 5159 \| PDGFRB \| DISEASES 5159 \| PDGFRB \| DISEASES 2324 \| FLT4 \| DISEASES 3690 \| ITGB3 \| DISEASES 3690 \| ITGB3 \| DISEASES 4141 \| MARS \| DISEASES 4141 \| MARS \| DISEASES 4223 \| MEOX2 \| DISEASES 4223 \| MEOX2 \| DISEASES 23531 \| MMD \| DISEASES 23531 \| MMD \| DISEASES 4481 \| MSR1 \| DISEASES 4481 \| MSR1 \| DISEASES 57045 \| TWSG1 \| DISEASES 57045 \| TWSG1 \| DISEASES 54947 \| LPCAT2 \| DISEASES 54947 \| LPCAT2 \| DISEASES 4087 \| SMAD2 \| DISEASES 4087 \| SMAD2 \| DISEASES 64788 \| LMF1 \| DISEASES 64788 \| LMF1 \| DISEASES 3674 \| ITGA2B \| DISEASES 3674 \| ITGA2B \| DISEASES 6521 \| SLC4A1 \| DISEASES 6521 \| SLC4A1 \| DISEASES 5465 \| PPARA \| DISEASES 5465 \| PPARA \| DISEASES 5052 \| PRDX1 \| DISEASES 5052 \| PRDX1 \| DISEASES 7077 \| TIMP2 \| DISEASES 7077 \| TIMP2 \| DISEASES 7224 \| TRPC5 \| DISEASES 7224 \| TRPC5 \| DISEASES 25939 \| SAMHD1 \| DISEASES 25939 \| SAMHD1 \| DISEASES 3783 \| KCNN4 \| DISEASES 3783 \| KCNN4 \| DISEASES 7350 \| UCP1 \| DISEASES 7350 \| UCP1 \| DISEASES 5595 \| MAPK3 \| DISEASES 5595 \| MAPK3 \| DISEASES 8578 \| SCARF1 \| DISEASES 8578 \| SCARF1 \| DISEASES 5338 \| PLD2 \| DISEASES 5338 \| PLD2 \| DISEASES 23523 \| CABIN1 \| DISEASES 2033 \| EP300 \| DISEASES 2033 \| EP300 \| DISEASES 50507 \| NOX4 \| DISEASES 50507 \| NOX4 \| DISEASES 27178 \| IL37 \| DISEASES 27178 \| IL37 \| DISEASES 3552 \| IL1A \| DISEASES 3552 \| IL1A \| DISEASES 3553 \| IL1B \| DISEASES 3553 \| IL1B \| DISEASES 4854 \| NOTCH3 \| DISEASES 4854 \| NOTCH3 \| DISEASES 1991 \| ELANE \| DISEASES 1991 \| ELANE \| DISEASES 6403 \| SELP \| DISEASES 6403 \| SELP \| DISEASES 7301 \| TYRO3 \| DISEASES 7301 \| TYRO3 \| DISEASES 4036 \| LRP2 \| DISEASES 4036 \| LRP2 \| DISEASES 5007 \| OSBP \| DISEASES 5007 \| OSBP \| DISEASES 3574 \| IL7 \| DISEASES 3574 \| IL7 \| DISEASES 3791 \| KDR \| DISEASES 3791 \| KDR \| DISEASES 6548 \| SLC9A1 \| DISEASES 6548 \| SLC9A1 \| DISEASES 51192 \| CKLF \| DISEASES 51192 \| CKLF \| DISEASES 3931 \| LCAT \| DISEASES 3931 \| LCAT \| DISEASES 4162 \| MCAM \| DISEASES 4162 \| MCAM \| DISEASES 10382 \| TUBB4A \| DISEASES 4811 \| NID1 \| DISEASES 941 \| CD80 \| DISEASES 941 \| CD80 \| DISEASES 9693 \| RAPGEF2 \| DISEASES 9693 \| RAPGEF2 \| DISEASES 2247 \| FGF2 \| DISEASES 2247 \| FGF2 \| DISEASES 1356 \| CP \| DISEASES 1356 \| CP \| DISEASES 7474 \| WNT5A \| DISEASES 7474 \| WNT5A \| DISEASES 6774 \| STAT3 \| DISEASES 6774 \| STAT3 \| DISEASES 5443 \| POMC \| DISEASES 5443 \| POMC \| DISEASES 118 \| ADD1 \| DISEASES 118 \| ADD1 \| DISEASES 65056 \| GPBP1 \| DISEASES 65056 \| GPBP1 \| DISEASES 56606 \| SLC2A9 \| DISEASES 56606 \| SLC2A9 \| DISEASES 3383 \| ICAM1 \| DISEASES 3383 \| ICAM1 \| DISEASES 10891 \| PPARGC1A \| DISEASES 10891 \| PPARGC1A \| DISEASES 950 \| SCARB2 \| DISEASES 950 \| SCARB2 \| DISEASES 3827 \| KNG1 \| DISEASES 3827 \| KNG1 \| DISEASES 64083 \| GOLPH3 \| DISEASES 64083 \| GOLPH3 \| DISEASES 4883 \| NPR3 \| DISEASES 4883 \| NPR3 \| DISEASES 1462 \| VCAN \| DISEASES 1462 \| VCAN \| DISEASES 6897 \| TARS \| DISEASES 6897 \| TARS \| DISEASES 1950 \| EGF \| DISEASES 1950 \| EGF \| DISEASES 6722 \| SRF \| DISEASES 6722 \| SRF \| DISEASES 25824 \| PRDX5 \| DISEASES 25824 \| PRDX5 \| DISEASES 4547 \| MTTP \| DISEASES 4547 \| MTTP \| DISEASES 22937 \| SCAP \| DISEASES 22937 \| SCAP \| DISEASES 4986 \| OPRK1 \| DISEASES 4986 \| OPRK1 \| DISEASES 64577 \| ALDH8A1 \| DISEASES 64577 \| ALDH8A1 \| DISEASES 5446 \| PON3 \| DISEASES 5446 \| PON3 \| DISEASES 1374 \| CPT1A \| DISEASES 1374 \| CPT1A \| DISEASES 1119 \| CHKA \| DISEASES 1119 \| CHKA \| DISEASES 29999 \| FSCN3 \| DISEASES 29999 \| FSCN3 \| DISEASES 51608 \| GET4 \| DISEASES 51608 \| GET4 \| DISEASES 79109 \| MAPKAP1 \| DISEASES 79109 \| MAPKAP1 \| DISEASES 5286 \| PIK3C2A \| DISEASES 5286 \| PIK3C2A \| DISEASES 3263 \| HPX \| DISEASES 3263 \| HPX \| DISEASES 7078 \| TIMP3 \| DISEASES 7078 \| TIMP3 \| DISEASES 6527 \| SLC5A4 \| DISEASES 4060 \| LUM \| DISEASES 4060 \| LUM \| DISEASES 1017 \| CDK2 \| DISEASES 1017 \| CDK2 \| DISEASES 3067 \| HDC \| DISEASES 3067 \| HDC \| DISEASES 597 \| BCL2A1 \| DISEASES 597 \| BCL2A1 \| DISEASES 3480 \| IGF1R \| DISEASES 3480 \| IGF1R \| DISEASES 4240 \| MFGE8 \| DISEASES 4240 \| MFGE8 \| DISEASES 5045 \| FURIN \| DISEASES 5045 \| FURIN \| DISEASES 3687 \| ITGAX \| DISEASES 3687 \| ITGAX \| DISEASES 3394 \| IRF8 \| DISEASES 3394 \| IRF8 \| DISEASES 1000 \| CDH2 \| DISEASES 1000 \| CDH2 \| DISEASES 4864 \| NPC1 \| DISEASES 4864 \| NPC1 \| DISEASES 409 \| ARRB2 \| DISEASES 409 \| ARRB2 \| DISEASES 7157 \| TP53 \| DISEASES 7157 \| TP53 \| DISEASES 3487 \| IGFBP4 \| DISEASES 3487 \| IGFBP4 \| DISEASES 6647 \| SOD1 \| DISEASES 6647 \| SOD1 \| DISEASES 207 \| AKT1 \| DISEASES 207 \| AKT1 \| DISEASES 5141 \| PDE4A \| DISEASES 1952 \| CELSR2 \| DISEASES 1952 \| CELSR2 \| DISEASES 2702 \| GJA5 \| DISEASES 2702 \| GJA5 \| DISEASES 2212 \| FCGR2A \| DISEASES 2212 \| FCGR2A \| DISEASES 1513 \| CTSK \| DISEASES 1513 \| CTSK \| DISEASES 3782 \| KCNN3 \| DISEASES 3782 \| KCNN3 \| DISEASES 52 \| ACP1 \| DISEASES 52 \| ACP1 \| DISEASES 5972 \| REN \| DISEASES 5972 \| REN \| DISEASES 388 \| RHOB \| DISEASES 64241 \| ABCG8 \| DISEASES 64241 \| ABCG8 \| DISEASES 805 \| CALM2 \| DISEASES 805 \| CALM2 \| DISEASES 22989 \| MYH15 \| DISEASES 22989 \| MYH15 \| DISEASES 185 \| AGTR1 \| DISEASES 185 \| AGTR1 \| DISEASES 7220 \| TRPC1 \| DISEASES 7220 \| TRPC1 \| DISEASES 2495 \| FTH1 \| DISEASES 2495 \| FTH1 \| DISEASES 2169 \| FABP2 \| DISEASES 2169 \| FABP2 \| DISEASES 7941 \| PLA2G7 \| DISEASES 7941 \| PLA2G7 \| DISEASES 1956 \| EGFR \| DISEASES 1956 \| EGFR \| DISEASES 3484 \| IGFBP1 \| DISEASES 3484 \| IGFBP1 \| DISEASES 4841 \| NONO \| DISEASES 4841 \| NONO \| DISEASES 6770 \| STAR \| DISEASES 6770 \| STAR \| DISEASES 123 \| PLIN2 \| DISEASES 123 \| PLIN2 \| DISEASES 1030 \| CDKN2B \| DISEASES 1030 \| CDKN2B \| DISEASES 3934 \| LCN2 \| DISEASES 3934 \| LCN2 \| DISEASES 4851 \| NOTCH1 \| DISEASES 4851 \| NOTCH1 \| DISEASES 3026 \| HABP2 \| DISEASES 3026 \| HABP2 \| DISEASES 133 \| ADM \| DISEASES 133 \| ADM \| DISEASES 6291 \| SAA4 \| DISEASES 6291 \| SAA4 \| DISEASES 472 \| ATM \| DISEASES 472 \| ATM \| DISEASES 22981 \| NINL \| DISEASES 22981 \| NINL \| DISEASES 90952 \| ESAM \| DISEASES 90952 \| ESAM \| DISEASES 6876 \| TAGLN \| DISEASES 6876 \| TAGLN \| DISEASES 4319 \| MMP10 \| DISEASES 4319 \| MMP10 \| DISEASES 7424 \| VEGFC \| DISEASES 7424 \| VEGFC \| DISEASES 3606 \| IL18 \| DISEASES 3606 \| IL18 \| DISEASES 2180 \| ACSL1 \| DISEASES 2180 \| ACSL1 \| DISEASES 7082 \| TJP1 \| DISEASES 7082 \| TJP1 \| DISEASES 7292 \| TNFSF4 \| DISEASES 7292 \| TNFSF4 \| DISEASES 57105 \| CYSLTR2 \| DISEASES 57105 \| CYSLTR2 \| DISEASES 5741 \| PTH \| DISEASES 5741 \| PTH \| DISEASES 2321 \| FLT1 \| DISEASES 2321 \| FLT1 \| DISEASES 2697 \| GJA1 \| DISEASES 2697 \| GJA1 \| DISEASES 10428 \| CFDP1 \| DISEASES 10428 \| CFDP1 \| DISEASES 23576 \| DDAH1 \| DISEASES 23576 \| DDAH1 \| DISEASES 118611 \| C10orf90 \| DISEASES 118611 \| C10orf90 \| DISEASES 23643 \| LY96 \| DISEASES 23643 \| LY96 \| DISEASES 351 \| APP \| DISEASES 351 \| APP \| DISEASES 9510 \| ADAMTS1 \| DISEASES 9510 \| ADAMTS1 \| DISEASES 7071 \| KLF10 \| DISEASES 7071 \| KLF10 \| DISEASES 231 \| AKR1B1 \| DISEASES 231 \| AKR1B1 \| DISEASES 1436 \| CSF1R \| DISEASES 1436 \| CSF1R \| DISEASES 114 \| ADCY8 \| DISEASES 114 \| ADCY8 \| DISEASES 221458 \| KIF6 \| DISEASES 221458 \| KIF6 \| DISEASES 7547 \| ZIC3 \| DISEASES 7547 \| ZIC3 \| DISEASES 7079 \| TIMP4 \| DISEASES 5468 \| PPARG \| DISEASES 5468 \| PPARG \| DISEASES 3156 \| HMGCR \| DISEASES 3156 \| HMGCR \| DISEASES 22808 \| MRAS \| DISEASES 22808 \| MRAS \| DISEASES 909 \| CD1A \| DISEASES 909 \| CD1A \| DISEASES 653361 \| NCF1 \| DISEASES 653361 \| NCF1 \| DISEASES 29881 \| NPC1L1 \| DISEASES 29881 \| NPC1L1 \| DISEASES 50848 \| F11R \| DISEASES 50848 \| F11R \| DISEASES 1636 \| ACE \| DISEASES 1636 \| ACE \| DISEASES 115650 \| TNFRSF13C \| DISEASES 115650 \| TNFRSF13C \| DISEASES 5739 \| PTGIR \| DISEASES 5739 \| PTGIR \| DISEASES 808 \| CALM3 \| DISEASES 808 \| CALM3 \| DISEASES 5152 \| PDE9A \| DISEASES 5152 \| PDE9A \| DISEASES 6285 \| S100B \| DISEASES 6285 \| S100B \| DISEASES 729230 \| CCR2 \| DISEASES 729230 \| CCR2 \| DISEASES 1234 \| CCR5 \| DISEASES 1234 \| CCR5 \| DISEASES 2264 \| FGFR4 \| DISEASES 2264 \| FGFR4 \| DISEASES 5731 \| PTGER1 \| DISEASES 5731 \| PTGER1 \| DISEASES 51 \| ACOX1 \| DISEASES 51 \| ACOX1 \| DISEASES 6352 \| CCL5 \| DISEASES 6352 \| CCL5 \| DISEASES 6368 \| CCL23 \| DISEASES 6368 \| CCL23 \| DISEASES 246 \| ALOX15 \| DISEASES 246 \| ALOX15 \| DISEASES 58191 \| CXCL16 \| DISEASES 58191 \| CXCL16 \| DISEASES 4041 \| LRP5 \| DISEASES 4041 \| LRP5 \| DISEASES 7412 \| VCAM1 \| DISEASES 7412 \| VCAM1 \| DISEASES 2215 \| FCGR3B \| DISEASES 2215 \| FCGR3B \| DISEASES 5937 \| RBMS1 \| DISEASES 5937 \| RBMS1 \| DISEASES 5966 \| REL \| DISEASES 5966 \| REL \| DISEASES 27306 \| HPGDS \| DISEASES 27306 \| HPGDS \| DISEASES 284996 \| RNF149 \| DISEASES 284996 \| RNF149 \| DISEASES 10461 \| MERTK \| DISEASES 10461 \| MERTK \| DISEASES 4880 \| NPPC \| DISEASES 4880 \| NPPC \| DISEASES 3577 \| CXCR1 \| DISEASES 152185 \| SPICE1 \| DISEASES 152185 \| SPICE1 \| DISEASES 213 \| ALB \| DISEASES 213 \| ALB \| DISEASES 5473 \| PPBP \| DISEASES 5473 \| PPBP \| DISEASES 5196 \| PF4 \| DISEASES 5196 \| PF4 \| DISEASES 1230 \| CCR1 \| DISEASES 1230 \| CCR1 \| DISEASES 28999 \| KLF15 \| DISEASES 308 \| ANXA5 \| DISEASES 308 \| ANXA5 \| DISEASES 2982 \| GUCY1A3 \| DISEASES 2982 \| GUCY1A3 \| DISEASES 3600 \| IL15 \| DISEASES 3600 \| IL15 \| DISEASES 3673 \| ITGA2 \| DISEASES 3673 \| ITGA2 \| DISEASES 9607 \| CARTPT \| DISEASES 9607 \| CARTPT \| DISEASES 7098 \| TLR3 \| DISEASES 7098 \| TLR3 \| DISEASES 1437 \| CSF2 \| DISEASES 1437 \| CSF2 \| DISEASES 221955 \| DAGLB \| DISEASES 221955 \| DAGLB \| DISEASES 2171 \| FABP5 \| DISEASES 2171 \| FABP5 \| DISEASES 4982 \| TNFRSF11B \| DISEASES 4982 \| TNFRSF11B \| DISEASES 4846 \| NOS3 \| DISEASES 4846 \| NOS3 \| DISEASES 7373 \| COL14A1 \| DISEASES 7373 \| COL14A1 \| DISEASES 115825 \| WDFY2 \| DISEASES 7486 \| WRN \| DISEASES 7486 \| WRN \| DISEASES 2350 \| FOLR2 \| DISEASES 2350 \| FOLR2 \| DISEASES 3636 \| INPPL1 \| DISEASES 3636 \| INPPL1 \| DISEASES 55176 \| SEC61A2 \| DISEASES 55176 \| SEC61A2 \| DISEASES 143872 \| ARHGAP42 \| DISEASES 143872 \| ARHGAP42 \| DISEASES 3990 \| LIPC \| DISEASES 3990 \| LIPC \| DISEASES 3611 \| ILK \| DISEASES 3611 \| ILK \| DISEASES 5896 \| RAG1 \| DISEASES 5896 \| RAG1 \| DISEASES 5055 \| SERPINB2 \| DISEASES 5055 \| SERPINB2 \| DISEASES 4314 \| MMP3 \| DISEASES 4314 \| MMP3 \| DISEASES 9382 \| COG1 \| DISEASES 9382 \| COG1 \| DISEASES 5346 \| PLIN1 \| DISEASES 5346 \| PLIN1 \| DISEASES 6778 \| STAT6 \| DISEASES 6778 \| STAT6 \| DISEASES 6786 \| STIM1 \| DISEASES 6786 \| STIM1 \| DISEASES 1549 \| CYP2A7 \| DISEASES 558 \| AXL \| DISEASES 558 \| AXL \| DISEASES 729359 \| PLIN4 \| DISEASES 729359 \| PLIN4 \| DISEASES 51129 \| ANGPTL4 \| DISEASES 51129 \| ANGPTL4 \| DISEASES 8435 \| SOAT2 \| DISEASES 8435 \| SOAT2 \| DISEASES 2125 \| EVPL \| DISEASES 2125 \| EVPL \| DISEASES 1581 \| CYP7A1 \| DISEASES 1581 \| CYP7A1 \| DISEASES 2848 \| GPR25 \| DISEASES 2848 \| GPR25 \| DISEASES 116285 \| ACSM1 \| DISEASES 116285 \| ACSM1 \| DISEASES 5724 \| PTAFR \| DISEASES 5724 \| PTAFR \| DISEASES 3960 \| LGALS4 \| DISEASES 3960 \| LGALS4 \| DISEASES 5617 \| PRL \| DISEASES 5617 \| PRL \| DISEASES 6356 \| CCL11 \| DISEASES 6356 \| CCL11 \| DISEASES 8460 \| TPST1 \| DISEASES 8460 \| TPST1 \| DISEASES 5604 \| MAP2K1 \| DISEASES 5604 \| MAP2K1 \| DISEASES 598 \| BCL2L1 \| DISEASES 598 \| BCL2L1 \| DISEASES 3479 \| IGF1 \| DISEASES 3479 \| IGF1 \| DISEASES 121340 \| SP7 \| DISEASES 121340 \| SP7 \| DISEASES 10296 \| MAEA \| DISEASES 10296 \| MAEA \| DISEASES 5734 \| PTGER4 \| DISEASES 5734 \| PTGER4 \| DISEASES 3308 \| HSPA4 \| DISEASES 3308 \| HSPA4 \| DISEASES 8841 \| HDAC3 \| DISEASES 8841 \| HDAC3 \| DISEASES 140738 \| TMEM37 \| DISEASES 140738 \| TMEM37 \| DISEASES 255738 \| PCSK9 \| DISEASES 255738 \| PCSK9 \| DISEASES 3689 \| ITGB2 \| DISEASES 3689 \| ITGB2 \| DISEASES 3688 \| ITGB1 \| DISEASES 3688 \| ITGB1 \| DISEASES 8988 \| HSPB3 \| DISEASES 8988 \| HSPB3 \| DISEASES 7804 \| LRP8 \| DISEASES 7804 \| LRP8 \| DISEASES 3643 \| INSR \| DISEASES 3643 \| INSR \| DISEASES 9778 \| KIAA0232 \| DISEASES 1493 \| CTLA4 \| DISEASES 1493 \| CTLA4 \| DISEASES 64137 \| ABCG4 \| DISEASES 64137 \| ABCG4 \| DISEASES 929 \| CD14 \| DISEASES 929 \| CD14 \| DISEASES 260434 \| PYDC1 \| DISEASES 260434 \| PYDC1 \| DISEASES 1281 \| COL3A1 \| DISEASES 1281 \| COL3A1 \| DISEASES 10663 \| CXCR6 \| DISEASES 10663 \| CXCR6 \| DISEASES 2194 \| FASN \| DISEASES 2194 \| FASN \| DISEASES 84913 \| ATOH8 \| DISEASES 84913 \| ATOH8 \| DISEASES 79071 \| ELOVL6 \| DISEASES 79071 \| ELOVL6 \| DISEASES 5028 \| P2RY1 \| DISEASES 5028 \| P2RY1 \| DISEASES 1448 \| CSN3 \| DISEASES 1448 \| CSN3 \| DISEASES 3667 \| IRS1 \| DISEASES 3667 \| IRS1 \| DISEASES 3596 \| IL13 \| DISEASES 3596 \| IL13 \| DISEASES 5046 \| PCSK6 \| DISEASES 643246 \| MAP1LC3B2 \| DISEASES 643246 \| MAP1LC3B2 \| DISEASES 154 \| ADRB2 \| DISEASES 154 \| ADRB2 \| DISEASES 1901 \| S1PR1 \| DISEASES 1901 \| S1PR1 \| DISEASES 1051 \| CEBPB \| DISEASES 1051 \| CEBPB \| DISEASES 8862 \| APLN \| DISEASES 8862 \| APLN \| DISEASES 3627 \| CXCL10 \| DISEASES 3627 \| CXCL10 \| DISEASES 2244 \| FGB \| DISEASES 2244 \| FGB \| DISEASES 2353 \| FOS \| DISEASES 2353 \| FOS \| DISEASES 6373 \| CXCL11 \| DISEASES 6373 \| CXCL11 \| DISEASES 3037 \| HAS2 \| DISEASES 3037 \| HAS2 \| DISEASES 9451 \| EIF2AK3 \| DISEASES 9451 \| EIF2AK3 \| DISEASES 64805 \| P2RY12 \| DISEASES 64805 \| P2RY12 \| DISEASES 1241 \| LTB4R \| DISEASES 1241 \| LTB4R \| DISEASES 4815 \| NINJ2 \| DISEASES 4815 \| NINJ2 \| DISEASES 54205 \| CYCS \| DISEASES 54205 \| CYCS \| DISEASES 948 \| CD36 \| DISEASES 948 \| CD36 \| DISEASES 4323 \| MMP14 \| DISEASES 4323 \| MMP14 \| DISEASES 3159 \| HMGA1 \| DISEASES 3159 \| HMGA1 \| DISEASES 79660 \| PPP1R3B \| DISEASES 2147 \| F2 \| DISEASES 2147 \| F2 \| DISEASES 5897 \| RAG2 \| DISEASES 5897 \| RAG2 \| DISEASES 51206 \| GP6 \| DISEASES 51206 \| GP6 \| DISEASES 6363 \| CCL19 \| DISEASES 6363 \| CCL19 \| DISEASES 5340 \| PLG \| DISEASES 5340 \| PLG \| DISEASES 4973 \| OLR1 \| DISEASES 4973 \| OLR1 \| DISEASES 84196 \| USP48 \| DISEASES 84196 \| USP48 \| DISEASES 7015 \| TERT \| DISEASES 7015 \| TERT \| DISEASES 1072 \| CFL1 \| DISEASES 1072 \| CFL1 \| DISEASES 4023 \| LPL \| DISEASES 4023 \| LPL \| DISEASES 152206 \| CCDC13 \| DISEASES 152206 \| CCDC13 \| DISEASES 6868 \| ADAM17 \| DISEASES 6868 \| ADAM17 \| DISEASES 947 \| CD34 \| DISEASES 947 \| CD34 \| DISEASES 3661 \| IRF3 \| DISEASES 3661 \| IRF3 \| DISEASES 8815 \| BANF1 \| DISEASES 8815 \| BANF1 \| DISEASES 5029 \| P2RY2 \| DISEASES 5029 \| P2RY2 \| DISEASES 9420 \| CYP7B1 \| DISEASES 136259 \| KLF14 \| DISEASES 136259 \| KLF14 \| DISEASES 1466 \| CSRP2 \| DISEASES 1466 \| CSRP2 \| DISEASES 5467 \| PPARD \| DISEASES 5467 \| PPARD \| DISEASES 5598 \| MAPK7 \| DISEASES 5598 \| MAPK7 \| DISEASES 836 \| CASP3 \| DISEASES 836 \| CASP3 \| DISEASES 7423 \| VEGFB \| DISEASES 7423 \| VEGFB \| DISEASES 122665 \| RNASE8 \| DISEASES 122665 \| RNASE8 \| DISEASES 2944 \| GSTM1 \| DISEASES 2944 \| GSTM1 \| DISEASES 10290 \| SPEG \| DISEASES 7351 \| UCP2 \| DISEASES 7351 \| UCP2 \| DISEASES 10221 \| TRIB1 \| DISEASES 10221 \| TRIB1 \| DISEASES 5319 \| PLA2G1B \| DISEASES 5319 \| PLA2G1B \| DISEASES 8639 \| AOC3 \| DISEASES 8639 \| AOC3 \| DISEASES 4778 \| NFE2 \| DISEASES 4778 \| NFE2 \| DISEASES 133522 \| PPARGC1B \| DISEASES 133522 \| PPARGC1B \| DISEASES 3952 \| LEP \| DISEASES 3952 \| LEP \| DISEASES 10645 \| CAMKK2 \| DISEASES 23166 \| STAB1 \| DISEASES 23166 \| STAB1 \| DISEASES 3172 \| HNF4A \| DISEASES 3172 \| HNF4A \| DISEASES 4793 \| NFKBIB \| DISEASES 4793 \| NFKBIB \| DISEASES 8877 \| SPHK1 \| DISEASES 8877 \| SPHK1 \| DISEASES 9448 \| MAP4K4 \| DISEASES 9448 \| MAP4K4 \| DISEASES 767 \| CA8 \| DISEASES 767 \| CA8 \| DISEASES 998 \| CDC42 \| DISEASES 998 \| CDC42 \| DISEASES 54472 \| TOLLIP \| DISEASES 54472 \| TOLLIP \| DISEASES 3556 \| IL1RAP \| DISEASES 3556 \| IL1RAP \| DISEASES 285 \| ANGPT2 \| DISEASES 285 \| ANGPT2 \| DISEASES 53832 \| IL20RA \| DISEASES 53832 \| IL20RA \| DISEASES 1909 \| EDNRA \| DISEASES 1909 \| EDNRA \| DISEASES 1191 \| CLU \| DISEASES 1191 \| CLU \| DISEASES 30835 \| CD209 \| DISEASES 30835 \| CD209 \| DISEASES 1776 \| DNASE1L3 \| DISEASES 1776 \| DNASE1L3 \| DISEASES 83953 \| FCAMR \| DISEASES 83953 \| FCAMR \| DISEASES 827 \| CAPN6 \| DISEASES 8542 \| APOL1 \| DISEASES 8542 \| APOL1 \| DISEASES 9377 \| COX5A \| DISEASES 9377 \| COX5A \| DISEASES 9475 \| ROCK2 \| DISEASES 9475 \| ROCK2 \| DISEASES 53905 \| DUOX1 \| DISEASES 53905 \| DUOX1 \| DISEASES 27319 \| BHLHE22 \| DISEASES 27319 \| BHLHE22 \| DISEASES 1582 \| CYP8B1 \| DISEASES 1582 \| CYP8B1 \| DISEASES 5912 \| RAP2B \| DISEASES 5912 \| RAP2B \| DISEASES 3579 \| CXCR2 \| DISEASES 3579 \| CXCR2 \| DISEASES 1728 \| NQO1 \| DISEASES 1728 \| NQO1 \| DISEASES 80381 \| CD276 \| DISEASES 80381 \| CD276 \| DISEASES 9520 \| NPEPPS \| DISEASES 9520 \| NPEPPS \| DISEASES 53829 \| P2RY13 \| DISEASES 53829 \| P2RY13 \| DISEASES 7182 \| NR2C2 \| DISEASES 7182 \| NR2C2 \| DISEASES 9370 \| ADIPOQ \| DISEASES 9370 \| ADIPOQ \| DISEASES 51085 \| MLXIPL \| DISEASES 51085 \| MLXIPL \| DISEASES 6517 \| SLC2A4 \| DISEASES 6517 \| SLC2A4 \| DISEASES 6863 \| TAC1 \| DISEASES 6863 \| TAC1 \| DISEASES 2149 \| F2R \| DISEASES 2149 \| F2R \| DISEASES 4018 \| LPA \| DISEASES 4018 \| LPA \| DISEASES 3996 \| LLGL1 \| DISEASES 3996 \| LLGL1 \| DISEASES 5345 \| SERPINF2 \| DISEASES 5345 \| SERPINF2 \| DISEASES 23212 \| RRS1 \| DISEASES 23212 \| RRS1 \| DISEASES 3039 \| HBA1 \| DISEASES 3039 \| HBA1 \| DISEASES 4312 \| MMP1 \| DISEASES 4312 \| MMP1 \| DISEASES 2837 \| UTS2R \| DISEASES 2837 \| UTS2R \| DISEASES 55600 \| ITLN1 \| DISEASES 55600 \| ITLN1 \| DISEASES 57491 \| AHRR \| DISEASES 57491 \| AHRR \| DISEASES 2 \| A2M \| DISEASES 2 \| A2M \| DISEASES 3309 \| HSPA5 \| DISEASES 3309 \| HSPA5 \| DISEASES 57674 \| RNF213 \| DISEASES 57674 \| RNF213 \| DISEASES 3032 \| HADHB \| DISEASES 3032 \| HADHB \| DISEASES 2200 \| FBN1 \| DISEASES 2200 \| FBN1 \| DISEASES 1585 \| CYP11B2 \| DISEASES 1585 \| CYP11B2 \| DISEASES 9159 \| PCSK7 \| DISEASES 9159 \| PCSK7 \| DISEASES 9622 \| KLK4 \| DISEASES 9622 \| KLK4 \| DISEASES 51330 \| TNFRSF12A \| DISEASES 51330 \| TNFRSF12A \| DISEASES 4094 \| MAF \| DISEASES 4094 \| MAF \| DISEASES 8204 \| NRIP1 \| DISEASES 8204 \| NRIP1 \| DISEASES 4843 \| NOS2 \| DISEASES 4843 \| NOS2 \| DISEASES 633 \| BGN \| DISEASES 633 \| BGN \| DISEASES 1435 \| CSF1 \| DISEASES 1435 \| CSF1 \| DISEASES 23467 \| NPTXR \| DISEASES 23467 \| NPTXR \| DISEASES 5034 \| P4HB \| DISEASES 5034 \| P4HB \| DISEASES 4772 \| NFATC1 \| DISEASES 4772 \| NFATC1 \| DISEASES 6524 \| SLC5A2 \| DISEASES 53833 \| IL20RB \| DISEASES 53833 \| IL20RB \| DISEASES 29933 \| GPR132 \| DISEASES 29933 \| GPR132 \| DISEASES 706 \| TSPO \| DISEASES 706 \| TSPO \| DISEASES 246329 \| STAC3 \| DISEASES 246329 \| STAC3 \| DISEASES 338328 \| GPIHBP1 \| DISEASES 338328 \| GPIHBP1 \| DISEASES 6667 \| SP1 \| DISEASES 6667 \| SP1 \| DISEASES 2811 \| GP1BA \| DISEASES 2811 \| GP1BA \| DISEASES 8651 \| SOCS1 \| DISEASES 8651 \| SOCS1 \| DISEASES 51547 \| SIRT7 \| DISEASES 51547 \| SIRT7 \| DISEASES 221692 \| PHACTR1 \| DISEASES 221692 \| PHACTR1 \| DISEASES 842 \| CASP9 \| DISEASES 842 \| CASP9 \| DISEASES 9021 \| SOCS3 \| DISEASES 9021 \| SOCS3 \| DISEASES 5155 \| PDGFB \| DISEASES 5155 \| PDGFB \| DISEASES 3953 \| LEPR \| DISEASES 3953 \| LEPR \| DISEASES 84439 \| HHIPL1 \| DISEASES 84439 \| HHIPL1 \| DISEASES 5069 \| PAPPA \| DISEASES 5069 \| PAPPA \| DISEASES 7850 \| IL1R2 \| DISEASES 7850 \| IL1R2 \| DISEASES 2192 \| FBLN1 \| DISEASES 5136 \| PDE1A \| DISEASES 5136 \| PDE1A \| DISEASES 6401 \| SELE \| DISEASES 6401 \| SELE \| DISEASES 2621 \| GAS6 \| DISEASES 2621 \| GAS6 \| DISEASES 10196 \| PRMT3 \| DISEASES 10196 \| PRMT3 \| DISEASES 942 \| CD86 \| DISEASES 942 \| CD86 \| DISEASES 8694 \| DGAT1 \| DISEASES 8694 \| DGAT1 \| DISEASES 144453 \| BEST3 \| DISEASES 144453 \| BEST3 \| DISEASES 55328 \| RNLS \| DISEASES 55328 \| RNLS \| DISEASES 84750 \| FUT10 \| DISEASES 84750 \| FUT10 \| DISEASES 2185 \| PTK2B \| DISEASES 2185 \| PTK2B \| DISEASES 4088 \| SMAD3 \| DISEASES 4088 \| SMAD3 \| DISEASES 8013 \| NR4A3 \| DISEASES 8013 \| NR4A3 \| DISEASES 8398 \| PLA2G6 \| DISEASES 8398 \| PLA2G6 \| DISEASES 10052 \| GJC1 \| DISEASES 10052 \| GJC1 \| DISEASES 338872 \| C1QTNF9 \| DISEASES 338872 \| C1QTNF9 \| DISEASES 682 \| BSG \| DISEASES 682 \| BSG \| DISEASES 3043 \| HBB \| DISEASES 3043 \| HBB \| DISEASES 5641 \| LGMN \| DISEASES 5641 \| LGMN \| DISEASES 2152 \| F3 \| DISEASES 2152 \| F3 \| DISEASES 153571 \| C5orf38 \| DISEASES 153571 \| C5orf38 \| DISEASES 55589 \| BMP2K \| DISEASES 55589 \| BMP2K \| DISEASES 51738 \| GHRL \| DISEASES 51738 \| GHRL \| DISEASES 3320 \| HSP90AA1 \| DISEASES 3320 \| HSP90AA1 \| DISEASES 245939 \| DEFB128 \| DISEASES 245939 \| DEFB128 \| DISEASES 8856 \| NR1I2 \| DISEASES 8856 \| NR1I2 \| DISEASES 283 \| ANG \| DISEASES 283 \| ANG \| DISEASES 468 \| ATF4 \| DISEASES 468 \| ATF4 \| DISEASES 1908 \| EDN3 \| DISEASES 1908 \| EDN3 \| DISEASES 51548 \| SIRT6 \| DISEASES 51548 \| SIRT6 \| DISEASES 3988 \| LIPA \| DISEASES 3988 \| LIPA \| DISEASES 114548 \| NLRP3 \| DISEASES 114548 \| NLRP3 \| DISEASES 4842 \| NOS1 \| DISEASES 4842 \| NOS1 \| DISEASES 57104 \| PNPLA2 \| DISEASES 57104 \| PNPLA2 \| DISEASES 7753 \| ZNF202 \| DISEASES 7753 \| ZNF202 \| DISEASES 7189 \| TRAF6 \| DISEASES 7189 \| TRAF6 \| DISEASES 3363 \| HTR7 \| DISEASES 3363 \| HTR7 \| DISEASES 3091 \| HIF1A \| DISEASES 3091 \| HIF1A \| DISEASES 6645 \| SNTB2 \| DISEASES 2246 \| FGF1 \| DISEASES 2246 \| FGF1 \| DISEASES 23583 \| SMUG1 \| DISEASES 23583 \| SMUG1 \| DISEASES 857 \| CAV1 \| DISEASES 857 \| CAV1 \| DISEASES 445329 \| SULT1A4 \| DISEASES 445329 \| SULT1A4 \| DISEASES 5329 \| PLAUR \| DISEASES 5329 \| PLAUR \| DISEASES 2309 \| FOXO3 \| DISEASES 2309 \| FOXO3 \| DISEASES 7060 \| THBS4 \| DISEASES 7060 \| THBS4 \| DISEASES 8459 \| TPST2 \| DISEASES 8459 \| TPST2 \| DISEASES 11188 \| NISCH \| DISEASES 11188 \| NISCH \| DISEASES 4602 \| MYB \| DISEASES 4602 \| MYB \| DISEASES 3329 \| HSPD1 \| DISEASES 3329 \| HSPD1 \| DISEASES 7100 \| TLR5 \| DISEASES 7100 \| TLR5 \| DISEASES 2358 \| FPR2 \| DISEASES 2358 \| FPR2 \| DISEASES 966 \| CD59 \| DISEASES 966 \| CD59 \| DISEASES 83860 \| TAF3 \| DISEASES 83860 \| TAF3 \| DISEASES 6609 \| SMPD1 \| DISEASES 6609 \| SMPD1 \| DISEASES 114897 \| C1QTNF1 \| DISEASES 114897 \| C1QTNF1 \| DISEASES 375056 \| MIA3 \| DISEASES 375056 \| MIA3 \| DISEASES 5781 \| PTPN11 \| DISEASES 5781 \| PTPN11 \| DISEASES 6614 \| SIGLEC1 \| DISEASES 6614 \| SIGLEC1 \| DISEASES 5747 \| PTK2 \| DISEASES 5747 \| PTK2 \| DISEASES 4306 \| NR3C2 \| DISEASES 4306 \| NR3C2 \| DISEASES 51094 \| ADIPOR1 \| DISEASES 51094 \| ADIPOR1 \| DISEASES 54345 \| SOX18 \| DISEASES 54345 \| SOX18 \| DISEASES 7137 \| TNNI3 \| DISEASES 7137 \| TNNI3 \| DISEASES 51513 \| ETV7 \| DISEASES 51513 \| ETV7 \| DISEASES 9588 \| PRDX6 \| DISEASES 9588 \| PRDX6 \| DISEASES 1508 \| CTSB \| DISEASES 1508 \| CTSB \| DISEASES 145264 \| SERPINA12 \| DISEASES 145264 \| SERPINA12 \| DISEASES 5174 \| PDZK1 \| DISEASES 5174 \| PDZK1 \| DISEASES 9536 \| PTGES \| DISEASES 9536 \| PTGES \| DISEASES 5962 \| RDX \| DISEASES 10811 \| NOXA1 \| DISEASES 10811 \| NOXA1 \| DISEASES 29949 \| IL19 \| DISEASES 29949 \| IL19 \| DISEASES 3146 \| HMGB1 \| DISEASES 3146 \| HMGB1 \| DISEASES 9474 \| ATG5 \| DISEASES 9474 \| ATG5 \| DISEASES 6818 \| SULT1A3 \| DISEASES 6818 \| SULT1A3 \| DISEASES 2701 \| GJA4 \| DISEASES 2701 \| GJA4 \| DISEASES 545 \| ATR \| DISEASES 545 \| ATR \| DISEASES 155 \| ADRB3 \| DISEASES 155 \| ADRB3 \| DISEASES 27068 \| PPA2 \| DISEASES 27068 \| PPA2 \| DISEASES 2100 \| ESR2 \| DISEASES 2100 \| ESR2 \| DISEASES 10313 \| RTN3 \| DISEASES 10313 \| RTN3 \| DISEASES 1003 \| CDH5 \| DISEASES 1003 \| CDH5 \| DISEASES 20 \| ABCA2 \| DISEASES 20 \| ABCA2 \| DISEASES 3605 \| IL17A \| DISEASES 3605 \| IL17A \| DISEASES 8720 \| MBTPS1 \| DISEASES 8720 \| MBTPS1 \| DISEASES 9962 \| SLC23A2 \| DISEASES 9962 \| SLC23A2 \| DISEASES 467 \| ATF3 \| DISEASES 467 \| ATF3 \| DISEASES 1499 \| CTNNB1 \| DISEASES 1499 \| CTNNB1 \| DISEASES 875 \| CBS \| DISEASES 875 \| CBS \| DISEASES 4929 \| NR4A2 \| DISEASES 4929 \| NR4A2 \| DISEASES 3638 \| INSIG1 \| DISEASES 3638 \| INSIG1 \| DISEASES 31 \| ACACA \| DISEASES 31 \| ACACA \| DISEASES 5606 \| MAP2K3 \| DISEASES 5606 \| MAP2K3 \| DISEASES 347 \| APOD \| DISEASES 5144 \| PDE4D \| DISEASES 5144 \| PDE4D \| DISEASES 222389 \| BEND7 \| DISEASES 222389 \| BEND7 \| DISEASES 3921 \| RPSA \| DISEASES 3921 \| RPSA \| DISEASES 4205 \| MEF2A \| DISEASES 4205 \| MEF2A \| DISEASES 5154 \| PDGFA \| DISEASES 5154 \| PDGFA \| DISEASES 2534 \| FYN \| DISEASES 2534 \| FYN \| DISEASES 2335 \| FN1 \| DISEASES 2335 \| FN1 \| DISEASES 2331 \| FMOD \| DISEASES 2331 \| FMOD \| DISEASES 8654 \| PDE5A \| DISEASES 8654 \| PDE5A \| DISEASES 728 \| C5AR1 \| DISEASES 728 \| C5AR1 \| DISEASES 100506658 \| OCLN \| DISEASES 100506658 \| OCLN \| DISEASES 80781 \| COL18A1 \| DISEASES 80781 \| COL18A1 \| DISEASES 1785 \| DNM2 \| DISEASES 1785 \| DNM2 \| DISEASES 5343 \| PLGLB1 \| DISEASES 5343 \| PLGLB1 \| DISEASES 355 \| FAS \| DISEASES 355 \| FAS \| DISEASES 5265 \| SERPINA1 \| DISEASES 5265 \| SERPINA1 \| DISEASES 6720 \| SREBF1 \| DISEASES 6720 \| SREBF1 \| DISEASES 3240 \| HP \| DISEASES 3240 \| HP \| DISEASES 140885 \| SIRPA \| DISEASES 140885 \| SIRPA \| DISEASES 10507 \| SEMA4D \| DISEASES 6288 \| SAA1 \| DISEASES 6288 \| SAA1 \| DISEASES 2224 \| FDPS \| DISEASES 2224 \| FDPS \| DISEASES 3683 \| ITGAL \| DISEASES 3683 \| ITGAL \| DISEASES 29116 \| MYLIP \| DISEASES 29116 \| MYLIP \| DISEASES 246778 \| IL27 \| DISEASES 246778 \| IL27 \| DISEASES 8751 \| ADAM15 \| DISEASES 8751 \| ADAM15 \| DISEASES 801 \| CALM1 \| DISEASES 801 \| CALM1 \| DISEASES 79602 \| ADIPOR2 \| DISEASES 79602 \| ADIPOR2 \| DISEASES 343263 \| MYBPHL \| DISEASES 343263 \| MYBPHL \| DISEASES 3663 \| IRF5 \| DISEASES 3663 \| IRF5 \| DISEASES 50485 \| SMARCAL1 \| DISEASES 57209 \| ZNF248 \| DISEASES 57209 \| ZNF248 \| DISEASES 60 \| ACTB \| DISEASES 60 \| ACTB \| DISEASES 2695 \| GIP \| DISEASES 2695 \| GIP \| DISEASES 2181 \| ACSL3 \| DISEASES 337 \| APOA4 \| DISEASES 337 \| APOA4 \| DISEASES 1903 \| S1PR3 \| DISEASES 1903 \| S1PR3 \| DISEASES 6714 \| SRC \| DISEASES 6714 \| SRC \| DISEASES 1524 \| CX3CR1 \| DISEASES 1524 \| CX3CR1 \| DISEASES 3182 \| HNRNPAB \| DISEASES 51592 \| TRIM33 \| DISEASES 51592 \| TRIM33 \| DISEASES 841 \| CASP8 \| DISEASES 841 \| CASP8 \| DISEASES 2213 \| FCGR2B \| DISEASES 2213 \| FCGR2B \| DISEASES 6525 \| SMTN \| DISEASES 6525 \| SMTN \| DISEASES 6364 \| CCL20 \| DISEASES 6364 \| CCL20 \| DISEASES 1902 \| LPAR1 \| DISEASES 1902 \| LPAR1 \| DISEASES 4217 \| MAP3K5 \| DISEASES 4217 \| MAP3K5 \| DISEASES 5139 \| PDE3A \| DISEASES 166929 \| SGMS2 \| DISEASES 166929 \| SGMS2 \| DISEASES 9332 \| CD163 \| DISEASES 9332 \| CD163 \| DISEASES 5294 \| PIK3CG \| DISEASES 5294 \| PIK3CG \| DISEASES 1786 \| DNMT1 \| DISEASES 1786 \| DNMT1 \| DISEASES 4151 \| MB \| DISEASES 4151 \| MB \| DISEASES 11005 \| SPINK5 \| DISEASES 11005 \| SPINK5 \| DISEASES 7037 \| TFRC \| DISEASES 7037 \| TFRC \| DISEASES 2157 \| F8 \| DISEASES 2157 \| F8 \| DISEASES 4478 \| MSN \| DISEASES 3164 \| NR4A1 \| DISEASES 3164 \| NR4A1 \| DISEASES 4638 \| MYLK \| DISEASES 4638 \| MYLK \| DISEASES 5599 \| MAPK8 \| DISEASES 5599 \| MAPK8 \| DISEASES 170482 \| CLEC4C \| DISEASES 170482 \| CLEC4C \| DISEASES 4311 \| MME \| DISEASES 4311 \| MME \| DISEASES 1066 \| CES1 \| DISEASES 1066 \| CES1 \| DISEASES 1803 \| DPP4 \| DISEASES 1803 \| DPP4 \| DISEASES 54106 \| TLR9 \| DISEASES 54106 \| TLR9 \| DISEASES 5167 \| ENPP1 \| DISEASES 5167 \| ENPP1 \| DISEASES 2673 \| GFPT1 \| DISEASES 2673 \| GFPT1 \| DISEASES 6772 \| STAT1 \| DISEASES 6772 \| STAT1 \| DISEASES 6721 \| SREBF2 \| DISEASES 6721 \| SREBF2 \| DISEASES 4519 \| MT-CYB \| DISEASES 4519 \| MT-CYB \| DISEASES 2475 \| MTOR \| DISEASES 2475 \| MTOR \| DISEASES 5742 \| PTGS1 \| DISEASES 5742 \| PTGS1 \| DISEASES 800 \| CALD1 \| DISEASES 800 \| CALD1 \| DISEASES 259230 \| SGMS1 \| DISEASES 259230 \| SGMS1 \| DISEASES 10724 \| MGEA5 \| DISEASES 4283 \| CXCL9 \| DISEASES 4283 \| CXCL9 \| DISEASES 7096 \| TLR1 \| DISEASES 7096 \| TLR1 \| DISEASES 9619 \| ABCG1 \| DISEASES 9619 \| ABCG1 \| DISEASES 8678 \| BECN1 \| DISEASES 8678 \| BECN1 \| DISEASES 23038 \| WDTC1 \| DISEASES 23038 \| WDTC1 \| DISEASES 7052 \| TGM2 \| DISEASES 7052 \| TGM2 \| DISEASES 961 \| CD47 \| DISEASES 961 \| CD47 \| DISEASES 29948 \| OSGIN1 \| DISEASES 29948 \| OSGIN1 \| DISEASES 3775 \| KCNK1 \| DISEASES 3775 \| KCNK1 \| DISEASES 183 \| AGT \| DISEASES 183 \| AGT \| DISEASES 22796 \| COG2 \| DISEASES 22796 \| COG2 \| DISEASES 28514 \| DLL1 \| DISEASES 28514 \| DLL1 \| DISEASES 116841 \| SNAP47 \| DISEASES 116841 \| SNAP47 \| DISEASES 7058 \| THBS2 \| DISEASES 7058 \| THBS2 \| DISEASES 142 \| PARP1 \| DISEASES 142 \| PARP1 \| DISEASES 2058 \| EPRS \| DISEASES 2058 \| EPRS \| DISEASES 7042 \| TGFB2 \| DISEASES 7042 \| TGFB2 \| DISEASES 3664 \| IRF6 \| DISEASES 3664 \| IRF6 \| DISEASES 1378 \| CR1 \| DISEASES 1378 \| CR1 \| DISEASES 6648 \| SOD2 \| DISEASES 6648 \| SOD2 \| DISEASES 1118 \| CHIT1 \| DISEASES 1118 \| CHIT1 \| DISEASES 7139 \| TNNT2 \| DISEASES 7139 \| TNNT2 \| DISEASES 2494 \| NR5A2 \| DISEASES 2494 \| NR5A2 \| DISEASES 5788 \| PTPRC \| DISEASES 5788 \| PTPRC \| DISEASES 5321 \| PLA2G4A \| DISEASES 5321 \| PLA2G4A \| DISEASES 5743 \| PTGS2 \| DISEASES 5743 \| PTGS2 \| DISEASES 6045 \| RNF2 \| DISEASES 6045 \| RNF2 \| DISEASES 4688 \| NCF2 \| DISEASES 4688 \| NCF2 \| DISEASES 57710 \| KIAA1614 \| DISEASES 57710 \| KIAA1614 \| DISEASES 6646 \| SOAT1 \| DISEASES 6646 \| SOAT1 \| DISEASES 462 \| SERPINC1 \| DISEASES 462 \| SERPINC1 \| DISEASES 356 \| FASLG \| DISEASES 356 \| FASLG \| DISEASES 92346 \| C1orf105 \| DISEASES 92346 \| C1orf105 \| DISEASES 2328 \| FMO3 \| DISEASES 2328 \| FMO3 \| DISEASES 4921 \| DDR2 \| DISEASES 4921 \| DDR2 \| DISEASES 22926 \| ATF6 \| DISEASES 22926 \| ATF6 \| DISEASES 26002 \| MOXD1 \| DISEASES 26002 \| MOXD1 \| DISEASES 2214 \| FCGR3A \| DISEASES 2214 \| FCGR3A \| DISEASES 1490 \| CTGF \| DISEASES 1490 \| CTGF \| DISEASES 336 \| APOA2 \| DISEASES 336 \| APOA2 \| DISEASES 7391 \| USF1 \| DISEASES 7391 \| USF1 \| DISEASES 5824 \| PEX19 \| DISEASES 383 \| ARG1 \| DISEASES 383 \| ARG1 \| DISEASES 9447 \| AIM2 \| DISEASES 9447 \| AIM2 \| DISEASES 911 \| CD1C \| DISEASES 911 \| CD1C \| DISEASES 912 \| CD1D \| DISEASES 912 \| CD1D \| DISEASES 2117 \| ETV3 \| DISEASES 2117 \| ETV3 \| DISEASES 632 \| BGLAP \| DISEASES 632 \| BGLAP \| DISEASES 4000 \| LMNA \| DISEASES 4000 \| LMNA \| DISEASES 10924 \| SMPDL3A \| DISEASES 10924 \| SMPDL3A \| DISEASES 6283 \| S100A12 \| DISEASES 6283 \| S100A12 \| DISEASES 6280 \| S100A9 \| DISEASES 6280 \| S100A9 \| DISEASES 8991 \| SELENBP1 \| DISEASES 8991 \| SELENBP1 \| DISEASES 5654 \| HTRA1 \| DISEASES 1520 \| CTSS \| DISEASES 1520 \| CTSS \| DISEASES 8349 \| HIST2H2BE \| DISEASES 2209 \| FCGR1A \| DISEASES 2209 \| FCGR1A \| DISEASES 5406 \| PNLIP \| DISEASES 5406 \| PNLIP \| DISEASES 9557 \| CHD1L \| DISEASES 9557 \| CHD1L \| DISEASES 10628 \| TXNIP \| DISEASES 10628 \| TXNIP \| DISEASES 1268 \| CNR1 \| DISEASES 1268 \| CNR1 \| DISEASES 4803 \| NGF \| DISEASES 4803 \| NGF \| DISEASES 9446 \| GSTO1 \| DISEASES 9446 \| GSTO1 \| DISEASES 5016 \| OVGP1 \| DISEASES 5016 \| OVGP1 \| DISEASES 57412 \| AS3MT \| DISEASES 57412 \| AS3MT \| DISEASES 118980 \| SFXN2 \| DISEASES 118980 \| SFXN2 \| DISEASES 84722 \| PSRC1 \| DISEASES 84722 \| PSRC1 \| DISEASES 3654 \| IRAK1 \| DISEASES 3654 \| IRAK1 \| DISEASES 83401 \| ELOVL3 \| DISEASES 83401 \| ELOVL3 \| DISEASES 2730 \| GCLM \| DISEASES 2730 \| GCLM \| DISEASES 1137 \| CHRNA4 \| DISEASES 1137 \| CHRNA4 \| DISEASES 6319 \| SCD \| DISEASES 6319 \| SCD \| DISEASES 1147 \| CHUK \| DISEASES 1147 \| CHUK \| DISEASES 1369 \| CPN1 \| DISEASES 1369 \| CPN1 \| DISEASES 51076 \| CUTC \| DISEASES 51076 \| CUTC \| DISEASES 8804 \| CREG1 \| DISEASES 8804 \| CREG1 \| DISEASES 60495 \| HPSE2 \| DISEASES 60495 \| HPSE2 \| DISEASES 2258 \| FGF13 \| DISEASES 2258 \| FGF13 \| DISEASES 959 \| CD40LG \| DISEASES 959 \| CD40LG \| DISEASES 55361 \| PI4K2A \| DISEASES 55361 \| PI4K2A \| DISEASES 5688 \| PSMA7 \| DISEASES 5688 \| PSMA7 \| DISEASES 1491 \| CTH \| DISEASES 1491 \| CTH \| DISEASES 2941 \| GSTA4 \| DISEASES 2941 \| GSTA4 \| DISEASES 27329 \| ANGPTL3 \| DISEASES 27329 \| ANGPTL3 \| DISEASES 1791 \| DNTT \| DISEASES 1791 \| DNTT \| DISEASES 1573 \| CYP2J2 \| DISEASES 1573 \| CYP2J2 \| DISEASES 953 \| ENTPD1 \| DISEASES 953 \| ENTPD1 \| DISEASES 3725 \| JUN \| DISEASES 3725 \| JUN \| DISEASES 860 \| RUNX2 \| DISEASES 860 \| RUNX2 \| DISEASES 5950 \| RBP4 \| DISEASES 5950 \| RBP4 \| DISEASES 5770 \| PTPN1 \| DISEASES 5730 \| PTGDS \| DISEASES 5730 \| PTGDS \| DISEASES 9023 \| CH25H \| DISEASES 9023 \| CH25H \| DISEASES 186 \| AGTR2 \| DISEASES 186 \| AGTR2 \| DISEASES 11093 \| ADAMTS13 \| DISEASES 11093 \| ADAMTS13 \| DISEASES 5728 \| PTEN \| DISEASES 5728 \| PTEN \| DISEASES 7422 \| VEGFA \| DISEASES 7422 \| VEGFA \| DISEASES 1056 \| CEL \| DISEASES 1056 \| CEL \| DISEASES 2889 \| RAPGEF1 \| DISEASES 2889 \| RAPGEF1 \| DISEASES 958 \| CD40 \| DISEASES 958 \| CD40 \| DISEASES 6441 \| SFTPD \| DISEASES 6441 \| SFTPD \| DISEASES 4318 \| MMP9 \| DISEASES 4318 \| MMP9 \| DISEASES 5360 \| PLTP \| DISEASES 5360 \| PLTP \| DISEASES 7075 \| TIE1 \| DISEASES 7075 \| TIE1 \| DISEASES 5476 \| CTSA \| DISEASES 5476 \| CTSA \| DISEASES 1907 \| EDN2 \| DISEASES 1907 \| EDN2 \| DISEASES 6385 \| SDC4 \| DISEASES 6385 \| SDC4 \| DISEASES 5328 \| PLAU \| DISEASES 5328 \| PLAU \| DISEASES 310 \| ANXA7 \| DISEASES 310 \| ANXA7 \| DISEASES 1759 \| DNM1 \| DISEASES 1759 \| DNM1 \| DISEASES 27035 \| NOX1 \| DISEASES 27035 \| NOX1 \| DISEASES 2022 \| ENG \| DISEASES 2022 \| ENG \| DISEASES 2740 \| GLP1R \| DISEASES 2740 \| GLP1R \| DISEASES 1025 \| CDK9 \| DISEASES 1025 \| CDK9 \| DISEASES 10800 \| CYSLTR1 \| DISEASES 10800 \| CYSLTR1 \| DISEASES 2739 \| GLO1 \| DISEASES 2739 \| GLO1 \| DISEASES 23452 \| ANGPTL2 \| DISEASES 23452 \| ANGPTL2 \| DISEASES 252995 \| FNDC5 \| DISEASES 252995 \| FNDC5 \| DISEASES 286205 \| SCAI \| DISEASES 286205 \| SCAI \| DISEASES 80312 \| TET1 \| DISEASES 80312 \| TET1 \| DISEASES 2833 \| CXCR3 \| DISEASES 2833 \| CXCR3 \| DISEASES 2170 \| FABP3 \| DISEASES 2170 \| FABP3 \| DISEASES 22839 \| DLGAP4 \| DISEASES 22839 \| DLGAP4 \| DISEASES 4153 \| MBL2 \| DISEASES 4153 \| MBL2 \| DISEASES 7099 \| TLR4 \| DISEASES 7099 \| TLR4 \| DISEASES 5592 \| PRKG1 \| DISEASES 5592 \| PRKG1 \| DISEASES 9966 \| TNFSF15 \| DISEASES 9966 \| TNFSF15 \| DISEASES 26119 \| LDLRAP1 \| DISEASES 26119 \| LDLRAP1 \| DISEASES 240 \| ALOX5 \| DISEASES 240 \| ALOX5 \| DISEASES 1269 \| CNR2 \| DISEASES 1269 \| CNR2 \| DISEASES 55741 \| EDEM2 \| DISEASES 55741 \| EDEM2 \| DISEASES 7295 \| TXN \| DISEASES 7295 \| TXN \| DISEASES 158833 \| AWAT1 \| DISEASES 158833 \| AWAT1 \| DISEASES 1896 \| EDA \| DISEASES 3399 \| ID3 \| DISEASES 3399 \| ID3 \| DISEASES 8518 \| IKBKAP \| DISEASES 8518 \| IKBKAP \| DISEASES 9314 \| KLF4 \| DISEASES 9314 \| KLF4 \| DISEASES 367 \| AR \| DISEASES 367 \| AR \| DISEASES 3339 \| HSPG2 \| DISEASES 3339 \| HSPG2 \| DISEASES 19 \| ABCA1 \| DISEASES 19 \| ABCA1 \| DISEASES 1889 \| ECE1 \| DISEASES 1889 \| ECE1 \| DISEASES 7046 \| TGFBR1 \| DISEASES 7046 \| TGFBR1 \| DISEASES 1306 \| COL15A1 \| DISEASES 1306 \| COL15A1 \| DISEASES 4855 \| NOTCH4 \| DISEASES 4855 \| NOTCH4 \| DISEASES 177 \| AGER \| DISEASES 177 \| AGER \| DISEASES 26279 \| PLA2G2D \| DISEASES 26279 \| PLA2G2D \| DISEASES 5320 \| PLA2G2A \| DISEASES 5320 \| PLA2G2A \| DISEASES 2159 \| F10 \| DISEASES 2159 \| F10 \| DISEASES 2155 \| F7 \| DISEASES 2155 \| F7 \| DISEASES 3303 \| HSPA1A \| DISEASES 3303 \| HSPA1A \| DISEASES 7407 \| VARS \| DISEASES 7407 \| VARS \| DISEASES 6850 \| SYK \| DISEASES 6850 \| SYK \| DISEASES 23564 \| DDAH2 \| DISEASES 23564 \| DDAH2 \| DISEASES 79048 \| SECISBP2 \| DISEASES 79048 \| SECISBP2 \| DISEASES 1282 \| COL4A1 \| DISEASES 1282 \| COL4A1 \| DISEASES 3055 \| HCK \| DISEASES 3055 \| HCK \| DISEASES 8660 \| IRS2 \| DISEASES 8660 \| IRS2 \| DISEASES 10673 \| TNFSF13B \| DISEASES 10673 \| TNFSF13B \| DISEASES 55937 \| APOM \| DISEASES 55937 \| APOM \| DISEASES 10006 \| ABI1 \| DISEASES 10006 \| ABI1 \| DISEASES 50943 \| FOXP3 \| DISEASES 50943 \| FOXP3 \| DISEASES 7133 \| TNFRSF1B \| DISEASES 7133 \| TNFRSF1B \| DISEASES 4879 \| NPPB \| DISEASES 4879 \| NPPB \| DISEASES 4878 \| NPPA \| DISEASES 4878 \| NPPA \| DISEASES 780 \| DDR1 \| DISEASES 780 \| DDR1 \| DISEASES 4524 \| MTHFR \| DISEASES 4524 \| MTHFR \| DISEASES 1471 \| CST3 \| DISEASES 1471 \| CST3 \| DISEASES 160897 \| GPR180 \| DISEASES 160897 \| GPR180 \| DISEASES 1676 \| DFFA \| DISEASES 1676 \| DFFA \| DISEASES 7056 \| THBD \| DISEASES 7056 \| THBD \| DISEASES 1910 \| EDNRB \| DISEASES 1910 \| EDNRB \| DISEASES 7536 \| SF1 \| DISEASES 7536 \| SF1 \| DISEASES 765 \| CA6 \| DISEASES 765 \| CA6 \| DISEASES 3604 \| TNFRSF9 \| DISEASES 3604 \| TNFRSF9 \| DISEASES 688 \| KLF5 \| DISEASES 688 \| KLF5 \| DISEASES 8029 \| CUBN \| DISEASES 8029 \| CUBN \| DISEASES 10050 \| SLC17A4 \| DISEASES 10050 \| SLC17A4 \| DISEASES 5100 \| PCDH8 \| DISEASES 5100 \| PCDH8 \| DISEASES 4609 \| MYC \| DISEASES 4609 \| MYC \| DISEASES 6354 \| CCL7 \| DISEASES 6354 \| CCL7 \| DISEASES 1536 \| CYBB \| DISEASES 1536 \| CYBB \| DISEASES 3356 \| HTR2A \| DISEASES 3356 \| HTR2A \| DISEASES 285440 \| CYP4V2 \| DISEASES 285440 \| CYP4V2 \| DISEASES 650 \| BMP2 \| DISEASES 650 \| BMP2 \| DISEASES 9308 \| CD83 \| DISEASES 9308 \| CD83 \| DISEASES 7293 \| TNFRSF4 \| DISEASES 7293 \| TNFRSF4 \| DISEASES 23408 \| SIRT5 \| DISEASES 23408 \| SIRT5 \| DISEASES 1906 \| EDN1 \| DISEASES 1906 \| EDN1 \| DISEASES 2308 \| FOXO1 \| DISEASES 2308 \| FOXO1 \| DISEASES 7222 \| TRPC3 \| DISEASES 7222 \| TRPC3 \| DISEASES 1543 \| CYP1A1 \| DISEASES 1543 \| CYP1A1 \| DISEASES 7010 \| TEK \| DISEASES 7010 \| TEK \| DISEASES 79689 \| STEAP4 \| DISEASES 79689 \| STEAP4 \| DISEASES 9365 \| KL \| DISEASES 9365 \| KL \| DISEASES 247 \| ALOX15B \| DISEASES 247 \| ALOX15B \| DISEASES 3456 \| IFNB1 \| DISEASES 3456 \| IFNB1 \| DISEASES 551 \| AVP \| DISEASES 551 \| AVP \| DISEASES 6462 \| SHBG \| DISEASES 6462 \| SHBG \| DISEASES 241 \| ALOX5AP \| DISEASES 241 \| ALOX5AP \| DISEASES 51284 \| TLR7 \| DISEASES 51284 \| TLR7 \| DISEASES 1992 \| SERPINB1 \| DISEASES 3486 \| IGFBP3 \| DISEASES 3486 \| IGFBP3 \| DISEASES 11082 \| ESM1 \| DISEASES 11082 \| ESM1 \| DISEASES 90865 \| IL33 \| DISEASES 90865 \| IL33 \| DISEASES 3717 \| JAK2 \| DISEASES 3717 \| JAK2 \| DISEASES 23464 \| GCAT \| DISEASES 23464 \| GCAT \| DISEASES 440503 \| PLIN5 \| DISEASES 440503 \| PLIN5 \| DISEASES 10333 \| TLR6 \| DISEASES 10333 \| TLR6 \| DISEASES 7436 \| VLDLR \| DISEASES 7436 \| VLDLR \| DISEASES 6649 \| SOD3 \| DISEASES 6649 \| SOD3 \| DISEASES 124220 \| ZG16B \| DISEASES 124220 \| ZG16B \| DISEASES 6624 \| FSCN1 \| DISEASES 6624 \| FSCN1 \| DISEASES 83650 \| SLC35G5 \| DISEASES 23410 \| SIRT3 \| DISEASES 23410 \| SIRT3 \| DISEASES 11173 \| ADAMTS7 \| DISEASES 11173 \| ADAMTS7 \| DISEASES 2878 \| GPX3 \| DISEASES 2878 \| GPX3 \| DISEASES 79400 \| NOX5 \| DISEASES 79400 \| NOX5 \| DISEASES 55576 \| STAB2 \| DISEASES 55576 \| STAB2 \| DISEASES 50506 \| DUOX2 \| DISEASES 50506 \| DUOX2 \| DISEASES 10411 \| RAPGEF3 \| DISEASES 10411 \| RAPGEF3 \| DISEASES 6263 \| RYR3 \| DISEASES 6263 \| RYR3 \| DISEASES 53353 \| LRP1B \| DISEASES 53353 \| LRP1B \| DISEASES 8878 \| SQSTM1 \| DISEASES 8878 \| SQSTM1 \| DISEASES 338442 \| HCAR2 \| DISEASES 338442 \| HCAR2 \| DISEASES 22900 \| CARD8 \| DISEASES 22900 \| CARD8 \| DISEASES 11132 \| CAPN10 \| DISEASES 11132 \| CAPN10 \| DISEASES 208 \| AKT2 \| DISEASES 208 \| AKT2 \| DISEASES 10203 \| CALCRL \| DISEASES 2113 \| ETS1 \| DISEASES 2113 \| ETS1 \| DISEASES 80310 \| PDGFD \| DISEASES 80310 \| PDGFD \| DISEASES 23041 \| MON2 \| DISEASES 23041 \| MON2 \| DISEASES 2172 \| FABP6 \| DISEASES 2172 \| FABP6 \| DISEASES 5627 \| PROS1 \| DISEASES 5627 \| PROS1 \| DISEASES 9560 \| CCL4L2 \| DISEASES 9560 \| CCL4L2 \| DISEASES 6355 \| CCL8 \| DISEASES 6355 \| CCL8 \| DISEASES 91807 \| MYLK3 \| DISEASES 64115 \| C10orf54 \| DISEASES 64115 \| C10orf54 \| DISEASES 79001 \| VKORC1 \| DISEASES 79001 \| VKORC1 \| DISEASES 6696 \| SPP1 \| DISEASES 6696 \| SPP1 \| DISEASES 2643 \| GCH1 \| DISEASES 2643 \| GCH1 \| DISEASES 2919 \| CXCL1 \| DISEASES 2919 \| CXCL1 \| DISEASES 6387 \| CXCL12 \| DISEASES 6387 \| CXCL12 \| DISEASES 831 \| CAST \| DISEASES 5137 \| PDE1C \| DISEASES 5137 \| PDE1C \| DISEASES 4629 \| MYH11 \| DISEASES 4629 \| MYH11 \| DISEASES 84807 \| NFKBID \| DISEASES 84807 \| NFKBID \| DISEASES 3676 \| ITGA4 \| DISEASES 3676 \| ITGA4 \| DISEASES 3269 \| HRH1 \| DISEASES 3269 \| HRH1 \| DISEASES 10786 \| SLC17A3 \| DISEASES 10786 \| SLC17A3 \| DISEASES 4780 \| NFE2L2 \| DISEASES 4780 \| NFE2L2 \| DISEASES 11069 \| RAPGEF4 \| DISEASES 4357 \| MPST \| DISEASES 4357 \| MPST \| DISEASES 23365 \| ARHGEF12 \| DISEASES 23365 \| ARHGEF12 \| DISEASES 5609 \| MAP2K7 \| DISEASES 5609 \| MAP2K7 \| DISEASES 594857 \| NPS \| DISEASES 594857 \| NPS \| DISEASES 319 \| APOF \| DISEASES 319 \| APOF \| DISEASES 7442 \| TRPV1 \| DISEASES 7442 \| TRPV1 \| DISEASES 375704 \| ENHO \| DISEASES 375704 \| ENHO \| DISEASES 6093 \| ROCK1 \| DISEASES 6093 \| ROCK1 \| DISEASES 4752 \| NEK3 \| DISEASES 4752 \| NEK3 \| DISEASES 8091 \| HMGA2 \| DISEASES 8091 \| HMGA2 \| DISEASES 9718 \| ECE2 \| DISEASES 9718 \| ECE2 \| DISEASES 5970 \| RELA \| DISEASES 5970 \| RELA \| DISEASES 340273 \| ABCB5 \| DISEASES 340273 \| ABCB5 \| DISEASES 1994 \| ELAVL1 \| DISEASES 1994 \| ELAVL1 \| DISEASES 8995 \| TNFSF18 \| DISEASES 8995 \| TNFSF18 \| DISEASES 333932 \| HIST2H3A \| DISEASES 333932 \| HIST2H3A \| DISEASES 728441 \| GGT2 \| DISEASES 728441 \| GGT2 \| DISEASES 7018 \| TF \| DISEASES 7018 \| TF \| DISEASES 1052 \| CEBPD \| DISEASES 1052 \| CEBPD \| DISEASES 6295 \| SAG \| DISEASES 6295 \| SAG \| DISEASES 7852 \| CXCR4 \| DISEASES 7852 \| CXCR4 \| DISEASES 57703 \| CWC22 \| DISEASES 501 \| ALDH7A1 \| DISEASES 501 \| ALDH7A1 \| DISEASES 51449 \| PCYOX1 \| DISEASES 51449 \| PCYOX1 \| DISEASES 2641 \| GCG \| DISEASES 2641 \| GCG \| DISEASES 1385 \| CREB1 \| DISEASES 1385 \| CREB1 \| DISEASES 10062 \| NR1H3 \| DISEASES 10062 \| NR1H3 \| DISEASES 5601 \| MAPK9 \| DISEASES 5601 \| MAPK9 \| DISEASES 6916 \| TBXAS1 \| DISEASES 6916 \| TBXAS1 \| DISEASES 51135 \| IRAK4 \| DISEASES 51135 \| IRAK4 \| DISEASES 8705 \| B3GALT4 \| DISEASES 8705 \| B3GALT4 \| DISEASES 9564 \| BCAR1 \| DISEASES 9564 \| BCAR1 \| DISEASES 3481 \| IGF2 \| DISEASES 3481 \| IGF2 \| DISEASES 2260 \| FGFR1 \| DISEASES 2260 \| FGFR1 \| DISEASES 6915 \| TBXA2R \| DISEASES 6915 \| TBXA2R \| DISEASES 8671 \| SLC4A4 \| DISEASES 8399 \| PLA2G10 \| DISEASES 8399 \| PLA2G10 \| DISEASES 197 \| AHSG \| DISEASES 197 \| AHSG \| DISEASES 1029 \| CDKN2A \| DISEASES 1029 \| CDKN2A \| DISEASES 23705 \| CADM1 \| DISEASES 23705 \| CADM1 \| DISEASES 83700 \| JAM3 \| DISEASES 83700 \| JAM3 \| DISEASES 10725 \| NFAT5 \| DISEASES 10725 \| NFAT5 \| DISEASES 3338 \| DNAJC4 \| DISEASES 3338 \| DNAJC4 \| DISEASES 79094 \| CHAC1 \| DISEASES 79094 \| CHAC1 \| DISEASES 960 \| CD44 \| DISEASES 960 \| CD44 \| DISEASES 7124 \| TNF \| DISEASES 7124 \| TNF \| DISEASES 3491 \| CYR61 \| DISEASES 3491 \| CYR61 \| DISEASES 84256 \| FLYWCH1 \| DISEASES 84256 \| FLYWCH1 \| DISEASES 387 \| RHOA \| DISEASES 387 \| RHOA \| DISEASES 6464 \| SHC1 \| DISEASES 6464 \| SHC1 \| DISEASES 4615 \| MYD88 \| DISEASES 4615 \| MYD88 \| DISEASES 11155 \| LDB3 \| DISEASES 2081 \| ERN1 \| DISEASES 2081 \| ERN1 \| DISEASES 93649 \| MYOCD \| DISEASES 93649 \| MYOCD \| DISEASES 5706 \| PSMC6 \| DISEASES 5706 \| PSMC6 \| DISEASES 4049 \| LTA \| DISEASES 4049 \| LTA \| DISEASES 5229 \| PGGT1B \| DISEASES 5229 \| PGGT1B \| DISEASES 388372 \| CCL4L1 \| DISEASES 388372 \| CCL4L1 \| DISEASES 9498 \| SLC4A8 \| DISEASES 9498 \| SLC4A8 \| DISEASES 2876 \| GPX1 \| DISEASES 2876 \| GPX1 \| DISEASES 9734 \| HDAC9 \| DISEASES 9734 \| HDAC9 \| DISEASES 1012 \| CDH13 \| DISEASES 1012 \| CDH13 \| DISEASES 5578 \| PRKCA \| DISEASES 5578 \| PRKCA \| DISEASES 6358 \| CCL14 \| DISEASES 6358 \| CCL14 \| DISEASES 1154 \| CISH \| DISEASES 1154 \| CISH \| DISEASES 834 \| CASP1 \| DISEASES 834 \| CASP1 \| DISEASES 8439 \| NSMAF \| DISEASES 8439 \| NSMAF \| DISEASES 10335 \| MRVI1 \| DISEASES 10335 \| MRVI1 \| DISEASES 3586 \| IL10 \| DISEASES 3586 \| IL10 \| DISEASES 114883 \| OSBPL9 \| DISEASES 114883 \| OSBPL9 \| DISEASES 123624 \| AGBL1 \| DISEASES 123624 \| AGBL1 \| DISEASES 54677 \| CROT \| DISEASES 54677 \| CROT \| DISEASES 627 \| BDNF \| DISEASES 8842 \| PROM1 \| DISEASES 8842 \| PROM1 \| DISEASES 133396 \| IL31RA \| DISEASES 133396 \| IL31RA \| DISEASES 721 \| C4B \| DISEASES 721 \| C4B \| DISEASES 3077 \| HFE \| DISEASES 79068 \| FTO \| DISEASES 79068 \| FTO \| DISEASES 5478 \| PPIA \| DISEASES 5478 \| PPIA \| DISEASES 8754 \| ADAM9 \| DISEASES 8754 \| ADAM9 \| DISEASES 6256 \| RXRA \| DISEASES 6256 \| RXRA \| DISEASES 846 \| CASR \| DISEASES 846 \| CASR \| DISEASES 2649 \| NR6A1 \| DISEASES 11267 \| SNF8 \| DISEASES 11267 \| SNF8 \| DISEASES 2638 \| GC \| DISEASES 2638 \| GC \| DISEASES 56034 \| PDGFC \| DISEASES 56034 \| PDGFC \| DISEASES 81792 \| ADAMTS12 \| DISEASES 51428 \| DDX41 \| DISEASES 51428 \| DDX41 \| DISEASES 100506742 \| CASP12 \| DISEASES 100506742 \| CASP12 \| DISEASES 23022 \| PALLD \| DISEASES 23022 \| PALLD \| DISEASES 2920 \| CXCL2 \| DISEASES 2920 \| CXCL2 \| DISEASES 9948 \| WDR1 \| DISEASES 9948 \| WDR1 \| DISEASES 284 \| ANGPT1 \| DISEASES 284 \| ANGPT1 \| DISEASES 151306 \| GPBAR1 \| DISEASES 151306 \| GPBAR1 \| DISEASES 4067 \| LYN \| DISEASES 4067 \| LYN \| DISEASES 51366 \| UBR5 \| DISEASES 51366 \| UBR5 \| DISEASES 2053 \| EPHX2 \| DISEASES 3551 \| IKBKB \| DISEASES 3551 \| IKBKB \| DISEASES 168455 \| CCDC71L \| DISEASES 168455 \| CCDC71L \| DISEASES 56114 \| PCDHGA1 \| DISEASES 56114 \| PCDHGA1 \| DISEASES 9404 \| LPXN \| DISEASES 9404 \| LPXN \| DISEASES 90378 \| SAMD1 \| DISEASES 90378 \| SAMD1 \| DISEASES 9776 \| ATG13 \| DISEASES 9776 \| ATG13 \| DISEASES 56413 \| LTB4R2 \| DISEASES 56413 \| LTB4R2 \| DISEASES 7296 \| TXNRD1 \| DISEASES 7296 \| TXNRD1 \| DISEASES 6195 \| RPS6KA1 \| DISEASES 6195 \| RPS6KA1 \| DISEASES 8843 \| HCAR3 \| DISEASES 8843 \| HCAR3 \| DISEASES 930 \| CD19 \| DISEASES 930 \| CD19 \| DISEASES 142891 \| SAMD8 \| DISEASES 142891 \| SAMD8 \| DISEASES 140836 \| BANF2 \| DISEASES 140836 \| BANF2 \| DISEASES 51271 \| UBAP1 \| DISEASES 51271 \| UBAP1 \| DISEASES 3684 \| ITGAM \| DISEASES 3684 \| ITGAM \| DISEASES 5027 \| P2RX7 \| DISEASES 5027 \| P2RX7 \| DISEASES 57552 \| NCEH1 \| DISEASES 57552 \| NCEH1 \| DISEASES 6934 \| TCF7L2 \| DISEASES 6934 \| TCF7L2 \| DISEASES 5125 \| PCSK5 \| DISEASES 5125 \| PCSK5 \| DISEASES 9971 \| NR1H4 \| DISEASES 9971 \| NR1H4 \| DISEASES 7421 \| VDR \| DISEASES 7421 \| VDR \| DISEASES 8972 \| MGAM \| DISEASES 8972 \| MGAM \| DISEASES 1649 \| DDIT3 \| DISEASES 1649 \| DDIT3 \| DISEASES 5228 \| PGF \| DISEASES 5228 \| PGF \| DISEASES 8742 \| TNFSF12 \| DISEASES 8742 \| TNFSF12 \| DISEASES 567 \| B2M \| DISEASES 567 \| B2M \| DISEASES 3949 \| LDLR \| DISEASES 3949 \| LDLR \| DISEASES 124491 \| TMEM170A \| DISEASES 124491 \| TMEM170A \| DISEASES 389422 \| C6orf183 \| DISEASES 389422 \| C6orf183 \| DISEASES 55911 \| APOBR \| DISEASES 55911 \| APOBR \| DISEASES 3316 \| HSPB2 \| DISEASES 3316 \| HSPB2 \| DISEASES 820 \| CAMP \| DISEASES 820 \| CAMP \| DISEASES 1506 \| CTRL \| DISEASES 1506 \| CTRL \| DISEASES 8792 \| TNFRSF11A \| DISEASES 8792 \| TNFRSF11A \| DISEASES 344 \| APOC2 \| DISEASES 344 \| APOC2 \| DISEASES 9294 \| S1PR2 \| DISEASES 9294 \| S1PR2 \| DISEASES 7138 \| TNNT1 \| DISEASES 7138 \| TNNT1 \| DISEASES 346 \| APOC4 \| DISEASES 346 \| APOC4 \| DISEASES 284424 \| MIR7-3HG \| DISEASES 284424 \| MIR7-3HG \| DISEASES 8740 \| TNFSF14 \| DISEASES 8740 \| TNFSF14 \| DISEASES 7409 \| VAV1 \| DISEASES 7409 \| VAV1 \| DISEASES 100302740 \| FAS-AS1 \| DISEASES 100302740 \| FAS-AS1 \| DISEASES 100874363 \| HOXC-AS1 \| DISEASES 100874363 \| HOXC-AS1 \| DISEASES 102723508 \| KANTR \| DISEASES 102723508 \| KANTR \| DISEASES 100885779 \| LINC-ROR \| DISEASES 100885779 \| LINC-ROR \| DISEASES 221241 \| LINC00305 \| DISEASES 221241 \| LINC00305 \| DISEASES 104266962 \| LINC01228 \| DISEASES 104266962 \| LINC01228 \| DISEASES 101927921 \| LINC01478 \| DISEASES 101927921 \| LINC01478 \| DISEASES 407975 \| MIR17HG \| DISEASES 407975 \| MIR17HG \| DISEASES 104457406 \| MIR222HG \| DISEASES 104457406 \| MIR222HG \| DISEASES 4568 \| MT-TL2 \| DISEASES 4568 \| MT-TL2 \| DISEASES 404744 \| NPSR1-AS1 \| DISEASES 100129858 \| SCOC-AS1 \| DISEASES 100129858 \| SCOC-AS1 \| DISEASES 106633813 \| SIRT1-AS \| DISEASES 106633813 \| SIRT1-AS \| DISEASES 197187 \| SNAI3-AS1 \| DISEASES 197187 \| SNAI3-AS1 \| DISEASES 677835 \| SNORA56 \| DISEASES 677835 \| SNORA56 \| DISEASES 103611157 \| TGFB2-OT1 \| DISEASES 103611157 \| TGFB2-OT1 \| DISEASES 7435 \| VIS1 \| DISEASES 7435 \| VIS1 \| DISEASES
Locus	(Waiting for update.)

Disease ID	535
Disease	arteriosclerosis
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:177) HP:0001297 \| Cerebral vascular events \| 82 HP:0000822 \| Hypertension \| 70 HP:0001677 \| Coronary artery disease \| 69 HP:0000819 \| Diabetes mellitus \| 68 HP:0001370 \| Rheumatoid arthritis \| 54 HP:0001658 \| Myocardial infarction \| 52 HP:0002725 \| Systemic lupus erythematosus \| 41 HP:0012622 \| Chronic kidney disease \| 40 HP:0001513 \| Obesity \| 36 HP:0001369 \| Arthritis \| 34 HP:0002140 \| Ischemic stroke \| 31 HP:0003774 \| End-stage renal failure \| 21 HP:0003124 \| Elevated serum cholesterol \| 21 HP:0000855 \| Insulin resistance \| 20 HP:0004950 \| Peripheral artery disease \| 20 HP:0003077 \| Hyperlipidemia \| 16 HP:0001397 \| Hepatic steatosis \| 14 HP:0002960 \| Autoimmune condition \| 13 HP:0004934 \| Vascular calcification \| 12 HP:0002617 \| Aneurysmal dilatation \| 11 HP:0010535 \| Sleep apnea \| 10 HP:0003765 \| Psoriasis \| 9 HP:0001635 \| Congestive heart failure \| 9 HP:0003074 \| High blood glucose \| 9 HP:0001681 \| Angina pectoris \| 8 HP:0004395 \| Malnutrition \| 8 HP:0000939 \| Osteoporosis \| 7 HP:0002870 \| Obstructive sleep apnea \| 6 HP:0100546 \| Narrowing of carotid artery \| 6 HP:0004929 \| Coronary artherosclerosis \| 6 HP:0002104 \| Absence of spontaneous respiration \| 6 HP:0000821 \| Underactive thyroid \| 6 HP:0200123 \| Chronic liver inflammation \| 6 HP:0001650 \| Valvular aortic stenosis \| 6 HP:0000083 \| Renal insufficiency \| 6 HP:0000704 \| Pyorrhea \| 5 HP:0000488 \| Noninflammatory retina disease \| 5 HP:0002155 \| Increased triglycerides \| 5 HP:0012592 \| Albuminuria \| 5 HP:0000716 \| Depression \| 5 HP:0002149 \| Hyperuricemia \| 5 HP:0002326 \| TIA \| 4 HP:0004417 \| Intermittent claudication \| 4 HP:0100033 \| Tic disorder \| 4 HP:0012594 \| High urine albumin levels \| 4 HP:0003207 \| Arterial calcification \| 4 HP:0012743 \| Central obesity \| 4 HP:0012115 \| Liver inflammation \| 4 HP:0100543 \| Cognitive deficits \| 4 HP:0000845 \| Acromegalic growth \| 4 HP:0002637 \| Brain ischemia \| 3 HP:0001645 \| Sudden cardiac death \| 3 HP:0007868 \| ARMD \| 3 HP:0001114 \| Fatty deposits on eyelids \| 3 HP:0004953 \| Abdominal aortic aneurysm \| 3 HP:0001717 \| Coronary artery calcification \| 3 HP:0001920 \| Renal artery stenosis \| 3 HP:0001997 \| Gout \| 3 HP:0000100 \| Nephrosis \| 3 HP:0000802 \| Erectile dysfunction \| 3 HP:0005145 \| Narrowing of coronary artery \| 3 HP:0004942 \| Aortic aneurysm \| 3 HP:0001988 \| hypoglycemia, recurrent \| 3 HP:0001638 \| Cardiomyopathy \| 3 HP:0001907 \| Thromboembolic disease \| 3 HP:0003651 \| Foam cells \| 3 HP:0002633 \| Vasculitis \| 2 HP:0012531 \| Pain \| 2 HP:0000833 \| Glucose intolerance \| 2 HP:0000739 \| Anxiety \| 2 HP:0002076 \| Migraine headaches \| 2 HP:0005681 \| Juvenile idiopathic arthritis \| 2 HP:0002583 \| Colitis \| 2 HP:0002955 \| Granulomatosis \| 2 HP:0001342 \| Intracerebral hemorrhage \| 2 HP:0004420 \| Arterial thrombosis \| 2 HP:0100279 \| Ulcerative colitis \| 2 HP:0003613 \| Antiphospholipid antibodies \| 2 HP:0000870 \| Hyperprolactinemia \| 2 HP:0009125 \| Lipodystrophy \| 2 HP:0003233 \| Low HDL-cholesterol \| 2 HP:0000726 \| Dementia \| 2 HP:0000969 \| Dropsy \| 2 HP:0003002 \| Breast carcinoma \| 2 HP:0100749 \| Thoracic pain \| 2 HP:0000842 \| Elevated insulin level \| 2 HP:0100785 \| Insomnia \| 2 HP:0005110 \| Atrial fibrillation \| 2 HP:0005181 \| Premature coronary artery disease \| 2 HP:0002758 \| Osteoarthritis \| 2 HP:0002597 \| Abnormality of blood vessels \| 2 HP:0001659 \| Aortic insufficiency \| 2 HP:0000545 \| Near sightedness \| 1 HP:0011877 \| Increased mean platelet volume \| 1 HP:0000872 \| Hashimoto's thyroiditis \| 1 HP:0001251 \| Ataxia \| 1 HP:0000554 \| Uveitis \| 1 HP:0001953 \| Diabetic ketosis \| 1 HP:0001394 \| Hepatic cirrhosis \| 1 HP:0001946 \| High levels of ketone bodies \| 1 HP:0001300 \| Parkinsonism \| 1 HP:0100582 \| Nasal polyps \| 1 HP:0000123 \| Nephritis \| 1 HP:0012311 \| High blood monocyte number \| 1 HP:0040171 \| Low serum testosterone levels \| 1 HP:0001945 \| Fever \| 1 HP:0012189 \| Hodgkin disease \| 1 HP:0002721 \| Immunodeficiency \| 1 HP:0005202 \| Helicobacter pylori infection \| 1 HP:0002608 \| Celiac disease \| 1 HP:0000938 \| Decreased bone mineral density \| 1 HP:0012492 \| Cerebral artery stenosis \| 1 HP:0010874 \| Tendon xanthomatosis \| 1 HP:0100646 \| Thyroiditis \| 1 HP:0000608 \| Macular degeneration \| 1 HP:0002092 \| Pulmonary artery hypertension \| 1 HP:0000159 \| Lip abnormality \| 1 HP:0000135 \| Hypogonadism \| 1 HP:0001644 \| Congestive cardiomyopathy \| 1 HP:0001289 \| Confusion \| 1 HP:0005116 \| Arterial tortuosity \| 1 HP:0008356 \| Combined hyperlipidaemia \| 1 HP:0006349 \| Agenesis of permanent dentition \| 1 HP:0012273 \| Increased carotid artery intimal medial thickness \| 1 HP:0002094 \| Dyspnea \| 1 HP:0000836 \| Overactive thyroid \| 1 HP:0000093 \| Proteinuria \| 1 HP:0002156 \| High urine homocystine levels \| 1 HP:0001698 \| Pericardial effusions \| 1 HP:0100806 \| Sepsis \| 1 HP:0002925 \| Increased serum thyroid-stimulating hormone \| 1 HP:0008221 \| Enlarged adrenal glands \| 1 HP:0011947 \| Respiratory infection \| 1 HP:0002647 \| Aortic dissection \| 1 HP:0100724 \| Hypercoagulability \| 1 HP:0002619 \| Varicose veins \| 1 HP:0001943 \| Hypoglycemia \| 1 HP:0001891 \| Iron-deficiency anemia \| 1 HP:0008258 \| Congenital adrenal hyperplasia \| 1 HP:0003040 \| Arthropathy \| 1 HP:0001685 \| Myocardial fibrosis \| 1 HP:0100021 \| Cerebral palsy \| 1 HP:0001680 \| Coarctation of aorta \| 1 HP:0001268 \| Mental deterioration \| 1 HP:0010766 \| Ectopic calcification \| 1 HP:0004944 \| Cerebral artery aneurysm \| 1 HP:0010980 \| Hyperlipoproteinemia \| 1 HP:0100545 \| Arterial stenosis \| 1 HP:0001548 \| Overgrowth \| 1 HP:0025019 \| Arterial rupture \| 1 HP:0001903 \| Anemia \| 1 HP:0005978 \| Noninsulin dependent diabetes mellitus \| 1 HP:0100512 \| Vitamin D deficiency \| 1 HP:0200034 \| Papule \| 1 HP:0001942 \| Metabolic acidosis \| 1 HP:0008629 \| Pulsatile tinnitus \| 1 HP:0200042 \| Skin ulcer \| 1 HP:0009800 \| gestational diabetes \| 1 HP:0004936 \| Blood clot in vein \| 1 HP:0000787 \| Renal calculi \| 1 HP:0004398 \| Peptic ulcer \| 1 HP:0012203 \| Onychomycosis \| 1 HP:0000112 \| Nephropathy \| 1 HP:0011710 \| Bundle-branch block \| 1 HP:0000360 \| Ringing in the ears \| 1 HP:0006510 \| Chronic obstructive pulmonary disease \| 1 HP:0012089 \| Arteritis \| 1 HP:0030760 \| Kidney fibrosis \| 1 HP:0000518 \| Cataract \| 1 HP:0009830 \| Peripheral neuritis \| 1 HP:0004963 \| Calcification of the aorta \| 1 HP:0000407 \| sensorineural hearing loss \| 1 HP:0000991 \| Xanthomata \| 1 HP:0012076 \| Borderline personality disorder \| 1 HP:0002097 \| Pulmonary emphysema \| 1 HP:0002621 \| Atherosclerosis \| 1 HP:0100805 \| Precocious menopause \| 1

Disease ID	535
Disease	arteriosclerosis
Manually Symptom	(Waiting for update.)
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:80) C0011847 \| diabetes \| 196 C0042373 \| vascular disease \| 114 C0007222 \| cardiovascular disease \| 89 C0038454 \| stroke \| 80 C0020538 \| hypertension \| 69 C0011849 \| diabetes mellitus \| 68 C0010068 \| coronary artery disease \| 66 C0856169 \| endothelial dysfunction \| 54 C0018799 \| heart disease \| 50 C0009814 \| stenosis \| 43 C0948265 \| metabolic syndrome \| 42 C0011860 \| type 2 diabetes mellitus \| 38 C0022658 \| kidney disease \| 36 C0021308 \| infarction \| 34 C0022116 \| ischemia \| 34 C0009450 \| infection \| 32 C0010068 \| coronary heart disease \| 30 C0427008 \| stiffness \| 23 C0027051 \| myocardial infarct \| 22 C0020443 \| hypercholesterolemia \| 21 C1393529 \| vascular complications \| 19 C0020473 \| hyperlipidemia \| 16 C0426768 \| o sign \| 16 C0242339 \| dyslipidemia \| 15 C0040053 \| thrombosis \| 15 C0042373 \| vascular diseases \| 14 C0038454 \| strokes \| 14 C0027051 \| myocardial infarction \| 14 C0007222 \| cardiovascular diseases \| 13 C0032285 \| pneumoniae \| 13 C0151744 \| ischemic heart disease \| 10 C0151744 \| myocardial ischemia \| 10 C0021311 \| infections \| 10 C0018801 \| heart failure \| 9 C1290886 \| chronic inflammatory disease \| 6 C0002940 \| aneurysm \| 6 C0085096 \| peripheral vascular disease \| 5 C0031099 \| periodontitis \| 5 C0740394 \| hyperuricemia \| 5 C0002940 \| aneurysms \| 5 C0020443 \| hypercholesterolaemia \| 5 C1456822 \| claudication \| 4 C0948008 \| ischaemic stroke \| 4 C1402315 \| vascular lesions \| 3 C0040188 \| tic disorders \| 3 C0003834 \| arterial insufficiency \| 3 C0086132 \| depressive symptoms \| 3 C0007785 \| cerebral ischemia \| 3 C0035067 \| renal artery stenosis \| 3 C0242231 \| coronary artery stenosis \| 3 C0008148 \| chlamydia \| 3 C1611184 \| coronary artery calcification \| 3 C0746556 \| metabolic disturbance \| 3 C0042384 \| vasculitis \| 2 C0025517 \| metabolic disorders \| 2 C0022116 \| ischaemia \| 2 C0020443 \| hypercholesteremia \| 2 C0021775 \| intermittent claudication \| 2 C1096458 \| vascular occlusion \| 2 C0850666 \| h. pylori infection \| 2 C0151942 \| arterial thrombosis \| 2 C0796095 \| c syndrome \| 2 C0010068 \| coronary disease \| 1 C0162871 \| abdominal aortic aneurysms \| 1 C0007282 \| carotid artery stenosis \| 1 C0013990 \| emphysema \| 1 C0042373 \| vascular disorder \| 1 C0018802 \| congestive heart failure \| 1 C0043325 \| xanthomatosis \| 1 C0020476 \| hyperlipoproteinemia \| 1 C0019080 \| hemorrhage \| 1 C1168154 \| true aneurysm \| 1 C0040038 \| thromboembolism \| 1 C0040053 \| thrombus \| 1 C0006384 \| bundle branch block \| 1 C0036690 \| sepsis \| 1 C0037998 \| splenic infarction \| 1 C0020473 \| lipemia \| 1 C0398623 \| hypercoagulability \| 1 C0598608 \| hyperhomocysteinemia \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:405)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs1010	18073581	399979	SNX19	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	VAMP8	2	85581859	T	G,C
rs1010	18073581	399979	SNX19	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	VAMP8	2	85581859	T	G,C
rs1010	18073581	221458	KIF6	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000814326	2007	VAMP8	2	85581859	T	G,C
rs1010	18073581	221458	KIF6	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.00554839	2007	VAMP8	2	85581859	T	G,C
rs1010	18073581	8673	VAMP8	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	VAMP8	2	85581859	T	G,C
rs1010	18073581	22989	MYH15	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	VAMP8	2	85581859	T	G,C
rs1010	18073581	22989	MYH15	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	VAMP8	2	85581859	T	G,C
rs1010	18073581	8673	VAMP8	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	VAMP8	2	85581859	T	G,C
rs1042713	17356698	154	ADRB2	umls:C0003850	BeFree	ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study.	0.003181358	2007	ADRB2	5	148826877	G	A
rs1042713	17356698	154	ADRB2	umls:C0004153	BeFree	ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study.	0.007915422	2007	ADRB2	5	148826877	G	A
rs10507130	17903303	27340	UTP20	umls:C0004153	GAD	[The results from this GWAS generate hypotheses regarding several SNPs that may be associated with SCA phenotypes in multiple arterial beds. Given the number of tests conducted, subsequent independent replication in a staged approach is essential to identi]	0.002367032	2007	UTP20	12	101360176	G	A
rs1061170	19076828	3075	CFH	umls:C0004153	BeFree	In this study, we examined whether the gene-gene interactions between CRP haplotypes and CFH Tyr402His functional polymorphism exerted an effect on early atherosclerosis.	0.010553895	2009	CFH	1	196690107	C	T
rs1061170	22067048	3075	CFH	umls:C0004153	BeFree	In addition, a specific Y402H polymorphism of the complement inhibitor factor H has been found to be associated with the incidence of both AMD and AS.	0.010553895	2012	CFH	1	196690107	C	T
rs1061170	19076828	3075	CFH	umls:C0003850	BeFree	In this study, we examined whether the gene-gene interactions between CRP haplotypes and CFH Tyr402His functional polymorphism exerted an effect on early atherosclerosis.	0.001085767	2009	CFH	1	196690107	C	T
rs1061170	22067048	3075	CFH	umls:C0003850	BeFree	In addition, a specific Y402H polymorphism of the complement inhibitor factor H has been found to be associated with the incidence of both AMD and AS.	0.001085767	2012	CFH	1	196690107	C	T
rs10846744	22628436	404677	CIMT	umls:C0003850	BeFree	Our analysis of the full Multi-Ethnic Study of Atherosclerosis cohort provides strong evidence for the association of rs10846744 with common carotid intimal-medial thickness (P=1.04E-4 in combined analysis of all 4 Multi-Ethnic Study of Atherosclerosis racial/ethnic groups).	0.000542884	2012	SCARB1	12	124827879	G	C
rs10846744	20160195	949	SCARB1	umls:C0004153	BeFree	Variation in SCARB1 at rs10846744 was significantly associated with CCIMT across racial/ethnic groups in Multi-Ethnic Study of Atherosclerosis.	0.013168625	2010	SCARB1	12	124827879	G	C
rs10846744	20160195	949	SCARB1	umls:C0003850	BeFree	Variation in SCARB1 at rs10846744 was significantly associated with CCIMT across racial/ethnic groups in Multi-Ethnic Study of Atherosclerosis.	0.002985861	2010	SCARB1	12	124827879	G	C
rs10846744	22628436	404677	CIMT	umls:C0004153	BeFree	Our analysis of the full Multi-Ethnic Study of Atherosclerosis cohort provides strong evidence for the association of rs10846744 with common carotid intimal-medial thickness (P=1.04E-4 in combined analysis of all 4 Multi-Ethnic Study of Atherosclerosis racial/ethnic groups).	0.000542884	2012	SCARB1	12	124827879	G	C
rs1137100	20874424	3953	LEPR	umls:C0004153	BeFree	Leptin receptor Lys109Arg and Gln223Arg polymorphisms are associated with early atherosclerosis.	0.003181358	2010	LEPR	1	65570758	A	G
rs1137100	20874424	3953	LEPR	umls:C0003850	BeFree	Leptin receptor Lys109Arg and Gln223Arg polymorphisms are associated with early atherosclerosis.	0.000814326	2010	LEPR	1	65570758	A	G
rs1137101	20874424	3953	LEPR	umls:C0004153	BeFree	Leptin receptor Lys109Arg and Gln223Arg polymorphisms are associated with early atherosclerosis.	0.003181358	2010	LEPR	1	65592830	A	G
rs1137101	20874424	3953	LEPR	umls:C0003850	BeFree	Leptin receptor Lys109Arg and Gln223Arg polymorphisms are associated with early atherosclerosis.	0.000814326	2010	LEPR	1	65592830	A	G
rs11556924	24286297	51530	ZC3HC1	umls:C0004153	BeFree	Our results indicate that ZC3HC1 rs11556924 polymorphism is associated with subclinical atherosclerosis in RA.	0.000271442	2013	ZC3HC1	7	130023656	C	T
rs11556924	24286297	51530	ZC3HC1	umls:C0003850	BeFree	Our results indicate that ZC3HC1 rs11556924 polymorphism is associated with subclinical atherosclerosis in RA.	0.000271442	2013	ZC3HC1	7	130023656	C	T
rs11591147	18436227	56955	MEPE	umls:C0004153	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.000542884	2009	PCSK9	1	55039974	G	T
rs11591147	18436227	255738	PCSK9	umls:C0003850	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.003800186	2009	PCSK9	1	55039974	G	T
rs11591147	18436227	56955	MEPE	umls:C0003850	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.000542884	2009	PCSK9	1	55039974	G	T
rs11591147	18436227	255738	PCSK9	umls:C0004153	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.011530042	2009	PCSK9	1	55039974	G	T
rs116843064	18599063	51129	ANGPTL4	umls:C0004153	BeFree	Carbohydrate intake modifies associations between ANGPTL4[E40K] genotype and HDL-cholesterol concentrations in White men from the Atherosclerosis Risk in Communities (ARIC) study.	0.006362715	2009	ANGPTL4	19	8364439	G	A
rs116843064	18599063	51129	ANGPTL4	umls:C0003850	BeFree	Carbohydrate intake modifies associations between ANGPTL4[E40K] genotype and HDL-cholesterol concentrations in White men from the Atherosclerosis Risk in Communities (ARIC) study.	0.001628651	2009	ANGPTL4	19	8364439	G	A
rs116843064	18809343	51129	ANGPTL4	umls:C0003850	BeFree	Longitudinal changes in triglycerides according to ANGPTL4[E40K] genotype and longitudinal body weight change in the atherosclerosis risk in communities study.	0.001628651	2008	ANGPTL4	19	8364439	G	A
rs116843064	18809343	51129	ANGPTL4	umls:C0004153	BeFree	Longitudinal changes in triglycerides according to ANGPTL4[E40K] genotype and longitudinal body weight change in the atherosclerosis risk in communities study.	0.006362715	2008	ANGPTL4	19	8364439	G	A
rs12190287	24573017	84830	ADTRP	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	TCF21	6	133893387	C	G
rs12190287	24573017	84439	HHIPL1	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	TCF21	6	133893387	C	G
rs12190287	24573017	11173	ADAMTS7	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.001085767	2015	TCF21	6	133893387	C	G
rs12190287	24573017	11173	ADAMTS7	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.003452799	2015	TCF21	6	133893387	C	G
rs12190287	24573017	84830	ADTRP	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	TCF21	6	133893387	C	G
rs12190287	24573017	84439	HHIPL1	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	TCF21	6	133893387	C	G
rs12190287	24573017	65264	UBE2Z	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	TCF21	6	133893387	C	G
rs12190287	24573017	65264	UBE2Z	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	TCF21	6	133893387	C	G
rs121918313	21245321	3949	LDLR	umls:C0003850	BeFree	We previously identified a mutation in LDL receptor-related protein 6 (LRP6), LRP6(R611C), that causes early atherosclerosis.	0.037654475	2011	LRP6	12	12164494	G	A
rs121918313	21245321	3949	LDLR	umls:C0004153	BeFree	We previously identified a mutation in LDL receptor-related protein 6 (LRP6), LRP6(R611C), that causes early atherosclerosis.	0.177848251	2011	LRP6	12	12164494	G	A
rs1256049	18939943	2100	ESR2	umls:C0004153	BeFree	In a Finnish population, the ESR2 rs1256049 polymorphism A allele is associated with preclinical atherosclerosis in young adulthood.	0.008815624	2008	ESR2	14	64257333	C	T
rs1256049	18939943	2100	ESR2	umls:C0003850	BeFree	In a Finnish population, the ESR2 rs1256049 polymorphism A allele is associated with preclinical atherosclerosis in young adulthood.	0.001357209	2008	ESR2	14	64257333	C	T
rs12953	14575520	5175	PECAM1	umls:C0004153	BeFree	The PECAM1 Leu125Val and Ser563Asn polymorphisms may increase the risk of atherosclerosis but not necessarily of MI.	0.009901391	2003	PECAM1	17	64356203	C	T,A
rs12953	14575520	5175	PECAM1	umls:C0003850	BeFree	The PECAM1 Leu125Val and Ser563Asn polymorphisms may increase the risk of atherosclerosis but not necessarily of MI.	0.002442977	2003	PECAM1	17	64356203	C	T,A
rs1333049	24573017	65264	UBE2Z	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	9	22125504	G	C
rs1333049	24573017	65264	UBE2Z	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	9	22125504	G	C
rs1333049	24573017	84830	ADTRP	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	9	22125504	G	C
rs1333049	24573017	84830	ADTRP	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	9	22125504	G	C
rs1333049	24573017	84439	HHIPL1	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	9	22125504	G	C
rs1333049	24573017	11173	ADAMTS7	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.003452799	2015	NA	9	22125504	G	C
rs1333049	24573017	84439	HHIPL1	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	9	22125504	G	C
rs1333049	24573017	11173	ADAMTS7	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.001085767	2015	NA	9	22125504	G	C
rs1376877	17903303	10152	ABI2	umls:C0004153	GWASCAT	Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study.	0.12	2007	ABI2	2	203407367	C	T
rs137852912	20448210	255738	PCSK9	umls:C0003850	BeFree	To produce transgenic mice expressing the D374Y variant of the human proprotein convertase subtilisin/kexin type 9 (PCSK9) gene at physiological levels to investigate the mechanisms causing hypercholesterolemia and accelerated atherosclerosis.	0.003800186	2010	PCSK9	1	55057454	G	A,T
rs137852912	20448210	255738	PCSK9	umls:C0004153	BeFree	To produce transgenic mice expressing the D374Y variant of the human proprotein convertase subtilisin/kexin type 9 (PCSK9) gene at physiological levels to investigate the mechanisms causing hypercholesterolemia and accelerated atherosclerosis.	0.011530042	2010	PCSK9	1	55057454	G	A,T
rs1447295	18248681	6934	TCF7L2	umls:C0004153	BeFree	We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).	0.016373727	2008	CASC8	8	127472793	A	C
rs1447295	18248681	6934	TCF7L2	umls:C0003850	BeFree	We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).	0.002171535	2008	CASC8	8	127472793	A	C
rs1447295	18248681	11132	CAPN10	umls:C0003850	BeFree	We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).	0.001085767	2008	CASC8	8	127472793	A	C
rs1447295	18248681	2784	GNB3	umls:C0004153	BeFree	We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).	0.011368221	2008	CASC8	8	127472793	A	C
rs1447295	18248681	2784	GNB3	umls:C0003850	BeFree	We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).	0.001900093	2008	CASC8	8	127472793	A	C
rs1447295	18248681	3075	CFH	umls:C0004153	BeFree	We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).	0.010553895	2008	CASC8	8	127472793	A	C
rs1447295	18248681	11132	CAPN10	umls:C0004153	BeFree	We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).	0.010911214	2008	CASC8	8	127472793	A	C
rs1447295	18248681	3075	CFH	umls:C0003850	BeFree	We investigated the prevalence of common polymorphisms that have been associated with diseases, such as atherosclerosis (ALOX5), hypertension (CYP3A5, AGT, GNB3), diabetes (CAPN10, TCF7L2, PTPN22), prostate cancer (DG8S737, rs1447295), Hirschsprung disease (RET), and age-related macular degeneration (CFH, LOC387715).	0.001085767	2008	CASC8	8	127472793	A	C
rs1535045	23166616	958	CD40	umls:C0003850	BeFree	Also, the CD40 rs1535045 gene variant may influence development of subclinical atherosclerosis in RA patients.	0.00434307	2012	CD40	20	46119460	C	A,T
rs1535045	23166616	959	CD40LG	umls:C0003850	BeFree	Although we did not observe a significant association of CD40-CD154 gene variants with the development of CV events, an ANCOVA model adjusted for sex, age at the time of the ultrasonography assessment, follow-up time, traditional CV risk factors and anti-cyclic citrullinated peptide antibodies disclosed a significant association (p=0.0047) between CD40 rs1535045 polymorphism and carotid intima media thickness, a surrogate marker of atherosclerosis.	0.005971721	2012	CD40	20	46119460	C	A,T
rs1535045	23166616	959	CD40LG	umls:C0004153	BeFree	Although we did not observe a significant association of CD40-CD154 gene variants with the development of CV events, an ANCOVA model adjusted for sex, age at the time of the ultrasonography assessment, follow-up time, traditional CV risk factors and anti-cyclic citrullinated peptide antibodies disclosed a significant association (p=0.0047) between CD40 rs1535045 polymorphism and carotid intima media thickness, a surrogate marker of atherosclerosis.	0.104327536	2012	CD40	20	46119460	C	A,T
rs1535045	23166616	958	CD40	umls:C0004153	BeFree	Also, the CD40 rs1535045 gene variant may influence development of subclinical atherosclerosis in RA patients.	0.091801484	2012	CD40	20	46119460	C	A,T
rs17228212	24204921	4088	SMAD3	umls:C0003850	BeFree	SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.	0.000542884	2013	SMAD3	15	67166301	T	C
rs17228212	24204921	1421	CRYGD	umls:C0003850	BeFree	SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.	0.000271442	2013	SMAD3	15	67166301	T	C
rs17228212	24204921	4088	SMAD3	umls:C0004153	BeFree	SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.	0.000271442	2013	SMAD3	15	67166301	T	C
rs17228212	24204921	1421	CRYGD	umls:C0004153	BeFree	SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients.	0.000271442	2013	SMAD3	15	67166301	T	C
rs1764391	21617605	2701	GJA4	umls:C0003850	BeFree	The association between subclinical atherosclerosis in carotid arteries and Connexin 37 gene polymorphism (1019C>T; Pro319Ser) in women.	0.002171535	2011	GJA4;LOC105378643	1	34795168	C	T
rs1764391	21617605	2701	GJA4	umls:C0004153	BeFree	The association between subclinical atherosclerosis in carotid arteries and Connexin 37 gene polymorphism (1019C>T; Pro319Ser) in women.	0.004538567	2011	GJA4;LOC105378643	1	34795168	C	T
rs1799883	11707533	2169	FABP2	umls:C0004153	BeFree	The FABP2 A54T missense mutation may contribute to the TG enrichment of HDL in the postprandial state that, in turn, may alter the risk of atherosclerotic vascular disease.	0.002909916	2001	FABP2	4	119320747	T	G,C,A
rs1799945	10719381	3077	HFE	umls:C0004153	BeFree	The finding of a similar prevalence of Cys282Tyr and His63Asp mutations in the HFE gene among controls and patients with coronary atherothrombotic disease, indirectly questions the possibility of an association between hereditary hemochromatosis and atherosclerosis.	0.008186863	2000	HFE	6	26090951	C	G
rs1799945	10719381	3077	HFE	umls:C0003850	BeFree	The finding of a similar prevalence of Cys282Tyr and His63Asp mutations in the HFE gene among controls and patients with coronary atherothrombotic disease, indirectly questions the possibility of an association between hereditary hemochromatosis and atherosclerosis.	0.001357209	2000	HFE	6	26090951	C	G
rs1799983	11905585	4846	NOS3	umls:C0003850	BeFree	Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort.	0.133843535	2002	NOS3	7	150999023	T	G
rs1799983	11298374	4846	NOS3	umls:C0004153	BeFree	Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis.	0.172688313	2001	NOS3	7	150999023	T	G
rs1799983	19960019	342977	NANOS3	umls:C0004153	BeFree	We investigated associations between the NOS3 Glu298Asp SNP (rs1799983) and hypertension, as well as the interaction between NOS3 genotypes and dietary fat intake using data from baseline examination in white and African American participants in the Atherosclerosis Risk in Community (ARIC) study.	0.002171535	2010	NOS3	7	150999023	T	G
rs1799983	11905585	4846	NOS3	umls:C0004153	BeFree	Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort.	0.172688313	2002	NOS3	7	150999023	T	G
rs1799983	11298374	4846	NOS3	umls:C0003850	BeFree	Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis.	0.133843535	2001	NOS3	7	150999023	T	G
rs1799983	19960019	342977	NANOS3	umls:C0003850	BeFree	We investigated associations between the NOS3 Glu298Asp SNP (rs1799983) and hypertension, as well as the interaction between NOS3 genotypes and dietary fat intake using data from baseline examination in white and African American participants in the Atherosclerosis Risk in Community (ARIC) study.	0.002171535	2010	NOS3	7	150999023	T	G
rs1799983	12641536	4846	NOS3	umls:C0004153	BeFree	Conflicting data exists about the possible contribution of the homozygous Asp/Asp genotype of the Glu298Asp polymorphism of endothelial nitric oxide synthase to human atherosclerotic vascular disease.	0.172688313	2003	NOS3	7	150999023	T	G
rs1800206	15199365	5465	PPARA	umls:C0004153	BeFree	The data suggest that the PPARalpha polymorphism L162V might protect against the development of atherosclerosis or CHD in patients with DM-2.	0.020345666	2004	PPARA	22	46218377	C	G
rs1800206	15199365	5465	PPARA	umls:C0003850	BeFree	The data suggest that the PPARalpha polymorphism L162V might protect against the development of atherosclerosis or CHD in patients with DM-2.	0.005428837	2004	PPARA	22	46218377	C	G
rs1800206	11914252	7827	NPHS2	umls:C0003850	BeFree	We investigated the association between the leucine 162 to valine (L162V) polymorphism and a G to C transversion in intron 7 of the PPARalpha gene and progression of atherosclerosis in the Lopid Coronary Angiography Trial (LOCAT), a trial examining the effect of gemfibrozil treatment on progression of atherosclerosis after bypass surgery and on risk of IHD in the second Northwick Park Heart Study (NPHS2), a prospective study of healthy middle-aged men in the United Kingdom.	0.000271442	2002	PPARA	22	46218377	C	G
rs1800206	11914252	7827	NPHS2	umls:C0004153	BeFree	We investigated the association between the leucine 162 to valine (L162V) polymorphism and a G to C transversion in intron 7 of the PPARalpha gene and progression of atherosclerosis in the Lopid Coronary Angiography Trial (LOCAT), a trial examining the effect of gemfibrozil treatment on progression of atherosclerosis after bypass surgery and on risk of IHD in the second Northwick Park Heart Study (NPHS2), a prospective study of healthy middle-aged men in the United Kingdom.	0.000271442	2002	PPARA	22	46218377	C	G
rs1800562	18593631	3077	HFE	umls:C0004153	BeFree	HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study.	0.008186863	2008	HFE	6	26092913	G	A
rs1800562	18593631	3077	HFE	umls:C0003850	BeFree	HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study.	0.001357209	2008	HFE	6	26092913	G	A
rs1800562	11257277	3077	HFE	umls:C0003850	BeFree	A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study.	0.001357209	2001	HFE	6	26092913	G	A
rs1800562	10719381	3077	HFE	umls:C0004153	BeFree	The finding of a similar prevalence of Cys282Tyr and His63Asp mutations in the HFE gene among controls and patients with coronary atherothrombotic disease, indirectly questions the possibility of an association between hereditary hemochromatosis and atherosclerosis.	0.008186863	2000	HFE	6	26092913	G	A
rs1800562	10719381	3077	HFE	umls:C0003850	BeFree	The finding of a similar prevalence of Cys282Tyr and His63Asp mutations in the HFE gene among controls and patients with coronary atherothrombotic disease, indirectly questions the possibility of an association between hereditary hemochromatosis and atherosclerosis.	0.001357209	2000	HFE	6	26092913	G	A
rs1800562	11257277	3077	HFE	umls:C0004153	BeFree	A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study.	0.008186863	2001	HFE	6	26092913	G	A
rs1801282	25159899	5468	PPARG	umls:C0003850	BeFree	Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis.	0.093777522	2014	PPARG	3	12351626	C	G
rs1801282	25159899	5468	PPARG	umls:C0004153	BeFree	Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis.	0.153428414	2014	PPARG	3	12351626	C	G
rs1801282	25096510	5468	PPARG	umls:C0003850	BeFree	The Pro12Ala and C161T polymorphisms in peroxisome proliferator-activated receptor γ (PPARγ) have been shown to be associated with carotid artery atherosclerosis.	0.093777522	2014	PPARG	3	12351626	C	G
rs1801282	25096510	5468	PPARG	umls:C0004153	BeFree	The Pro12Ala and C161T polymorphisms in peroxisome proliferator-activated receptor γ (PPARγ) have been shown to be associated with carotid artery atherosclerosis.	0.153428414	2014	PPARG	3	12351626	C	G
rs1805192	25096510	5468	PPARG	umls:C0003850	BeFree	The Pro12Ala and C161T polymorphisms in peroxisome proliferator-activated receptor γ (PPARγ) have been shown to be associated with carotid artery atherosclerosis.	0.093777522	2014	PPARG	3	12379739	C	G
rs1805192	25096510	5468	PPARG	umls:C0004153	BeFree	The Pro12Ala and C161T polymorphisms in peroxisome proliferator-activated receptor γ (PPARγ) have been shown to be associated with carotid artery atherosclerosis.	0.153428414	2014	PPARG	3	12379739	C	G
rs1805192	25159899	5468	PPARG	umls:C0003850	BeFree	Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis.	0.093777522	2014	PPARG	3	12379739	C	G
rs1805192	25159899	5468	PPARG	umls:C0004153	BeFree	Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis.	0.153428414	2014	PPARG	3	12379739	C	G
rs1862513	21345288	56729	RETN	umls:C0003850	BeFree	RETN rs1862513 polymorphism does not seem to be a genetic risk factor for both clinically evident CV disease and subclinical atherosclerosis in patients with RA.	0.00434307	2011	RETN	19	7668907	C	G
rs1862513	21345288	56729	RETN	umls:C0004153	BeFree	RETN rs1862513 polymorphism does not seem to be a genetic risk factor for both clinically evident CV disease and subclinical atherosclerosis in patients with RA.	0.017250185	2011	RETN	19	7668907	C	G
rs1866389	12952849	7060	THBS4	umls:C0003850	BeFree	In a recent large-scale genetic association study, a single nucleotide polymorphism in the thrombospondin-4 (TSP-4) gene, resulting in a proline-for-alanine substitution at position 387, was associated with a significantly increased risk for premature atherosclerosis.	0.000271442	2003	THBS4	5	80065442	G	C
rs1866389	12952849	7060	THBS4	umls:C0004153	BeFree	In a recent large-scale genetic association study, a single nucleotide polymorphism in the thrombospondin-4 (TSP-4) gene, resulting in a proline-for-alanine substitution at position 387, was associated with a significantly increased risk for premature atherosclerosis.	0.002638474	2003	THBS4	5	80065442	G	C
rs1883832	24828072	958	CD40	umls:C0004153	BeFree	The SNP rs1883832 in CD40 gene and risk of atherosclerosis in Chinese population: a meta-analysis.	0.091801484	2014	CD40	20	46118343	T	C
rs1883832	24828072	958	CD40	umls:C0003850	BeFree	The SNP rs1883832 in CD40 gene and risk of atherosclerosis in Chinese population: a meta-analysis.	0.00434307	2014	CD40	20	46118343	T	C
rs198389	19413180	4879	NPPB	umls:C0004153	GAD	[SNP rs198389 (T-381 C) polymorphism in the B-type natriuretic peptide gene promoter in patients with atherosclerotic renovascular hypertension.]	0.003181358	2009	NPPB	1	11859214	A	G
rs20417	19046748	5743	PTGS2	umls:C0003850	BeFree	A secondary aim was to replicate the interaction of PTGS2 rs20417 (-765G to C) with aspirin use on coronary heart disease risk observed in the Atherosclerosis Risk in Communities Study (ARIC).	0.00434307	2009	PTGS2;PACERR	1	186681189	C	G
rs20417	19046748	5743	PTGS2	umls:C0004153	BeFree	A secondary aim was to replicate the interaction of PTGS2 rs20417 (-765G to C) with aspirin use on coronary heart disease risk observed in the Atherosclerosis Risk in Communities Study (ARIC).	0.139259898	2009	PTGS2;PACERR	1	186681189	C	G
rs20455	18222354	1917	EEF1A2	umls:C0004153	BeFree	The 719Arg allele of KIF6 (rs20455) has been reported to be associated with increased risk of CHD in a large population-based prospective study, ARIC (Atherosclerosis Risk in Communities), and in the placebo arms of 2 statin trials, CARE (Cholesterol and Recurrent Events) and WOSCOPS (West of Scotland Coronary Prevention Study).	0.001900093	2008	KIF6	6	39357302	A	G
rs20455	18222354	221458	KIF6	umls:C0003850	BeFree	The 719Arg allele of KIF6 (rs20455) has been reported to be associated with increased risk of CHD in a large population-based prospective study, ARIC (Atherosclerosis Risk in Communities), and in the placebo arms of 2 statin trials, CARE (Cholesterol and Recurrent Events) and WOSCOPS (West of Scotland Coronary Prevention Study).	0.000814326	2008	KIF6	6	39357302	A	G
rs20455	18073581	221458	KIF6	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000814326	2007	KIF6	6	39357302	A	G
rs20455	18073581	22989	MYH15	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	KIF6	6	39357302	A	G
rs20455	18073581	399979	SNX19	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	KIF6	6	39357302	A	G
rs20455	18073581	8673	VAMP8	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	KIF6	6	39357302	A	G
rs20455	18073581	8673	VAMP8	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	KIF6	6	39357302	A	G
rs20455	18073581	22989	MYH15	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	KIF6	6	39357302	A	G
rs20455	18073581	221458	KIF6	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.00554839	2007	KIF6	6	39357302	A	G
rs20455	18073581	399979	SNX19	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	KIF6	6	39357302	A	G
rs20455	18222354	1917	EEF1A2	umls:C0003850	BeFree	The 719Arg allele of KIF6 (rs20455) has been reported to be associated with increased risk of CHD in a large population-based prospective study, ARIC (Atherosclerosis Risk in Communities), and in the placebo arms of 2 statin trials, CARE (Cholesterol and Recurrent Events) and WOSCOPS (West of Scotland Coronary Prevention Study).	0.002171535	2008	KIF6	6	39357302	A	G
rs20455	18222354	221458	KIF6	umls:C0004153	BeFree	The 719Arg allele of KIF6 (rs20455) has been reported to be associated with increased risk of CHD in a large population-based prospective study, ARIC (Atherosclerosis Risk in Communities), and in the placebo arms of 2 statin trials, CARE (Cholesterol and Recurrent Events) and WOSCOPS (West of Scotland Coronary Prevention Study).	0.00554839	2008	KIF6	6	39357302	A	G
rs2066714	24466114	19	ABCA1	umls:C0004153	BeFree	Influence of ATP-binding cassette transporter 1 R219K and M883I polymorphisms on development of atherosclerosis: a meta-analysis of 58 studies.	0.184528185	2013	ABCA1	9	104824472	T	C
rs2066714	24466114	19	ABCA1	umls:C0003850	BeFree	Influence of ATP-binding cassette transporter 1 R219K and M883I polymorphisms on development of atherosclerosis: a meta-analysis of 58 studies.	0.020629582	2013	ABCA1	9	104824472	T	C
rs2066715	25527331	19	ABCA1	umls:C0004153	BeFree	ATP-binding cassette transporter 1 C69T and V825I polymorphisms in the development of atherosclerosis: a meta-analysis of 18,320 subjects.	0.184528185	2014	ABCA1	9	104825752	C	T
rs2066715	25527331	19	ABCA1	umls:C0003850	BeFree	ATP-binding cassette transporter 1 C69T and V825I polymorphisms in the development of atherosclerosis: a meta-analysis of 18,320 subjects.	0.020629582	2014	ABCA1	9	104825752	C	T
rs2071590	24439028	7124	TNF	umls:C0004153	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.172949823	2013	LTA;LOC100287329	6	31571991	A	G
rs2071590	24439028	4094	MAF	umls:C0003850	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.000271442	2013	LTA;LOC100287329	6	31571991	A	G
rs2071590	24439028	9146	HGS	umls:C0004153	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.000271442	2013	LTA;LOC100287329	6	31571991	A	G
rs2071590	24439028	4094	MAF	umls:C0004153	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.000271442	2013	LTA;LOC100287329	6	31571991	A	G
rs2071590	24439028	7124	TNF	umls:C0003850	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.01601507	2013	LTA;LOC100287329	6	31571991	A	G
rs2071590	24439028	9146	HGS	umls:C0003850	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.000271442	2013	LTA;LOC100287329	6	31571991	A	G
rs2071746	25016572	3162	HMOX1	umls:C0003850	BeFree	We undertook this study to investigate whether HO-1 gene rs2071746 polymorphism was associated with clinical outcomes in atherosclerosis ischemic stroke patients.	0.003528744	2014	HMOX1	22	35380679	A	T
rs2071746	25016572	3162	HMOX1	umls:C0004153	BeFree	We undertook this study to investigate whether HO-1 gene rs2071746 polymorphism was associated with clinical outcomes in atherosclerosis ischemic stroke patients.	0.019160209	2014	HMOX1	22	35380679	A	T
rs212528	24595843	1889	ECE1	umls:C0003850	BeFree	Recent studies have demonstrated that two genetic variants of ECE1 gene, rs212528 and rs213045 (C338A), are associated with hypertension and atherosclerosis formation.	0.001357209	2014	ECE1	1	21259168	T	C
rs212528	24595843	1889	ECE1	umls:C0004153	BeFree	Recent studies have demonstrated that two genetic variants of ECE1 gene, rs212528 and rs213045 (C338A), are associated with hypertension and atherosclerosis formation.	0.003724241	2014	ECE1	1	21259168	T	C
rs213045	24595843	1889	ECE1	umls:C0003850	BeFree	Recent studies have demonstrated that two genetic variants of ECE1 gene, rs212528 and rs213045 (C338A), are associated with hypertension and atherosclerosis formation.	0.001357209	2014	ECE1	1	21290752	G	T
rs213045	24595843	1889	ECE1	umls:C0004153	BeFree	Recent studies have demonstrated that two genetic variants of ECE1 gene, rs212528 and rs213045 (C338A), are associated with hypertension and atherosclerosis formation.	0.003724241	2014	ECE1	1	21290752	G	T
rs2144908	18162503	3630	INS	umls:C0003850	BeFree	The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.	0.021172466	2008	HNF4A;LOC105372629	20	44357077	G	A
rs2144908	18162503	3172	HNF4A	umls:C0004153	BeFree	The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.	0.002638474	2008	HNF4A;LOC105372629	20	44357077	G	A
rs2144908	18162503	3172	HNF4A	umls:C0003850	BeFree	The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.	0.000271442	2008	HNF4A;LOC105372629	20	44357077	G	A
rs2144908	18162503	5468	PPARG	umls:C0003850	BeFree	The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.	0.093777522	2008	HNF4A;LOC105372629	20	44357077	G	A
rs2144908	18162503	5468	PPARG	umls:C0004153	BeFree	The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.	0.153428414	2008	HNF4A;LOC105372629	20	44357077	G	A
rs2144908	18162503	3630	INS	umls:C0004153	BeFree	The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.	0.034265146	2008	HNF4A;LOC105372629	20	44357077	G	A
rs2167270	21385539	3952	LEP	umls:C0004153	BeFree	LEP rs2167270 polymorphism does not seem to be a genetic risk factor for disease susceptibility or clinically evident CV disease and subclinical atherosclerosis in patients with RA.	0.002985861	2011	LEP	7	128241296	G	A
rs2167270	21385539	3952	LEP	umls:C0003850	BeFree	LEP rs2167270 polymorphism does not seem to be a genetic risk factor for disease susceptibility or clinically evident CV disease and subclinical atherosclerosis in patients with RA.	0.002985861	2011	LEP	7	128241296	G	A
rs2228145	24717336	3570	IL6R	umls:C0003850	BeFree	Since the pathogenesis of AS and atherosclerosis shares several similarities, we tested the hypothesis that IL-6R Asp358Ala polymorphism is associated with the severity of AS.	0.000814326	2014	IL6R	1	154454494	A	C,T
rs2228145	24717336	3570	IL6R	umls:C0004153	BeFree	Since the pathogenesis of AS and atherosclerosis shares several similarities, we tested the hypothesis that IL-6R Asp358Ala polymorphism is associated with the severity of AS.	0.000814326	2014	IL6R	1	154454494	A	C,T
rs2229116	22627881	6263	RYR3	umls:C0004153	BeFree	To replicate the association of variants in RYR3 gene with common carotid intima-media thickness (cIMT), a surrogate marker of atherosclerosis, we genotyped single nucleotide polymorphisms (SNPs) rs2229116 and rs7177922 in a sub-population of 244 HIV-positive and HIV-negative men.	0.001085767	2012	RYR3	15	33613209	A	G
rs2229116	22627881	6263	RYR3	umls:C0003850	BeFree	To replicate the association of variants in RYR3 gene with common carotid intima-media thickness (cIMT), a surrogate marker of atherosclerosis, we genotyped single nucleotide polymorphisms (SNPs) rs2229116 and rs7177922 in a sub-population of 244 HIV-positive and HIV-negative men.	0.001085767	2012	RYR3	15	33613209	A	G
rs2229238	21835044	3570	IL6R	umls:C0003850	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.000814326	2011	IL6R	1	154465420	T	C
rs2229238	21835044	3570	IL6R	umls:C0004153	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.000814326	2011	IL6R	1	154465420	T	C
rs2229238	21835044	5265	SERPINA1	umls:C0004153	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.005005506	2011	IL6R	1	154465420	T	C
rs2229238	21835044	5265	SERPINA1	umls:C0003850	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.120271442	2011	IL6R	1	154465420	T	C
rs2229616	17587397	3952	LEP	umls:C0004153	BeFree	To investigate the effects of variation in the leptin [LEP (19A>G)] and melanocortin-4 receptor [MC4R (V103I)] genes on obesity-related traits in 13 405 African-American (AA) and white participants from the Atherosclerosis Risk in Communities (ARIC) Study.	0.002985861	2007	MC4R	18	60372043	C	T
rs2229616	17587397	3952	LEP	umls:C0003850	BeFree	To investigate the effects of variation in the leptin [LEP (19A>G)] and melanocortin-4 receptor [MC4R (V103I)] genes on obesity-related traits in 13 405 African-American (AA) and white participants from the Atherosclerosis Risk in Communities (ARIC) Study.	0.002985861	2007	MC4R	18	60372043	C	T
rs2229616	17587397	4160	MC4R	umls:C0003850	BeFree	To investigate the effects of variation in the leptin [LEP (19A>G)] and melanocortin-4 receptor [MC4R (V103I)] genes on obesity-related traits in 13 405 African-American (AA) and white participants from the Atherosclerosis Risk in Communities (ARIC) Study.	0.000271442	2007	MC4R	18	60372043	C	T
rs2229616	17587397	4160	MC4R	umls:C0004153	BeFree	To investigate the effects of variation in the leptin [LEP (19A>G)] and melanocortin-4 receptor [MC4R (V103I)] genes on obesity-related traits in 13 405 African-American (AA) and white participants from the Atherosclerosis Risk in Communities (ARIC) Study.	0.000271442	2007	MC4R	18	60372043	C	T
rs2230806	24466114	19	ABCA1	umls:C0003850	BeFree	Influence of ATP-binding cassette transporter 1 R219K and M883I polymorphisms on development of atherosclerosis: a meta-analysis of 58 studies.	0.020629582	2013	ABCA1	9	104858586	C	T
rs2230806	12624133	19	ABCA1	umls:C0003850	BeFree	The K allele of the R219K variant was significantly more frequent in FH subjects without premature CHD (0.32, 95% CI 0.27 to 0.37) than in FH subjects with premature CHD (0.25, 95% CI 0.21 to 0.29) (p<0.05), suggesting that the genetic variant R219K in ABCA1 could influence the development and progression of atherosclerosis in FH subjects.	0.020629582	2003	ABCA1	9	104858586	C	T
rs2230806	12700893	19	ABCA1	umls:C0003850	BeFree	The R219K polymorphism in the ATP-binding cassette transporter 1 gene ( ABCA1) has been associated with reduced severity of atherosclerosis, fewer coronary events, decreased triglycerides and a trend to increased HDL in men with coronary heart disease (CHD).	0.020629582	2003	ABCA1	9	104858586	C	T
rs2230806	12624133	19	ABCA1	umls:C0004153	BeFree	The K allele of the R219K variant was significantly more frequent in FH subjects without premature CHD (0.32, 95% CI 0.27 to 0.37) than in FH subjects with premature CHD (0.25, 95% CI 0.21 to 0.29) (p<0.05), suggesting that the genetic variant R219K in ABCA1 could influence the development and progression of atherosclerosis in FH subjects.	0.184528185	2003	ABCA1	9	104858586	C	T
rs2230806	12700893	19	ABCA1	umls:C0004153	BeFree	The R219K polymorphism in the ATP-binding cassette transporter 1 gene ( ABCA1) has been associated with reduced severity of atherosclerosis, fewer coronary events, decreased triglycerides and a trend to increased HDL in men with coronary heart disease (CHD).	0.184528185	2003	ABCA1	9	104858586	C	T
rs2230806	24466114	19	ABCA1	umls:C0004153	BeFree	Influence of ATP-binding cassette transporter 1 R219K and M883I polymorphisms on development of atherosclerosis: a meta-analysis of 58 studies.	0.184528185	2013	ABCA1	9	104858586	C	T
rs2248690	22024217	197	AHSG	umls:C0004153	BeFree	Our data do not support a significant direct association between AHSG variants rs4917, rs2248690, and rs2518136 and clinical atherosclerosis as exemplified by angiographically characterized coronary atherosclerosis.	0.003452799	2012	AHSG	3	186612299	T	A
rs2248690	22024217	197	AHSG	umls:C0003850	BeFree	Our data do not support a significant direct association between AHSG variants rs4917, rs2248690, and rs2518136 and clinical atherosclerosis as exemplified by angiographically characterized coronary atherosclerosis.	0.001085767	2012	AHSG	3	186612299	T	A
rs2277680	25142184	58191	CXCL16	umls:C0004153	BeFree	The aim of this study was to analyze the association between I123T and A181V polymorphism haplotypes and the accumulation of carotid plaque as well as the effect of the haplotype on the CXCL16 mRNA expression in carotid plaques in patients with advanced atherosclerosis.	0.003724241	2016	CXCL16	17	4735268	G	A
rs2277680	25142184	58191	CXCL16	umls:C0003850	BeFree	The aim of this study was to analyze the association between I123T and A181V polymorphism haplotypes and the accumulation of carotid plaque as well as the effect of the haplotype on the CXCL16 mRNA expression in carotid plaques in patients with advanced atherosclerosis.	0.001357209	2016	CXCL16	17	4735268	G	A
rs2295490	20693163	57761	TRIB3	umls:C0003850	BeFree	We wanted to replicate this latter association and, if so, to get deeper insights about the molecular mechanisms underlying the role of the TRIB3 Q84R polymorphism in atherosclerosis.	0.000542884	2011	TRIB3	20	388261	A	G
rs2295490	20693163	57761	TRIB3	umls:C0004153	BeFree	We wanted to replicate this latter association and, if so, to get deeper insights about the molecular mechanisms underlying the role of the TRIB3 Q84R polymorphism in atherosclerosis.	0.000542884	2011	TRIB3	20	388261	A	G
rs2298566	18073581	22989	MYH15	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	SNX19	11	130880747	A	C,T
rs2298566	18073581	8673	VAMP8	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	SNX19	11	130880747	A	C,T
rs2298566	18073581	221458	KIF6	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.00554839	2007	SNX19	11	130880747	A	C,T
rs2298566	18073581	8673	VAMP8	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	SNX19	11	130880747	A	C,T
rs2298566	18073581	399979	SNX19	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	SNX19	11	130880747	A	C,T
rs2298566	18073581	399979	SNX19	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	SNX19	11	130880747	A	C,T
rs2298566	18073581	221458	KIF6	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000814326	2007	SNX19	11	130880747	A	C,T
rs2298566	18073581	22989	MYH15	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	SNX19	11	130880747	A	C,T
rs2390582	17903303	284695	ZNF326	umls:C0004153	GAD	[The results from this GWAS generate hypotheses regarding several SNPs that may be associated with SCA phenotypes in multiple arterial beds. Given the number of tests conducted, subsequent independent replication in a staged approach is essential to identi]	0.002367032	2007	LOC105378851	1	90478350	A	G
rs2518136	22024217	197	AHSG	umls:C0004153	BeFree	Our data do not support a significant direct association between AHSG variants rs4917, rs2248690, and rs2518136 and clinical atherosclerosis as exemplified by angiographically characterized coronary atherosclerosis.	0.003452799	2012	AHSG	3	186620038	T	C
rs2518136	22024217	197	AHSG	umls:C0003850	BeFree	Our data do not support a significant direct association between AHSG variants rs4917, rs2248690, and rs2518136 and clinical atherosclerosis as exemplified by angiographically characterized coronary atherosclerosis.	0.001085767	2012	AHSG	3	186620038	T	C
rs2569190	17098305	929	CD14	umls:C0003850	BeFree	These data provide insight into the pathogenetic role of the CD14 C-260T polymorphism in atherosclerosis as -260TT genotype may favour increased inflammation in atheroma promoting possible worsening atherosclerosis, at least in Central of Italy elderly population.	0.003800186	2007	CD14;TMCO6	5	140633331	A	G
rs2569190	17098305	929	CD14	umls:C0004153	BeFree	These data provide insight into the pathogenetic role of the CD14 C-260T polymorphism in atherosclerosis as -260TT genotype may favour increased inflammation in atheroma promoting possible worsening atherosclerosis, at least in Central of Italy elderly population.	0.021169923	2007	CD14;TMCO6	5	140633331	A	G
rs2736100	24465664	7015	TERT	umls:C0004153	BeFree	The GG genotype of telomerase reverse transcriptase at genetic locus rs2736100 is associated with human atherosclerosis risk in the Han Chinese population.	0.003538676	2013	TERT	5	1286401	C	A
rs2736100	24465664	7015	TERT	umls:C0003850	BeFree	The GG genotype of telomerase reverse transcriptase at genetic locus rs2736100 is associated with human atherosclerosis risk in the Han Chinese population.	0.000814326	2013	TERT	5	1286401	C	A
rs28362286	18436227	56955	MEPE	umls:C0004153	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.000542884	2009	PCSK9	1	55063542	C	A,T
rs28362286	18436227	56955	MEPE	umls:C0003850	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.000542884	2009	PCSK9	1	55063542	C	A,T
rs28362286	18436227	255738	PCSK9	umls:C0003850	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.003800186	2009	PCSK9	1	55063542	C	A,T
rs28362286	18436227	255738	PCSK9	umls:C0004153	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.011530042	2009	PCSK9	1	55063542	C	A,T
rs28937313	24196952	19	ABCA1	umls:C0004153	BeFree	We compared the consequences of an ABCA1 mutation that produced an apparent lack of atherosclerosis (Tangier family 1, N935S) with an ABCA1 mutation with functional ABCA1 knockout that was associated with severe atherosclerosis (Tangier family 2, Leu(548):Leu(575)-End), using primary and telomerase-immortalized fibroblasts.	0.184528185	2014	ABCA1	9	104822520	T	C
rs28937313	24196952	19	ABCA1	umls:C0003850	BeFree	We compared the consequences of an ABCA1 mutation that produced an apparent lack of atherosclerosis (Tangier family 1, N935S) with an ABCA1 mutation with functional ABCA1 knockout that was associated with severe atherosclerosis (Tangier family 2, Leu(548):Leu(575)-End), using primary and telomerase-immortalized fibroblasts.	0.020629582	2014	ABCA1	9	104822520	T	C
rs2895811	24573017	84830	ADTRP	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	HHIPL1	14	99667605	T	C
rs2895811	24573017	65264	UBE2Z	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	HHIPL1	14	99667605	T	C
rs2895811	24573017	84439	HHIPL1	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	HHIPL1	14	99667605	T	C
rs2895811	24573017	65264	UBE2Z	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	HHIPL1	14	99667605	T	C
rs2895811	24573017	84439	HHIPL1	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	HHIPL1	14	99667605	T	C
rs2895811	24573017	84830	ADTRP	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	HHIPL1	14	99667605	T	C
rs2895811	24573017	11173	ADAMTS7	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.001085767	2015	HHIPL1	14	99667605	T	C
rs2895811	24573017	11173	ADAMTS7	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.003452799	2015	HHIPL1	14	99667605	T	C
rs2910164	24952884	406938	MIR146A	umls:C0004153	BeFree	In subgroup meta-analysis, rs2910164 in miR-146a and large-artery atherosclerosis, rather than small-vessel disease, showed the significant association under the dominant model (CC vs CG+GG, OR 1.694; 95 % CI 1.199-2.395 p = 0.003).	0.000542884	2014	LOC285628;MIR146A	5	160485411	C	G
rs2910164	24952884	406938	MIR146A	umls:C0003850	BeFree	In subgroup meta-analysis, rs2910164 in miR-146a and large-artery atherosclerosis, rather than small-vessel disease, showed the significant association under the dominant model (CC vs CG+GG, OR 1.694; 95 % CI 1.199-2.395 p = 0.003).	0.000542884	2014	LOC285628;MIR146A	5	160485411	C	G
rs3135506	14729863	116519	APOA5	umls:C0004153	BeFree	We examined the relationship of APOA5 -1131T>C and S19W with lipid subfractions and progression of atherosclerosis in the Lopid Coronary Angiography Trial.	0.011996981	2004	APOA5	11	116791691	G	A,C
rs3135506	14729863	116519	APOA5	umls:C0003850	BeFree	We examined the relationship of APOA5 -1131T>C and S19W with lipid subfractions and progression of atherosclerosis in the Lopid Coronary Angiography Trial.	0.002171535	2004	APOA5	11	116791691	G	A,C
rs3732378	15644279	1524	CX3CR1	umls:C0003850	BeFree	The contribution to atherosclerosis of two CX3CR1 single nucleotide polymorphisms, V249I and T280M has been recently reported.	0.004614512	2005	CX3CR1	3	39265671	G	A
rs3732378	16675737	1524	CX3CR1	umls:C0003850	BeFree	CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis.	0.004614512	2006	CX3CR1	3	39265671	G	A
rs3732378	16675737	3037	HAS2	umls:C0003850	BeFree	CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis.	0.000814326	2006	CX3CR1	3	39265671	G	A
rs3732378	16675737	1524	CX3CR1	umls:C0004153	BeFree	CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis.	0.01743575	2006	CX3CR1	3	39265671	G	A
rs3732378	15644279	1524	CX3CR1	umls:C0004153	BeFree	The contribution to atherosclerosis of two CX3CR1 single nucleotide polymorphisms, V249I and T280M has been recently reported.	0.01743575	2005	CX3CR1	3	39265671	G	A
rs3732378	16675737	3037	HAS2	umls:C0004153	BeFree	CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis.	0.003538676	2006	CX3CR1	3	39265671	G	A
rs3732379	16675737	3037	HAS2	umls:C0004153	BeFree	CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis.	0.003538676	2006	CX3CR1	3	39265765	C	T
rs3732379	15644279	1524	CX3CR1	umls:C0003850	BeFree	The contribution to atherosclerosis of two CX3CR1 single nucleotide polymorphisms, V249I and T280M has been recently reported.	0.004614512	2005	CX3CR1	3	39265765	C	T
rs3732379	15644279	1524	CX3CR1	umls:C0004153	BeFree	The contribution to atherosclerosis of two CX3CR1 single nucleotide polymorphisms, V249I and T280M has been recently reported.	0.01743575	2005	CX3CR1	3	39265765	C	T
rs3732379	16675737	3037	HAS2	umls:C0003850	BeFree	CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis.	0.000814326	2006	CX3CR1	3	39265765	C	T
rs3732379	16675737	1524	CX3CR1	umls:C0004153	BeFree	CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis.	0.01743575	2006	CX3CR1	3	39265765	C	T
rs3732379	16675737	1524	CX3CR1	umls:C0003850	BeFree	CX3CR1 has 2 common coding polymorphisms, namely V249I and T280M, that have been associated with interindividual differences in susceptibility to atherosclerosis.	0.004614512	2006	CX3CR1	3	39265765	C	T
rs3736234	25904137	3159	HMGA1	umls:C0004153	BeFree	Our results suggest that antagonism between SRSF1 and SRSF2/HMGA1, and differential recognition of their regulatory motifs depending on the identity of the rs3736234 polymorphism, influence OLR1 exon 5 inclusion and the efficiency of Ox-LDL uptake, with potential implications for atherosclerosis and coronary disease.	0.000271442	2015	OLR1	12	10160535	G	A
rs3736234	25904137	6426	SRSF1	umls:C0004153	BeFree	Our results suggest that antagonism between SRSF1 and SRSF2/HMGA1, and differential recognition of their regulatory motifs depending on the identity of the rs3736234 polymorphism, influence OLR1 exon 5 inclusion and the efficiency of Ox-LDL uptake, with potential implications for atherosclerosis and coronary disease.	0.000271442	2015	OLR1	12	10160535	G	A
rs3736234	25904137	4973	OLR1	umls:C0003850	BeFree	Our results suggest that antagonism between SRSF1 and SRSF2/HMGA1, and differential recognition of their regulatory motifs depending on the identity of the rs3736234 polymorphism, influence OLR1 exon 5 inclusion and the efficiency of Ox-LDL uptake, with potential implications for atherosclerosis and coronary disease.	0.007328931	2015	OLR1	12	10160535	G	A
rs3736234	25904137	4973	OLR1	umls:C0004153	BeFree	Our results suggest that antagonism between SRSF1 and SRSF2/HMGA1, and differential recognition of their regulatory motifs depending on the identity of the rs3736234 polymorphism, influence OLR1 exon 5 inclusion and the efficiency of Ox-LDL uptake, with potential implications for atherosclerosis and coronary disease.	0.025327427	2015	OLR1	12	10160535	G	A
rs3736234	25904137	3159	HMGA1	umls:C0003850	BeFree	Our results suggest that antagonism between SRSF1 and SRSF2/HMGA1, and differential recognition of their regulatory motifs depending on the identity of the rs3736234 polymorphism, influence OLR1 exon 5 inclusion and the efficiency of Ox-LDL uptake, with potential implications for atherosclerosis and coronary disease.	0.000271442	2015	OLR1	12	10160535	G	A
rs3736234	25904137	6426	SRSF1	umls:C0003850	BeFree	Our results suggest that antagonism between SRSF1 and SRSF2/HMGA1, and differential recognition of their regulatory motifs depending on the identity of the rs3736234 polymorphism, influence OLR1 exon 5 inclusion and the efficiency of Ox-LDL uptake, with potential implications for atherosclerosis and coronary disease.	0.000271442	2015	OLR1	12	10160535	G	A
rs375752214	15494775	4846	NOS3	umls:C0004153	BeFree	The guanine to thymine polymorphism at position 894 of the eNOS gene (resulting in a change from glutamate to aspartate [Asp] at codon 298 [Asp298]) and the methylenetetrahydrofolate reductase (MTHFR) gene polymorphism (C677T) have been reported to be associated with atherosclerosis and cardiovascular disease.	0.172688313	2004	NOS3	7	150998541	C	T
rs375752214	15494775	4846	NOS3	umls:C0003850	BeFree	The guanine to thymine polymorphism at position 894 of the eNOS gene (resulting in a change from glutamate to aspartate [Asp] at codon 298 [Asp298]) and the methylenetetrahydrofolate reductase (MTHFR) gene polymorphism (C677T) have been reported to be associated with atherosclerosis and cardiovascular disease.	0.133843535	2004	NOS3	7	150998541	C	T
rs3825807	23415669	11173	ADAMTS7	umls:C0004153	BeFree	The results of our study indicate that rs3825807 has an effect on ADAMTS7 maturation, thrombospondin-5 cleavage, and VSMC migration, with the variant associated with protection from atherosclerosis and CAD rendering a reduction in ADAMTS7 function.	0.003452799	2013	ADAMTS7	15	78796769	A	G
rs3825807	23415669	11173	ADAMTS7	umls:C0003850	BeFree	The results of our study indicate that rs3825807 has an effect on ADAMTS7 maturation, thrombospondin-5 cleavage, and VSMC migration, with the variant associated with protection from atherosclerosis and CAD rendering a reduction in ADAMTS7 function.	0.001085767	2013	ADAMTS7	15	78796769	A	G
rs3825807	23415669	1311	COMP	umls:C0004153	BeFree	The results of our study indicate that rs3825807 has an effect on ADAMTS7 maturation, thrombospondin-5 cleavage, and VSMC migration, with the variant associated with protection from atherosclerosis and CAD rendering a reduction in ADAMTS7 function.	0.000271442	2013	ADAMTS7	15	78796769	A	G
rs3825807	23415669	1311	COMP	umls:C0003850	BeFree	The results of our study indicate that rs3825807 has an effect on ADAMTS7 maturation, thrombospondin-5 cleavage, and VSMC migration, with the variant associated with protection from atherosclerosis and CAD rendering a reduction in ADAMTS7 function.	0.000271442	2013	ADAMTS7	15	78796769	A	G
rs3850641	23184501	7292	TNFSF4	umls:C0004153	BeFree	TNFSF4 gene polymorphism rs3861950, but not rs3850641, is associated with the risk of atherosclerosis CI in a Chinese population.	0.004267125	2014	TNFSF4	1	173206693	A	G
rs3850641	23184501	7292	TNFSF4	umls:C0003850	BeFree	TNFSF4 gene polymorphism rs3861950, but not rs3850641, is associated with the risk of atherosclerosis CI in a Chinese population.	0.004624443	2014	TNFSF4	1	173206693	A	G
rs3861950	23184501	7292	TNFSF4	umls:C0004153	BeFree	TNFSF4 gene polymorphism rs3861950, but not rs3850641, is associated with the risk of atherosclerosis CI in a Chinese population.	0.004267125	2014	TNFSF4	1	173187153	T	C
rs3861950	23184501	7292	TNFSF4	umls:C0003850	BeFree	TNFSF4 gene polymorphism rs3861950, but not rs3850641, is associated with the risk of atherosclerosis CI in a Chinese population.	0.004624443	2014	TNFSF4	1	173187153	T	C
rs386539811	21746772	4852	NPY	umls:C0003850	BeFree	The results indicate significant associations between inflammatory cell activation in blood and vascular atherosclerosis in genetically prone subjects, and provide possible mechanistic information about the role of NPY and the Leu7Pro polymorphism in the development of atherosclerosis.	0.001357209	2011	NA	NA	NA	NA	NA
rs386539811	21746772	4852	NPY	umls:C0004153	BeFree	The results indicate significant associations between inflammatory cell activation in blood and vascular atherosclerosis in genetically prone subjects, and provide possible mechanistic information about the role of NPY and the Leu7Pro polymorphism in the development of atherosclerosis.	0.009172942	2011	NA	NA	NA	NA	NA
rs3900940	18073581	8673	VAMP8	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	MYH15	3	108428881	T	C
rs3900940	18073581	8673	VAMP8	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	MYH15	3	108428881	T	C
rs3900940	18073581	221458	KIF6	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000814326	2007	MYH15	3	108428881	T	C
rs3900940	18073581	22989	MYH15	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	MYH15	3	108428881	T	C
rs3900940	18073581	221458	KIF6	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.00554839	2007	MYH15	3	108428881	T	C
rs3900940	18073581	22989	MYH15	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	MYH15	3	108428881	T	C
rs3900940	18073581	399979	SNX19	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	MYH15	3	108428881	T	C
rs3900940	18073581	399979	SNX19	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	MYH15	3	108428881	T	C
rs405509	19808960	348	APOE	umls:C0003850	BeFree	This association is biologically plausible as SNP rs405509 was shown to modify protein binding and transcriptional activity of the APOE protein in vitro and is in linkage disequilibrium with key known variants defining the e2, e3, and e4 alleles that modify risk of atherosclerosis, Alzheimer's disease risk, and progression to AIDS.	0.207296	2009	APOE	19	44905579	T	G
rs405509	19808960	348	APOE	umls:C0004153	BeFree	This association is biologically plausible as SNP rs405509 was shown to modify protein binding and transcriptional activity of the APOE protein in vitro and is in linkage disequilibrium with key known variants defining the e2, e3, and e4 alleles that modify risk of atherosclerosis, Alzheimer's disease risk, and progression to AIDS.	0.301890017	2009	APOE	19	44905579	T	G
rs4380028	24573017	84439	HHIPL1	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	15	78818751	C	T
rs4380028	24573017	65264	UBE2Z	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	15	78818751	C	T
rs4380028	24573017	84439	HHIPL1	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	15	78818751	C	T
rs4380028	24573017	84830	ADTRP	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	15	78818751	C	T
rs4380028	24573017	65264	UBE2Z	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	15	78818751	C	T
rs4380028	24573017	11173	ADAMTS7	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.001085767	2015	NA	15	78818751	C	T
rs4380028	24573017	11173	ADAMTS7	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.003452799	2015	NA	15	78818751	C	T
rs4380028	24573017	84830	ADTRP	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	15	78818751	C	T
rs46522	24573017	84439	HHIPL1	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	UBE2Z	17	48911235	C	T
rs46522	24573017	84439	HHIPL1	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	UBE2Z	17	48911235	C	T
rs46522	24573017	11173	ADAMTS7	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.001085767	2015	UBE2Z	17	48911235	C	T
rs46522	24573017	65264	UBE2Z	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	UBE2Z	17	48911235	C	T
rs46522	24573017	11173	ADAMTS7	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.003452799	2015	UBE2Z	17	48911235	C	T
rs46522	24573017	84830	ADTRP	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	UBE2Z	17	48911235	C	T
rs46522	24573017	65264	UBE2Z	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	UBE2Z	17	48911235	C	T
rs46522	24573017	84830	ADTRP	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	UBE2Z	17	48911235	C	T
rs4712972	21909108	10050	SLC17A4	umls:C0004153	GAD	[Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque.]	0.002638474	2011	SLC17A4	6	25771819	A	G
rs4773144	24573017	84439	HHIPL1	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	COL4A1;COL4A2	13	110308365	A	G
rs4773144	24573017	84830	ADTRP	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	COL4A1;COL4A2	13	110308365	A	G
rs4773144	24573017	84439	HHIPL1	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	COL4A1;COL4A2	13	110308365	A	G
rs4773144	24573017	84830	ADTRP	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	COL4A1;COL4A2	13	110308365	A	G
rs4773144	24573017	11173	ADAMTS7	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.003452799	2015	COL4A1;COL4A2	13	110308365	A	G
rs4773144	24573017	65264	UBE2Z	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	COL4A1;COL4A2	13	110308365	A	G
rs4773144	24573017	11173	ADAMTS7	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.001085767	2015	COL4A1;COL4A2	13	110308365	A	G
rs4773144	24573017	65264	UBE2Z	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	COL4A1;COL4A2	13	110308365	A	G
rs4821480	21429915	966	CD59	umls:C0004153	BeFree	To examine the association of genetic polymorphisms in this region with chronic kidney disease (CKD; estimated glomerular filtration rate <60 ml/min/1.73 m(2)) in individuals of European ancestry, we examined rs4821480, an MYH9 single-nucleotide polymorphism (SNP) recently identified as associated with kidney disease in African-Americans, in 13 133 participants from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) Study.	0.003810118	2011	MYH9	22	36299201	G	T
rs4821480	21429915	4627	MYH9	umls:C0004153	BeFree	To examine the association of genetic polymorphisms in this region with chronic kidney disease (CKD; estimated glomerular filtration rate <60 ml/min/1.73 m(2)) in individuals of European ancestry, we examined rs4821480, an MYH9 single-nucleotide polymorphism (SNP) recently identified as associated with kidney disease in African-Americans, in 13 133 participants from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) Study.	0.000271442	2011	MYH9	22	36299201	G	T
rs4821480	21429915	4627	MYH9	umls:C0003850	BeFree	To examine the association of genetic polymorphisms in this region with chronic kidney disease (CKD; estimated glomerular filtration rate <60 ml/min/1.73 m(2)) in individuals of European ancestry, we examined rs4821480, an MYH9 single-nucleotide polymorphism (SNP) recently identified as associated with kidney disease in African-Americans, in 13 133 participants from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) Study.	0.000271442	2011	MYH9	22	36299201	G	T
rs4821480	21429915	966	CD59	umls:C0003850	BeFree	To examine the association of genetic polymorphisms in this region with chronic kidney disease (CKD; estimated glomerular filtration rate <60 ml/min/1.73 m(2)) in individuals of European ancestry, we examined rs4821480, an MYH9 single-nucleotide polymorphism (SNP) recently identified as associated with kidney disease in African-Americans, in 13 133 participants from the Framingham Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) Study.	0.001085767	2011	MYH9	22	36299201	G	T
rs4845617	21835044	3570	IL6R	umls:C0003850	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.000814326	2011	IL6R;LOC101928101	1	154405422	G	A
rs4845617	21835044	5265	SERPINA1	umls:C0004153	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.005005506	2011	IL6R;LOC101928101	1	154405422	G	A
rs4845617	21835044	3570	IL6R	umls:C0004153	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.000814326	2011	IL6R;LOC101928101	1	154405422	G	A
rs4845617	21835044	5265	SERPINA1	umls:C0003850	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.120271442	2011	IL6R;LOC101928101	1	154405422	G	A
rs4845623	21835044	3570	IL6R	umls:C0004153	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.000814326	2011	IL6R	1	154443301	A	G
rs4845623	21835044	5265	SERPINA1	umls:C0003850	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.120271442	2011	IL6R	1	154443301	A	G
rs4845623	21835044	5265	SERPINA1	umls:C0004153	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.005005506	2011	IL6R	1	154443301	A	G
rs4845623	21835044	3570	IL6R	umls:C0003850	BeFree	The AAT haplotype of the IL-6R gene (rs4845617 G/A, rs4845623 A/G, and rs2229238 C/T) may play an important role in the pathogenesis of dyslipidemia and atherosclerosis in girls.	0.000814326	2011	IL6R	1	154443301	A	G
rs4917	22024217	197	AHSG	umls:C0004153	BeFree	Our data do not support a significant direct association between AHSG variants rs4917, rs2248690, and rs2518136 and clinical atherosclerosis as exemplified by angiographically characterized coronary atherosclerosis.	0.003452799	2012	AHSG	3	186619924	T	C
rs4917	22024217	197	AHSG	umls:C0003850	BeFree	Our data do not support a significant direct association between AHSG variants rs4917, rs2248690, and rs2518136 and clinical atherosclerosis as exemplified by angiographically characterized coronary atherosclerosis.	0.001085767	2012	AHSG	3	186619924	T	C
rs4925	17717316	3552	IL1A	umls:C0003850	BeFree	Association of the glutathione S-transferase omega-1 Ala140Asp polymorphism with cerebrovascular atherosclerosis and plaque-associated interleukin-1 alpha expression.	0.006167218	2007	GSTO1	10	104263031	C	A
rs4925	17717316	9446	GSTO1	umls:C0003850	BeFree	Association of the glutathione S-transferase omega-1 Ala140Asp polymorphism with cerebrovascular atherosclerosis and plaque-associated interleukin-1 alpha expression.	0.000271442	2007	GSTO1	10	104263031	C	A
rs4925	17717316	9446	GSTO1	umls:C0004153	BeFree	Association of the glutathione S-transferase omega-1 Ala140Asp polymorphism with cerebrovascular atherosclerosis and plaque-associated interleukin-1 alpha expression.	0.005362824	2007	GSTO1	10	104263031	C	A
rs4925	17717316	3552	IL1A	umls:C0004153	BeFree	Association of the glutathione S-transferase omega-1 Ala140Asp polymorphism with cerebrovascular atherosclerosis and plaque-associated interleukin-1 alpha expression.	0.010901282	2007	GSTO1	10	104263031	C	A
rs4961	12052841	118	ADD1	umls:C0003850	BeFree	For this reason, we examined the association between the alpha-adducin (ADD1) G460W and G-protein beta3 subunit (GNB3) 825C>T polymorphisms and the prevalence of peripheral arterial disease (PAD) and incidence of coronary heart disease (CHD) in non-Hispanic whites from the Atherosclerosis Risk in Communities (ARIC) Study.	0.000814326	2002	ADD1	4	2904980	G	T
rs4961	12052841	2784	GNB3	umls:C0004153	BeFree	For this reason, we examined the association between the alpha-adducin (ADD1) G460W and G-protein beta3 subunit (GNB3) 825C>T polymorphisms and the prevalence of peripheral arterial disease (PAD) and incidence of coronary heart disease (CHD) in non-Hispanic whites from the Atherosclerosis Risk in Communities (ARIC) Study.	0.011368221	2002	ADD1	4	2904980	G	T
rs4961	11283377	118	ADD1	umls:C0004153	BeFree	For this reason, we sought to examine the association between the alpha-adducin (ADD1) G/W460 and G-protein beta3 subunit (GNbeta3) 825C/T polymorphisms and subclinical and clinical stroke in the Atherosclerosis Risk in Communities (ARIC) Study.	0.000814326	2001	ADD1	4	2904980	G	T
rs4961	12052841	118	ADD1	umls:C0004153	BeFree	For this reason, we examined the association between the alpha-adducin (ADD1) G460W and G-protein beta3 subunit (GNB3) 825C>T polymorphisms and the prevalence of peripheral arterial disease (PAD) and incidence of coronary heart disease (CHD) in non-Hispanic whites from the Atherosclerosis Risk in Communities (ARIC) Study.	0.000814326	2002	ADD1	4	2904980	G	T
rs4961	11283377	118	ADD1	umls:C0003850	BeFree	For this reason, we sought to examine the association between the alpha-adducin (ADD1) G/W460 and G-protein beta3 subunit (GNbeta3) 825C/T polymorphisms and subclinical and clinical stroke in the Atherosclerosis Risk in Communities (ARIC) Study.	0.000814326	2001	ADD1	4	2904980	G	T
rs4961	12052841	2784	GNB3	umls:C0003850	BeFree	For this reason, we examined the association between the alpha-adducin (ADD1) G460W and G-protein beta3 subunit (GNB3) 825C>T polymorphisms and the prevalence of peripheral arterial disease (PAD) and incidence of coronary heart disease (CHD) in non-Hispanic whites from the Atherosclerosis Risk in Communities (ARIC) Study.	0.001900093	2002	ADD1	4	2904980	G	T
rs4986790	17101559	7099	TLR4	umls:C0004153	BeFree	The purpose of this study was to investigate the role of a common Asp299Gly polymorphism of the TLR-4 gene in atherosclerosis.	0.158128803	2006	TLR4	9	117713024	A	G
rs4986790	22360682	7099	TLR4	umls:C0003850	BeFree	In summary, results in our study do not support the hypothesis that the rs4986790 (+896A>G, Asp299Gly) TLR4 variant may influence predisposition for subclinical atherosclerosis and clinically evident CV disease in RA patients.	0.013300652	2012	TLR4	9	117713024	A	G
rs4986790	17996871	7099	TLR4	umls:C0003850	BeFree	The G allele of the Toll-like receptor 4 (TLR-4) gene Asp299Gly polymorphism has been previously associated with decreased development of atherosclerosis and with lower risk of myocardial infractions.	0.013300652	2008	TLR4	9	117713024	A	G
rs4986790	22857799	7099	TLR4	umls:C0003850	BeFree	Lack of association between TLR4 Asp299Gly polymorphism and atherosclerosis: evidence from meta-analysis.	0.013300652	2012	TLR4	9	117713024	A	G
rs4986790	12957699	7099	TLR4	umls:C0003850	BeFree	1400 participants (mean age: 63 years, 31% female) in the Southampton Atherosclerosis Study were genotyped for the TLR4 Asp299Gly polymorphism using the tetra-primer PCR method.	0.013300652	2003	TLR4	9	117713024	A	G
rs4986790	17101559	7099	TLR4	umls:C0003850	BeFree	The purpose of this study was to investigate the role of a common Asp299Gly polymorphism of the TLR-4 gene in atherosclerosis.	0.013300652	2006	TLR4	9	117713024	A	G
rs4986790	12124407	7099	TLR4	umls:C0004153	BeFree	The Asp299Gly TLR4 polymorphism, which attenuates receptor signaling and diminishes the inflammatory response to gram-negative pathogens, is associated with a decreased risk of atherosclerosis.	0.158128803	2002	TLR4	9	117713024	A	G
rs4986790	14764071	7099	TLR4	umls:C0004153	BeFree	Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia.	0.158128803	2004	TLR4	9	117713024	A	G
rs4986790	20169003	7099	TLR4	umls:C0004153	BeFree	For this purpose we investigated the prevalence and any possible associations of common TLR polymorphisms (TLR2-R753Q, TLR4-D299G, and TLR4-T399I) in a group of 240 heavy smokers (>20 pack years), without overt atherosclerosis disease, of whom 136 had developed COPD and 104 had not.	0.158128803	2009	TLR4	9	117713024	A	G
rs4986790	12957699	7099	TLR4	umls:C0004153	BeFree	1400 participants (mean age: 63 years, 31% female) in the Southampton Atherosclerosis Study were genotyped for the TLR4 Asp299Gly polymorphism using the tetra-primer PCR method.	0.158128803	2003	TLR4	9	117713024	A	G
rs4986790	14764071	7099	TLR4	umls:C0003850	BeFree	Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia.	0.013300652	2004	TLR4	9	117713024	A	G
rs4986790	12124407	7099	TLR4	umls:C0003850	BeFree	The Asp299Gly TLR4 polymorphism, which attenuates receptor signaling and diminishes the inflammatory response to gram-negative pathogens, is associated with a decreased risk of atherosclerosis.	0.013300652	2002	TLR4	9	117713024	A	G
rs4986790	22857799	7099	TLR4	umls:C0004153	BeFree	Lack of association between TLR4 Asp299Gly polymorphism and atherosclerosis: evidence from meta-analysis.	0.158128803	2012	TLR4	9	117713024	A	G
rs4986790	17996871	7099	TLR4	umls:C0004153	BeFree	The G allele of the Toll-like receptor 4 (TLR-4) gene Asp299Gly polymorphism has been previously associated with decreased development of atherosclerosis and with lower risk of myocardial infractions.	0.158128803	2008	TLR4	9	117713024	A	G
rs4986790	20169003	7099	TLR4	umls:C0003850	BeFree	For this purpose we investigated the prevalence and any possible associations of common TLR polymorphisms (TLR2-R753Q, TLR4-D299G, and TLR4-T399I) in a group of 240 heavy smokers (>20 pack years), without overt atherosclerosis disease, of whom 136 had developed COPD and 104 had not.	0.013300652	2009	TLR4	9	117713024	A	G
rs4986790	22360682	7099	TLR4	umls:C0004153	BeFree	In summary, results in our study do not support the hypothesis that the rs4986790 (+896A>G, Asp299Gly) TLR4 variant may influence predisposition for subclinical atherosclerosis and clinically evident CV disease in RA patients.	0.158128803	2012	TLR4	9	117713024	A	G
rs4986791	20169003	7099	TLR4	umls:C0003850	BeFree	For this purpose we investigated the prevalence and any possible associations of common TLR polymorphisms (TLR2-R753Q, TLR4-D299G, and TLR4-T399I) in a group of 240 heavy smokers (>20 pack years), without overt atherosclerosis disease, of whom 136 had developed COPD and 104 had not.	0.013300652	2009	TLR4	9	117713324	C	T
rs4986791	20169003	7099	TLR4	umls:C0004153	BeFree	For this purpose we investigated the prevalence and any possible associations of common TLR polymorphisms (TLR2-R753Q, TLR4-D299G, and TLR4-T399I) in a group of 240 heavy smokers (>20 pack years), without overt atherosclerosis disease, of whom 136 had developed COPD and 104 had not.	0.158128803	2009	TLR4	9	117713324	C	T
rs4987262	18323528	5739	PTGIR	umls:C0004153	BeFree	We conclude that for haploinsufficient mutants, such as the R212C, the enhanced atherothrombotic phenotype is likely dependent on the presence of existing atherosclerosis or injury (high risk factors), analogous to what has been observed in the cyclooxygenase-2 inhibition studies or prostacyclin receptor knockout mice studies.	0.000814326	2008	PTGIR	19	46623592	G	A
rs4987262	18323528	5743	PTGS2	umls:C0003850	BeFree	We conclude that for haploinsufficient mutants, such as the R212C, the enhanced atherothrombotic phenotype is likely dependent on the presence of existing atherosclerosis or injury (high risk factors), analogous to what has been observed in the cyclooxygenase-2 inhibition studies or prostacyclin receptor knockout mice studies.	0.00434307	2008	PTGIR	19	46623592	G	A
rs4987262	18323528	5743	PTGS2	umls:C0004153	BeFree	We conclude that for haploinsufficient mutants, such as the R212C, the enhanced atherothrombotic phenotype is likely dependent on the presence of existing atherosclerosis or injury (high risk factors), analogous to what has been observed in the cyclooxygenase-2 inhibition studies or prostacyclin receptor knockout mice studies.	0.139259898	2008	PTGIR	19	46623592	G	A
rs4987262	18323528	5739	PTGIR	umls:C0003850	BeFree	We conclude that for haploinsufficient mutants, such as the R212C, the enhanced atherothrombotic phenotype is likely dependent on the presence of existing atherosclerosis or injury (high risk factors), analogous to what has been observed in the cyclooxygenase-2 inhibition studies or prostacyclin receptor knockout mice studies.	0.000814326	2008	PTGIR	19	46623592	G	A
rs501120	22386691	6387	CXCL12	umls:C0004153	BeFree	In conclusion, our results do not confirm an association of the CXCL12 rs501120 polymorphism with atherosclerosis or with CV disease in RA.	0.009629949	2012	NA	10	44258419	T	C
rs501120	22386691	6387	CXCL12	umls:C0003850	BeFree	In conclusion, our results do not confirm an association of the CXCL12 rs501120 polymorphism with atherosclerosis or with CV disease in RA.	0.002171535	2012	NA	10	44258419	T	C
rs5182	17298481	183	AGT	umls:C0004153	BeFree	To investigate whether the angiotensin-converting enzyme (ACE) insertion/deletion (I/D), angiotensinogen M235T or angiotensin II receptor type 1 573C/T polymorphism modify the risk of atherosclerosis associated with beta-blocker or ACE-inhibitor therapy.	0.240705144	2007	AGTR1	3	148741608	C	T
rs5182	17298481	185	AGTR1	umls:C0003850	BeFree	To investigate whether the angiotensin-converting enzyme (ACE) insertion/deletion (I/D), angiotensinogen M235T or angiotensin II receptor type 1 573C/T polymorphism modify the risk of atherosclerosis associated with beta-blocker or ACE-inhibitor therapy.	0.002171535	2007	AGTR1	3	148741608	C	T
rs5182	17298481	185	AGTR1	umls:C0004153	BeFree	To investigate whether the angiotensin-converting enzyme (ACE) insertion/deletion (I/D), angiotensinogen M235T or angiotensin II receptor type 1 573C/T polymorphism modify the risk of atherosclerosis associated with beta-blocker or ACE-inhibitor therapy.	0.038391651	2007	AGTR1	3	148741608	C	T
rs5182	17298481	183	AGT	umls:C0003850	BeFree	To investigate whether the angiotensin-converting enzyme (ACE) insertion/deletion (I/D), angiotensinogen M235T or angiotensin II receptor type 1 573C/T polymorphism modify the risk of atherosclerosis associated with beta-blocker or ACE-inhibitor therapy.	0.012214884	2007	AGTR1	3	148741608	C	T
rs5443	15033462	2784	GNB3	umls:C0004153	BeFree	The GNB3 C825T polymorphism may therefore be associated with many atherosclerosis-related phenotypes.	0.011368221	2004	GNB3;CDCA3	12	6845711	C	T
rs5443	18551043	2784	GNB3	umls:C0004153	BeFree	The GNB3 C825T polymorphism has been shown to affect lipid parameters, atherosclerosis progression, and incidence of myocardial infarction (MI).	0.011368221	2008	GNB3;CDCA3	12	6845711	C	T
rs5443	15033462	2784	GNB3	umls:C0003850	BeFree	The GNB3 C825T polymorphism may therefore be associated with many atherosclerosis-related phenotypes.	0.001900093	2004	GNB3;CDCA3	12	6845711	C	T
rs5443	18551043	2784	GNB3	umls:C0003850	BeFree	The GNB3 C825T polymorphism has been shown to affect lipid parameters, atherosclerosis progression, and incidence of myocardial infarction (MI).	0.001900093	2008	GNB3;CDCA3	12	6845711	C	T
rs5498	15736117	3383	ICAM1	umls:C0004153	BeFree	In conclusion, K469E polymorphism of the ICAM-1 gene had impact on plasma fibrinogen level independently of other clinical factors in 360 type 2 diabetic patients, suggesting that fibrinogen is a candidate which links the ICAM-1 gene polymorphism to atherosclerosis.	0.144069907	2005	ICAM1;ICAM4;LOC105372272	19	10285007	A	G
rs5498	15736117	3383	ICAM1	umls:C0003850	BeFree	In conclusion, K469E polymorphism of the ICAM-1 gene had impact on plasma fibrinogen level independently of other clinical factors in 360 type 2 diabetic patients, suggesting that fibrinogen is a candidate which links the ICAM-1 gene polymorphism to atherosclerosis.	0.006786047	2005	ICAM1;ICAM4;LOC105372272	19	10285007	A	G
rs57137919	24972087	9619	ABCG1	umls:C0004153	BeFree	These findings demonstrated that the ABCG1 promoter rs57137919G>A variant had an allele-specific effect on ABCG1 expression and was associated with an increased apoptosis in cholesterol-loaded macrophages, providing functional evidence to explain the reduced risk for atherosclerosis in subjects with the ABCG1 promoter rs57137919A allele as reported in our previous study.	0.009358507	2014	ABCG1;LOC105372814	21	42218908	G	A
rs57137919	24972087	9619	ABCG1	umls:C0003850	BeFree	These findings demonstrated that the ABCG1 promoter rs57137919G>A variant had an allele-specific effect on ABCG1 expression and was associated with an increased apoptosis in cholesterol-loaded macrophages, providing functional evidence to explain the reduced risk for atherosclerosis in subjects with the ABCG1 promoter rs57137919A allele as reported in our previous study.	0.001900093	2014	ABCG1;LOC105372814	21	42218908	G	A
rs57920071	23846499	4000	LMNA	umls:C0004153	BeFree	Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.	0.006634157	2013	LMNA	1	156136984	C	T
rs57920071	23846499	4000	LMNA	umls:C0003850	BeFree	Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.	0.081628651	2013	LMNA	1	156136984	C	T
rs5985	11834540	2162	F13A1	umls:C0003850	BeFree	Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study.	0.000542884	2002	F13A1	6	6318562	C	T,A
rs5985	11834540	2162	F13A1	umls:C0004153	BeFree	Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study.	0.00764398	2002	F13A1	6	6318562	C	T,A
rs662	19126404	1535	CYBA	umls:C0004153	BeFree	In this study, we enrolled 1746 type 2 diabetic subjects, determined 4 common genetic variants related to oxidative stress (glutamate-cysteine ligase modifier subunit (GCLM) C-588T, myeloperoxidase G-463A, human paraoxonase 1 Gln192Arg and NAD(P)H oxidase p22phox C242T polymorphisms), and measured carotid intima-media thickness (IMT) as a surrogate marker for atherosclerosis.	0.145089661	2009	PON1	7	95308134	T	C
rs662	21302675	5444	PON1	umls:C0004153	BeFree	Two common polymorphisms of the paraoxonase (PON1) gene, L55M and Q192R, were proven to mitigate atherosclerosis pathogenesis by protecting lipoproteins against peroxidation.	0.203334957	2010	PON1	7	95308134	T	C
rs662	21982484	5444	PON1	umls:C0004153	BeFree	To investigate the potential interaction between folate intake and the paraoxonase 1 (PON1) Q192R polymorphism with the risk of incident coronary heart disease (CHD) and ischemic stroke in the Atherosclerosis Risk in Communities study, a population-based prospective cohort of cardiovascular disease in 15,792 white and African-American subject.	0.203334957	2011	PON1	7	95308134	T	C
rs662	19126404	1535	CYBA	umls:C0003850	BeFree	In this study, we enrolled 1746 type 2 diabetic subjects, determined 4 common genetic variants related to oxidative stress (glutamate-cysteine ligase modifier subunit (GCLM) C-588T, myeloperoxidase G-463A, human paraoxonase 1 Gln192Arg and NAD(P)H oxidase p22phox C242T polymorphisms), and measured carotid intima-media thickness (IMT) as a surrogate marker for atherosclerosis.	0.002714419	2009	PON1	7	95308134	T	C
rs662	21302675	5444	PON1	umls:C0003850	BeFree	Two common polymorphisms of the paraoxonase (PON1) gene, L55M and Q192R, were proven to mitigate atherosclerosis pathogenesis by protecting lipoproteins against peroxidation.	0.027415629	2010	PON1	7	95308134	T	C
rs662	23625196	5444	PON1	umls:C0004153	BeFree	The Q192R (rs662; A/G) polymorphism, which results in the glutamine to arginine substitution at position 192, of the PON1 gene has been linked to increased atherosclerosis risk in several but not all population studies.	0.203334957	2013	PON1	7	95308134	T	C
rs662	19126404	2730	GCLM	umls:C0004153	BeFree	In this study, we enrolled 1746 type 2 diabetic subjects, determined 4 common genetic variants related to oxidative stress (glutamate-cysteine ligase modifier subunit (GCLM) C-588T, myeloperoxidase G-463A, human paraoxonase 1 Gln192Arg and NAD(P)H oxidase p22phox C242T polymorphisms), and measured carotid intima-media thickness (IMT) as a surrogate marker for atherosclerosis.	0.007372538	2009	PON1	7	95308134	T	C
rs662	22188760	5444	PON1	umls:C0003850	BeFree	Serum PON-1 activity but not Q192R polymorphism is related to the extent of atherosclerosis.	0.027415629	2012	PON1	7	95308134	T	C
rs662	19126404	4353	MPO	umls:C0003850	BeFree	In this study, we enrolled 1746 type 2 diabetic subjects, determined 4 common genetic variants related to oxidative stress (glutamate-cysteine ligase modifier subunit (GCLM) C-588T, myeloperoxidase G-463A, human paraoxonase 1 Gln192Arg and NAD(P)H oxidase p22phox C242T polymorphisms), and measured carotid intima-media thickness (IMT) as a surrogate marker for atherosclerosis.	0.006243163	2009	PON1	7	95308134	T	C
rs662	19126404	5444	PON1	umls:C0003850	BeFree	In this study, we enrolled 1746 type 2 diabetic subjects, determined 4 common genetic variants related to oxidative stress (glutamate-cysteine ligase modifier subunit (GCLM) C-588T, myeloperoxidase G-463A, human paraoxonase 1 Gln192Arg and NAD(P)H oxidase p22phox C242T polymorphisms), and measured carotid intima-media thickness (IMT) as a surrogate marker for atherosclerosis.	0.027415629	2009	PON1	7	95308134	T	C
rs662	22188760	5444	PON1	umls:C0004153	BeFree	Serum PON-1 activity but not Q192R polymorphism is related to the extent of atherosclerosis.	0.203334957	2012	PON1	7	95308134	T	C
rs662	19126404	5444	PON1	umls:C0004153	BeFree	In this study, we enrolled 1746 type 2 diabetic subjects, determined 4 common genetic variants related to oxidative stress (glutamate-cysteine ligase modifier subunit (GCLM) C-588T, myeloperoxidase G-463A, human paraoxonase 1 Gln192Arg and NAD(P)H oxidase p22phox C242T polymorphisms), and measured carotid intima-media thickness (IMT) as a surrogate marker for atherosclerosis.	0.203334957	2009	PON1	7	95308134	T	C
rs662	21982484	5444	PON1	umls:C0003850	BeFree	To investigate the potential interaction between folate intake and the paraoxonase 1 (PON1) Q192R polymorphism with the risk of incident coronary heart disease (CHD) and ischemic stroke in the Atherosclerosis Risk in Communities study, a population-based prospective cohort of cardiovascular disease in 15,792 white and African-American subject.	0.027415629	2011	PON1	7	95308134	T	C
rs662	23625196	5444	PON1	umls:C0003850	BeFree	The Q192R (rs662; A/G) polymorphism, which results in the glutamine to arginine substitution at position 192, of the PON1 gene has been linked to increased atherosclerosis risk in several but not all population studies.	0.027415629	2013	PON1	7	95308134	T	C
rs662	19126404	4353	MPO	umls:C0004153	BeFree	In this study, we enrolled 1746 type 2 diabetic subjects, determined 4 common genetic variants related to oxidative stress (glutamate-cysteine ligase modifier subunit (GCLM) C-588T, myeloperoxidase G-463A, human paraoxonase 1 Gln192Arg and NAD(P)H oxidase p22phox C242T polymorphisms), and measured carotid intima-media thickness (IMT) as a surrogate marker for atherosclerosis.	0.028261087	2009	PON1	7	95308134	T	C
rs668	14575520	5175	PECAM1	umls:C0003850	BeFree	The PECAM1 Leu125Val and Ser563Asn polymorphisms may increase the risk of atherosclerosis but not necessarily of MI.	0.002442977	2003	NA	NA	NA	NA	NA
rs668	14575520	5175	PECAM1	umls:C0004153	BeFree	The PECAM1 Leu125Val and Ser563Asn polymorphisms may increase the risk of atherosclerosis but not necessarily of MI.	0.009901391	2003	NA	NA	NA	NA	NA
rs67608943	18436227	255738	PCSK9	umls:C0003850	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.003800186	2009	PCSK9	1	55046549	C	G
rs67608943	18436227	255738	PCSK9	umls:C0004153	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.011530042	2009	PCSK9	1	55046549	C	G
rs67608943	18436227	56955	MEPE	umls:C0004153	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.000542884	2009	PCSK9	1	55046549	C	G
rs67608943	18436227	56955	MEPE	umls:C0003850	BeFree	The Atherosclerosis Risk in Communities (ARIC) Study assessed risk factors and PCSK9 variants Y142X and C679X (relevant to blacks) and R46L (relevant to whites) in a cohort of 45-64-year olds in 1987-1989 (n=13,634).	0.000542884	2009	PCSK9	1	55046549	C	G
rs6903956	24573017	11173	ADAMTS7	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.001085767	2015	ADTRP	6	11774350	A	G
rs6903956	24573017	84830	ADTRP	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	ADTRP	6	11774350	A	G
rs6903956	24573017	84830	ADTRP	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	ADTRP	6	11774350	A	G
rs6903956	24573017	84439	HHIPL1	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	ADTRP	6	11774350	A	G
rs6903956	24573017	11173	ADAMTS7	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.003452799	2015	ADTRP	6	11774350	A	G
rs6903956	24573017	65264	UBE2Z	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	ADTRP	6	11774350	A	G
rs6903956	24573017	65264	UBE2Z	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	ADTRP	6	11774350	A	G
rs6903956	24573017	84439	HHIPL1	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	ADTRP	6	11774350	A	G
rs7177922	22627881	6263	RYR3	umls:C0003850	BeFree	To replicate the association of variants in RYR3 gene with common carotid intima-media thickness (cIMT), a surrogate marker of atherosclerosis, we genotyped single nucleotide polymorphisms (SNPs) rs2229116 and rs7177922 in a sub-population of 244 HIV-positive and HIV-negative men.	0.001085767	2012	RYR3	15	33616418	G	A
rs7177922	22627881	6263	RYR3	umls:C0004153	BeFree	To replicate the association of variants in RYR3 gene with common carotid intima-media thickness (cIMT), a surrogate marker of atherosclerosis, we genotyped single nucleotide polymorphisms (SNPs) rs2229116 and rs7177922 in a sub-population of 244 HIV-positive and HIV-negative men.	0.001085767	2012	RYR3	15	33616418	G	A
rs7439293	18073581	8673	VAMP8	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	PALLD	4	168756335	G	A
rs7439293	18073581	22989	MYH15	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	PALLD	4	168756335	G	A
rs7439293	18073581	399979	SNX19	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000271442	2007	PALLD	4	168756335	G	A
rs7439293	18073581	8673	VAMP8	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	PALLD	4	168756335	G	A
rs7439293	18073581	221458	KIF6	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.00554839	2007	PALLD	4	168756335	G	A
rs7439293	18073581	22989	MYH15	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	PALLD	4	168756335	G	A
rs7439293	18073581	221458	KIF6	umls:C0003850	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.000814326	2007	PALLD	4	168756335	G	A
rs7439293	18073581	399979	SNX19	umls:C0004153	BeFree	We considered five variants that were associated with coronary heart disease in two studies and confirmed in the Atherosclerosis Risk in Communities study: rs20455 (KIF6), rs3900940 (MYH15), rs7439293 (PALLD), rs2298566 (SNX19), and rs1010 (VAMP8).	0.002638474	2007	PALLD	4	168756335	G	A
rs7629265	25065297	1130	LYST	umls:C0004153	BeFree	Using genotyping data on over 7,000 African Americans from 5 cohorts (Atherosclerosis Risk in Communities [ARIC], Cleveland Family Study [CFS], Jackson Heart Study [JHS], Multi-Ethnic Study of Atherosclerosis [MESA], Cardiovascular Health Study [CHS]), we examined the association of rs7629265 with electrocardiographic PR, QRS, and QT intervals, and with incident AF and SCD.	0.000271442	2014	SCN5A	3	38607330	C	T
rs7629265	25065297	1130	LYST	umls:C0003850	BeFree	Using genotyping data on over 7,000 African Americans from 5 cohorts (Atherosclerosis Risk in Communities [ARIC], Cleveland Family Study [CFS], Jackson Heart Study [JHS], Multi-Ethnic Study of Atherosclerosis [MESA], Cardiovascular Health Study [CHS]), we examined the association of rs7629265 with electrocardiographic PR, QRS, and QT intervals, and with incident AF and SCD.	0.000271442	2014	SCN5A	3	38607330	C	T
rs780094	20661421	2646	GCKR	umls:C0004153	GAD	[Our findings indicate rs780094 has independent associations with multiple metabolic traits as well as incident diabetes, but not incident CHD or stroke. The magnitude of association between the SNP and most traits was of lower magnitude among African Amer]	0.004734064	2010	GCKR	2	27518370	T	C
rs79681911	23357645	6288	SAA1	umls:C0004153	BeFree	Variant screening of the serum amyloid A1 gene and functional study of the p.Gly90Asp variant for its role in atherosclerosis.	0.002171535	2013	SAA1	11	18269755	G	A
rs79681911	23357645	6288	SAA1	umls:C0003850	BeFree	Variant screening of the serum amyloid A1 gene and functional study of the p.Gly90Asp variant for its role in atherosclerosis.	0.002171535	2013	SAA1	11	18269755	G	A
rs80356814	16117820	4000	LMNA	umls:C0004153	BeFree	The LMNA 1908C/T polymorphism has been reported to be associated with dyslipidaemia, metabolic syndrome, adipose tissue metabolism and obesity phenotypes, suggesting that this polymorphism presents an increased risk of atherosclerosis and vascular diseases.	0.006634157	2005	LMNA	1	156138697	C	T
rs80356814	16117820	4000	LMNA	umls:C0003850	BeFree	The LMNA 1908C/T polymorphism has been reported to be associated with dyslipidaemia, metabolic syndrome, adipose tissue metabolism and obesity phenotypes, suggesting that this polymorphism presents an increased risk of atherosclerosis and vascular diseases.	0.081628651	2005	LMNA	1	156138697	C	T
rs8070488	24439028	7124	TNF	umls:C0003850	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.01601507	2013	HGS	17	81696901	T	C
rs8070488	24439028	4094	MAF	umls:C0003850	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.000271442	2013	HGS	17	81696901	T	C
rs8070488	24439028	9146	HGS	umls:C0004153	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.000271442	2013	HGS	17	81696901	T	C
rs8070488	24439028	4094	MAF	umls:C0004153	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.000271442	2013	HGS	17	81696901	T	C
rs8070488	24439028	9146	HGS	umls:C0003850	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.000271442	2013	HGS	17	81696901	T	C
rs8070488	24439028	7124	TNF	umls:C0004153	BeFree	Significant associations were observed with multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 × 10(-5)), which plays a role in the clathrin-mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, OR = 0.89, p = 1.17 × 10(-5)), which is a member of the atherosclerosis signaling and the LXR/RXR activation pathways.	0.172949823	2013	HGS	17	81696901	T	C
rs854560	21302675	5444	PON1	umls:C0003850	BeFree	Two common polymorphisms of the paraoxonase (PON1) gene, L55M and Q192R, were proven to mitigate atherosclerosis pathogenesis by protecting lipoproteins against peroxidation.	0.027415629	2010	PON1	7	95316772	A	C,G,N,T
rs854560	21302675	5444	PON1	umls:C0004153	BeFree	Two common polymorphisms of the paraoxonase (PON1) gene, L55M and Q192R, were proven to mitigate atherosclerosis pathogenesis by protecting lipoproteins against peroxidation.	0.203334957	2010	PON1	7	95316772	A	C,G,N,T
rs854560	14642403	5444	PON1	umls:C0004153	BeFree	We studied the association of the PON1 M/L55 genotype with the extent of atherosclerosis in an autopsy series of Finnish males.	0.203334957	2003	PON1	7	95316772	A	C,G,N,T
rs854560	15284530	5444	PON1	umls:C0003850	BeFree	We related the PON1 M55L genotypes to the extent of atherosclerosis in left anterior descending coronary artery (LAD) in alcohol abstainers (0-1 g of alcohol/day), moderate consumers (1-36 g of alcohol/day) and drinkers (> 36 g of alcohol/day).	0.027415629	2004	PON1	7	95316772	A	C,G,N,T
rs854560	14642403	5444	PON1	umls:C0003850	BeFree	We studied the association of the PON1 M/L55 genotype with the extent of atherosclerosis in an autopsy series of Finnish males.	0.027415629	2003	PON1	7	95316772	A	C,G,N,T
rs854560	15284530	5444	PON1	umls:C0004153	BeFree	We related the PON1 M55L genotypes to the extent of atherosclerosis in left anterior descending coronary artery (LAD) in alcohol abstainers (0-1 g of alcohol/day), moderate consumers (1-36 g of alcohol/day) and drinkers (> 36 g of alcohol/day).	0.203334957	2004	PON1	7	95316772	A	C,G,N,T
rs854560	11472729	5444	PON1	umls:C0004153	BeFree	Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis.	0.203334957	2001	PON1	7	95316772	A	C,G,N,T
rs854560	11472729	5444	PON1	umls:C0003850	BeFree	Paraoxonase producing PON1 gene M/L55 polymorphism is related to autopsy-verified artery-wall atherosclerosis.	0.027415629	2001	PON1	7	95316772	A	C,G,N,T
rs974819	24573017	11173	ADAMTS7	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.001085767	2015	NA	11	103789839	T	C
rs974819	24573017	84439	HHIPL1	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	11	103789839	T	C
rs974819	24573017	84439	HHIPL1	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	11	103789839	T	C
rs974819	24573017	65264	UBE2Z	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	11	103789839	T	C
rs974819	24573017	65264	UBE2Z	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	11	103789839	T	C
rs974819	24573017	84830	ADTRP	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	11	103789839	T	C
rs974819	24573017	84830	ADTRP	umls:C0003850	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.000271442	2015	NA	11	103789839	T	C
rs974819	24573017	11173	ADAMTS7	umls:C0004153	BeFree	The present study attempted to replicate the results for eight of these loci, CDKN2A/B(rs1333049), ADTRP(rs6903956), PDGFD(rs974819), TCF21(rs12190287), COL4A1-A2(rs4773144), HHIPL1(rs2895811), ADAMTS7(rs4380028) and UBE2Z(rs46522), in patients with pathologically defined atherosclerosis of the coronary arteries.	0.003452799	2015	NA	11	103789839	T	C
rs9939609	21593801	79068	FTO	umls:C0003850	BeFree	Here we tested the hypothesis that physical activity (PA) modifies the association of the FTO single-nucleotide polymorphism (SNP) rs9939609 with adiposity traits in 2,656 African Americans (AA) (1,626 women and 1,030 men) and 9,867 European Americans (EA) (5,286 women and 4,581 men) aged 45-66 years in the Atherosclerosis Risk in Communities (ARIC) study.	0.001085767	2011	FTO	16	53786615	T	A
rs9939609	21593801	79068	FTO	umls:C0004153	BeFree	Here we tested the hypothesis that physical activity (PA) modifies the association of the FTO single-nucleotide polymorphism (SNP) rs9939609 with adiposity traits in 2,656 African Americans (AA) (1,626 women and 1,030 men) and 9,867 European Americans (EA) (5,286 women and 4,581 men) aged 45-66 years in the Atherosclerosis Risk in Communities (ARIC) study.	0.005819831	2011	FTO	16	53786615	T	A

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:437)
CHR	POS	SNPID	REF	ALT	ORI_SNPID	PMID	P_VALUE	P_VALUE_TEXT	OR/BETA	CI95_TEXT	GWAS_INITIAL_SAMPLE_SIZE	SUB_POPULATION	SUPER_POPULATION	GWAS_TRAIT	HPO_ID	HPO_TERM	DO_ID	DO_TERM	MESH_ID	MESH_TERM	EFO_ID	EFO_TERM	DOLITE_TERM	RISK_ALLELE	PUBLICATION_TYPE	AA	GENE_SYMBOL	TYPE	REFGENE
1	31869669	rs6659255	C	T	rs6659255	23152477	0.000072	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
1	54696743	rs4061073	A	G	rs4061073	23152477	0.0000131	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
1	55494877	rs2479418	A	G	rs2479418	pha002902	5.28E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2479418-G	NA	C
1	55520864	rs557435	A	G	rs557435	pha002902	4.34E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs557435-A	NA	G
1	55662680	rs4926670	C	T	rs4926670	pha002902	3.07E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4926670-T	NA	C
1	55806465	rs207150	T	C	rs207150	pha002902	1.10E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs207150-T	NA	G
1	55815584	rs207127	G	A	rs207127	pha002902	3.92E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs207127-G	NA	T
1	55958030	rs1998013	C	T	rs1998013	22916037	5.00E-13	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	NA
1	60815316	rs12137879	C	T	rs12137879	pha002902	5.41E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs12137879-T	NA	C
1	62950858	rs10889332	C	T	rs10889332	22916037	8.00E-15	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	C	DOCK7
1	63055280	rs12048208	G	A	rs12048208	pha002902	9.52E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs12048208-A	NA	G
1	63118196	rs10889353	A	C	rs10889353	pha002902	4.07E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10889353-C	NA	A
1	74623448	rs10493529	A	T	rs10493529	17903303	1.90E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	LRRIQ3
1	77221362	rs2221083	A	G	rs2221083	pha002902	4.28E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2221083-A	NA	G
1	109815252	rs611917	A	G	rs611917	pha002902	2.49E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs611917-G	NA	C
1	109818530	rs646776	C	T	rs646776	pha002902	2.19E-12	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs646776-C	NA	A
1	153656650	rs10082235	C	T	rs10082235	19679847	5.40E-05	Carotid intima-media thickness (IMT)	NA	NA	328 South Asian samples; 302 Chinese samples; 268 European ancestry samples	South Asian(328)	European(268)	Chinese(302)	ALL(898)	ASN(302)	EUR(268)	SAN(328)	ALL(898)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis
1	163372030	rs17359359	G	A	rs17359359	24675659	1.10E-04	NA	NA	NA	1,973 European ancestry individuals	European(1973)	ALL(1973)	EUR(1973)	ALL(1973)	Plasma trimethylamine N-oxide levels	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	Comparative Study
1	165170050	rs7416223	C	T	rs7416223	23246012	0.00000781	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	C
1	172346174	rs6676665	C	A	rs6676665	23246012	0.00000016	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	A
1	172346396	rs4916251	T	A	rs4916251	23246012	0.000000188	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	A
1	172349921	rs3213564	G	A	rs3213564	23246012	0.000000327	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	C
1	172351052	rs9425586	T	C	rs9425586	23246012	0.000000158	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	T
1	172355132	rs1023479	G	A	rs1023479	23246012	0.000000159	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	T
1	172359815	rs2213731	C	A	rs2213731	23246012	0.000000208	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	T
1	172362949	rs3768445	G	T	rs3768445	23246012	8.15E-08	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	NA
1	172453197	rs16844585	T	G	rs16844585	23246012	0.00000855	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	T
1	189861404	rs1400544	A	T	rs1400544	17903303	6.00E-06	NA	NA	NA	Up to 984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	NA
1	200594005	rs2808257	C	T	rs2808257	23246012	0.0000013	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	C
1	207803595	rs12034383	G	A	rs12034383	pha002902	1.65E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs12034383-G	NA	G
1	207875175	rs4844614	G	T	rs4844614	pha002902	2.38E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4844614-T	NA	G
1	230295789	rs10127775	A	G,T	rs10127775	22916037	1.00E-09	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	GALNT2
1	230300586	rs4846918	C	T	rs4846918	21592478	3.20E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
1	230301776	rs2296065	G	A	rs2296065	21592478	3.80E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
1	230324364	rs612577	T	C	rs612577	21592478	3.72E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
1	235015199	rs2802955	C	T	rs2802955	pha002902	3.65E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2802955-C	NA	T
2	19774399	rs11897302	T	C	rs11897302	23152477	0.00000778	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	T
2	21133883	rs10198175	A	G	rs10198175	pha002902	4.58E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10198175-A	NA	G
2	21135577	rs4341893	A	G	rs4341893	pha002902	1.90E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4341893-A	NA	G
2	21148274	rs3923037	A	C	rs3923037	pha002902	2.29E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs3923037-C	NA	T
2	21186891	rs4665639	A	G	rs4665639	pha002902	2.60E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4665639-A	NA	A
2	21193946	rs6728178	G	A	rs6728178	pha002902	2.13E-08	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6728178-A	NA	G
2	21196112	rs10495712	A	G	rs10495712	pha002902	1.03E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10495712-A	NA	G
2	21198136	rs6733447	G	A	rs6733447	pha002902	3.93E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6733447-G	NA	G,A
2	21206183	rs6754295	T	G	rs6754295	pha002902	1.40E-08	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6754295-G	NA	T
2	21231524	rs676210	G	A	rs676210	23247145	3.00E-47	NA	10.5	[NA] U/L increase	2,080 European ancestry individuals	European(2080)	ALL(2080)	EUR(2080)	ALL(2080)	LDL (oxidized)	HPOID:0010979	Abnormality of the level of lipoprotein cholesterol	DOID:1936	atherosclerosis	D008077	Lipoproteins, LDL	EFOID:0004611	low density lipoprotein cholesterol measurement	Atherosclerosis	rs676210-G	Research Support, Non-U.S. Gov't	G	APOB
2	21231524	rs676210	G	A	rs676210	pha002902	2.60E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs676210-A	NA	G
2	21232195	rs693	G	A	rs693	pha002902	2.99E-11	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs693-C	NA	C
2	21237544	rs673548	G	A	rs673548	22916037	1.00E-13	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	APOB
2	21237544	rs673548	G	A	rs673548	pha002902	2.28E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs673548-A	NA	G
2	21250914	rs679899	G	A	rs679899	pha002902	9.04E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs679899-G	NA	G
2	21271323	rs1713222	A	G	rs1713222	pha002902	9.33E-08	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1713222-A	NA	C
2	21300770	rs1429974	C	A	rs1429974	pha002902	2.18E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1429974-A	NA	T
2	21311541	rs754524	T	G	rs754524	pha002902	2.03E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs754524-T	NA	A
2	21311691	rs754523	A	G	rs754523	pha002902	1.12E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs754523-G	NA	T
2	27730940	rs1260326	T	C	rs1260326	22916037	1.00E-12	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	C	GCKR
2	33975365	rs6749326	G	A	rs6749326	pha002902	8.96E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6749326-G	NA	G
2	55127601	rs10171653	A	G	rs10171653	23152477	0.0000923	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
2	60606571	rs243030	C	T	rs243030	17903303	3.10E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	NA
2	65208074	rs10211524	G	A	rs10211524	22916037	3.00E-10	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	A	NA
2	88428571	rs2919872	C	T	rs2919872	21592478	8.98E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
2	117867857	rs332880	C	T	rs332880	pha002902	9.26E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs332880-C	NA	T
2	118474016	rs4849613	C	T	rs4849613	pha002902	7.20E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4849613-T	NA	C
2	130616955	rs4662999	G	T	rs4662999	pha002902	5.97E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4662999-T	NA	T
2	169763148	rs560887	T	C	rs560887	22916037	4.00E-15	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	G6PC2
2	191515442	rs1023568	A	T	rs1023568	17903303	1.20E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NAB1
2	204272090	rs1376877	C	T	rs1376877	17903303	4.00E-07	NA	NA	NA	Up to 984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	ABI2
2	208536536	rs2551968	C	A	rs2551968	23152477	0.0000498	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
2	240025666	rs3791398	G	A	rs3791398	19679847	1.80E-05	Carotid intima-media thickness (IMT)	NA	NA	328 South Asian samples; 302 Chinese samples; 268 European ancestry samples	South Asian(328)	European(268)	Chinese(302)	ALL(898)	ASN(302)	EUR(268)	SAN(328)	ALL(898)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis
3	1190111	rs9823028	G	A	rs9823028	21909108	1.30E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
3	19574945	rs33915638	A	G	rs33915638	21592478	8.72E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
3	54807240	rs1997463	A	G	rs1997463	17903303	3.80E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	CACNA2D3
3	59727802	rs1155530	A	G	rs1155530	23152477	0.0000497	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
3	66768364	rs17045031	G	A	rs17045031	21909108	4.00E-07	Plaque	0.3	[0.18-0.42] unit decrease	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs17045031-A	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
3	76721413	rs1349008	T	G	rs1349008	17903303	4.90E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	ROBO2
3	93681489	rs8178591	C	T	rs8178591	19679847	4.60E-05	Carotid intima-media thickness (IMT)	NA	NA	328 South Asian samples; 302 Chinese samples; 268 European ancestry samples	South Asian(328)	European(268)	Chinese(302)	ALL(898)	ASN(302)	EUR(268)	SAN(328)	ALL(898)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis
3	96746928	rs2213260	G	A	rs2213260	pha002902	1.61E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2213260-A	NA	A
3	96779326	rs7612669	A	G	rs7612669	pha002902	4.98E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs7612669-G	NA	A
3	96789865	rs7640007	G	A	rs7640007	pha002902	9.81E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs7640007-A	NA	G
3	115565706	rs2972481	G	A	rs2972481	23152477	0.0000207	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
3	157050165	rs1581413	T	C	rs1581413	17903303	2.20E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	VEPH1
4	5055774	rs9799796	C	T	rs9799796	pha002902	9.82E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9799796-T	NA	T
4	23818884	rs2932971	C	T	rs2932971	21592478	4.40E-04	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
4	23822328	rs2932976	G	A	rs2932976	21592478	1.90E-04	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
4	24057266	rs590183	C	T	rs590183	17903303	8.60E-06	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
4	24057536	rs6832344	A	G	rs6832344	17903303	1.00E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	NA
4	72707821	rs1851024	G	A	rs1851024	22916037	1.00E-14	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	A	NA
4	73645351	rs12507628	G	A	rs12507628	22916037	3.00E-09	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	NA
4	74872445	rs16850360	A	G	rs16850360	22916037	3.00E-10	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	A	NA
4	75223711	rs2168889	A	G	rs2168889	22916037	6.00E-14	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	T	NA
4	88568984	rs1381632	T	A	rs1381632	17903303	1.80E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NA
4	89226422	rs1440581	T	C	rs1440581	22916037	1.00E-10	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	NA
4	122292481	rs6842600	G	A	rs6842600	21592478	7.96E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
4	126933292	rs1320267	G	C	rs1320267	17903303	7.00E-06	NA	NA	NA	Up to 984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
4	137604609	rs10519394	C	A	rs10519394	17903303	1.10E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
4	148393664	rs1878406	C	G,T	rs1878406	21909108	7.00E-07	cIMT	0.01	[0.01-0.01] per unit increase	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs1878406-T	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
4	148393664	rs1878406	C	G,T	rs1878406	21909108	7.00E-12	Plaque	0.2	[0.14-0.26] unit increase	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs1878406-T	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
4	159399146	rs10517691	A	G	rs10517691	pha002902	4.30E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10517691-G	NA	A
4	183680605	rs10520541	C	G	rs10520541	17903303	7.00E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	ODZ3
4	187149540	rs1912826	G	A	rs1912826	22916037	4.00E-12	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	KLKB1
5	13214852	rs28207	C	T	rs28207	17903303	1.90E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
5	13764419	rs2896103	G	A	rs2896103	17903303	5.00E-06	NA	NA	NA	Up to 984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	DNAH5
5	13769974	rs7715811	C	T	rs7715811	17903303	6.00E-06	NA	NA	NA	Up to 984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	DNAH5
5	13779743	rs1502050	T	C	rs1502050	17903303	9.00E-06	NA	NA	NA	Up to 984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	DNAH5
5	40850343	rs323564	T	C	rs323564	23246012	0.00000407	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	G
5	74565153	rs10062361	C	T	rs10062361	pha002902	4.95E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10062361-T	NA	NA
5	74569856	rs4704200	G	T	rs4704200	pha002902	6.66E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4704200-T	NA	T
5	74570531	rs1551894	G	A	rs1551894	pha002902	6.59E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1551894-A	NA	G
5	74574984	rs2126736	A	G	rs2126736	pha002902	6.90E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2126736-G	NA	G
5	74605220	rs10056811	G	A	rs10056811	pha002902	2.57E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10056811-A	NA	G
5	74632133	rs3761740	C	A	rs3761740	pha002902	1.44E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs3761740-A	NA	C
5	74787310	rs6896136	T	C	rs6896136	pha002902	7.69E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6896136-C	NA	C
5	113273198	rs1905155	G	T	rs1905155	17903303	1.60E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
5	114122165	rs289034	T	C	rs289034	pha002902	9.40E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs289034-T	NA	C
5	149707778	rs11750343	A	G	rs11750343	pha002902	9.64E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11750343-G	NA	A
5	159270713	rs959931	C	T	rs959931	pha002902	3.49E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs959931-T	NA	C
5	176842474	rs2731672	T	C	rs2731672	22916037	3.00E-14	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	NA
6	4057160	rs853406	T	G	rs853406	17903303	2.20E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	PRPF4B
6	4057233	rs853407	C	T	rs853407	17903303	2.20E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	PRPF4B
6	11040423	rs3798722	A	G	rs3798722	22916037	4.00E-09	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	ELOVL2
6	25772047	rs4712972	A	G	rs4712972	21909108	8.00E-08	cIMT	0.01	[0.01-0.01] unit increase	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs4712972-A	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
6	27815494	rs200991	C	A	rs200991	23152477	0.00000883	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	T
6	31157593	rs9295957	G	A	rs9295957	23152477	0.0000827	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
6	40351841	rs4145199	G	A	rs4145199	pha002902	9.06E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4145199-G	NA	A
6	40356181	rs9462616	T	G	rs9462616	pha002902	9.23E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9462616-T	NA	G
6	43890983	rs1776721	G	T	rs1776721	21757650	1.30E-26	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
6	43897727	rs9472155	C	T	rs9472155	21757650	2.00E-26	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	rs9472155-T	Research Support, N.I.H., Extramural
6	43900707	rs844294	T	C	rs844294	21757650	1.20E-18	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
6	43904901	rs1886979	G	A	rs1886979	21757650	7.07E-25	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
6	43925526	rs4513773	A	G	rs4513773	21757650	1E-584	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	rs4513773-G	Research Support, N.I.H., Extramural
6	43950453	rs4416670	T	C	rs4416670	21757650	3.14E-15	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
6	43950851	rs910611	T	C	rs910611	21757650	8.62E-15	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
6	43951336	rs1776717	G	A	rs1776717	21757650	8.47E-27	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
6	72401403	rs2754042	A	G	rs2754042	pha002902	5.54E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2754042-A	NA	G
6	119079800	rs67456868	G	A	rs67456868	23152477	0.0000307	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
6	132694751	rs6569792	A	G	rs6569792	17903303	6.40E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	MOXD1
6	132905187	rs9321354	C	A	rs9321354	17903303	3.40E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	NA
6	152820395	rs2623963	G	C	rs2623963	pha002870	7.61E-10	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2623963-G	NA	C	SYNE1	intron	NM_182961
6	152852284	rs7745725	A	G	rs7745725	pha002870	1.87E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs7745725-A	NA	G	SYNE1	intron	NM_182961
6	152865556	rs1358317	A	G	rs1358317	pha002870	1.61E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1358317-A	NA	C	SYNE1	intron	NM_182961
6	153065487	rs633596	A	G	rs633596	pha002870	5.06E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs633596-A	NA	C	NA	NA	NA
6	153118810	rs546599	C	A	rs546599	pha002870	2.19E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs546599-C	NA	G	NA	NA	NA
6	153423252	rs487972	A	G	rs487972	pha002870	1.96E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs487972-G	NA	G	RGS17	intron	NM_012419
6	153924868	rs4598087	A	G	rs4598087	pha002870	1.11E-10	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4598087-A	NA	G	NA	NA	NA
6	153926453	rs7754521	C	T	rs7754521	pha002870	9.74E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs7754521-C	NA	C	NA	NA	NA
6	154005613	rs2186140	C	T	rs2186140	pha002870	5.36E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2186140-C	NA	A	NA	NA	NA
6	155530844	rs9384296	G	A	rs9384296	pha002870	1.71E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9384296-G	NA	G	TIAM2	intron	NM_012454
6	155727016	rs9322522	G	A	rs9322522	pha002870	1.42E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9322522-G	NA	G	NOX3	intron	NM_015718
6	155771250	rs7754577	G	C	rs7754577	pha002870	2.73E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs7754577-C	NA	G	NOX3	intron	NM_015718
6	156620306	rs9480303	T	C	rs9480303	pha002870	1.47E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9480303-C	NA	C	NA	NA	NA
6	156628874	rs9397922	T	C	rs9397922	pha002870	5.74E-10	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9397922-C	NA	T	NA	NA	NA
6	156886655	rs288944	C	T	rs288944	pha002870	3.28E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	NA	C	NA	NA	NA
6	156886834	rs288945	G	A	rs288945	pha002870	5.18E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	NA	G	NA	NA	NA
6	156955041	rs2817460	T	A	rs2817460	pha002870	1.40E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2817460-A	NA	T	NA	NA	NA
6	156969316	rs1246182	G	A	rs1246182	pha002870	1.54E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1246182-G	NA	A	NA	NA	NA
6	157443353	rs6917698	A	G	rs6917698	pha002870	2.61E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6917698-A	NA	A	ARID1B	intron	NM_017519
6	158085284	rs9365242	T	C	rs9365242	pha002870	6.70E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9365242-C	NA	C	ZDHHC14	intron	NM_024630
6	158085403	rs9365243	A	C	rs9365243	pha002870	4.53E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9365243-C	NA	A	ZDHHC14	intron	NM_024630
6	158111700	rs6903041	C	G	rs6903041	pha002870	1.19E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6903041-C	NA	G	NA	NA	NA
6	158812361	rs705936	A	G	rs705936	pha002870	4.15E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs705936-G	NA	C	TULP4	intron	NM_020245
6	158870547	rs6920842	G	C	rs6920842	pha002870	3.36E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6920842-G	NA	G	TULP4	intron	NM_020245
6	159122084	rs9364496	G	A	rs9364496	pha002870	1.79E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9364496-G	NA	G	SYTL3	intron	NM_001242384
6	159146871	rs6455600	C	T	rs6455600	pha002870	1.19E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6455600-T	NA	T	SYTL3	intron	NM_001242384
6	159155998	rs2129209	A	C	rs2129209	pha002870	2.62E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2129209-C	NA	T	SYTL3	intron	NM_001242384
6	159167285	rs9456350	A	G	rs9456350	pha002870	2.32E-10	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9456350-G	NA	G	SYTL3	intron	NM_001242384
6	159202240	rs744893	G	C	rs744893	pha002870	2.53E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs744893-C	NA	G	EZR	intron	NM_003379
6	159340672	rs9365009	A	C	rs9365009	pha002870	4.19E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9365009-C	NA	A	NA	NA	NA
6	159425707	rs2016588	C	T	rs2016588	pha002870	1.29E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2016588-C	NA	G	NA	NA	NA
6	159436594	rs2057061	G	T	rs2057061	pha002870	3.47E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2057061-G	NA	C	NA	NA	NA
6	159721945	rs10806706	A	C	rs10806706	pha002870	6.83E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10806706-C	NA	C	NA	NA	NA
6	159723503	rs4708818	C	G	rs4708818	pha002870	6.79E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4708818-G	NA	C	NA	NA	NA
6	159942955	rs12197995	G	A	rs12197995	pha002870	1.53E-14	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs12197995-A	NA	G	NA	NA	NA
6	160471191	rs8191818	T	G	rs8191818	pha002870	3.11E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs8191818-T	NA	T	IGF2R	intron	NM_000876
6	160479478	rs8191829	G	A	rs8191829	pha002870	3.39E-14	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs8191829-G	NA	G	IGF2R	intron	NM_000876
6	160528057	rs7753051	T	C	rs7753051	pha002870	1.14E-12	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs7753051-T	NA	C	IGF2R	nearGene-3	NM_000876
6	160735746	rs410569	T	G	rs410569	pha002870	2.45E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs410569-T	NA	C	NA	NA	NA
6	160737581	rs446809	C	A	rs446809	pha002870	6.51E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs446809-C	NA	A	NA	NA	NA
6	160738920	rs667538	T	G	rs667538	pha002870	3.09E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs667538-T	NA	C	NA	NA	NA
6	160739505	rs415897	C	T	rs415897	pha002870	2.91E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs415897-C	NA	A	NA	NA	NA
6	160745751	rs384156	A	C	rs384156	pha002870	9.10E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs384156-A	NA	G	NA	NA	NA
6	160755657	rs316169	T	G	rs316169	pha002870	5.08E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs316169-T	NA	C	NA	NA	NA
6	160756037	rs316170	C	T	rs316170	pha002870	2.21E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs316170-C	NA	A	NA	NA	NA
6	160960359	rs6919346	T	C	rs6919346	pha002870	4.74E-12	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6919346-C	NA	C	LPA	intron	NM_005577
6	161010118	rs10455872	A	G	rs10455872	21592478	1.95E-04	LDL cholesterol	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
6	161010118	rs10455872	A	G	rs10455872	21592478	2.26E-04	APOB (apolipoprotein B)	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
6	161010118	rs10455872	A	G	rs10455872	21592478	2.94E-306	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
6	161137663	rs4252109	T	G	rs4252109	pha002870	3.07E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4252109-T	NA	T	PLG	intron	NM_000301
6	161137779	rs14224	T	C	rs14224	pha002870	3.04E-19	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	NA	C	PLG	cds-synon	NM_000301
6	161143376	rs4252117	A	G	rs4252117	pha002870	3.07E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4252117-A	NA	A	PLG	intron	NM_000301
6	161143608	rs4252120	T	C	rs4252120	pha002870	4.79E-10	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4252120-T	NA	T	PLG	intron	NM_000301
6	161152240	rs4252125	G	A	rs4252125	pha002870	1.55E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4252125-G	NA	A	PLG	missense	NM_000301
6	161152294	rs4252126	A	G	rs4252126	pha002870	1.06E-10	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4252126-A	NA	A	PLG	intron	NM_000301
6	161153080	rs4252130	A	C	rs4252130	pha002870	3.57E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4252130-A	NA	A	PLG	intron	NM_000301
6	161154232	rs4252135	G	T	rs4252135	pha002870	1.09E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4252135-G	NA	G	PLG	intron	NM_000301
6	161189018	rs1247555	A	C	rs1247555	pha002870	1.91E-13	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1247555-C	NA	G	NA	NA	NA
6	161189670	rs1247557	A	G	rs1247557	pha002870	1.63E-14	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1247557-G	NA	A	NA	NA	NA
6	161197087	rs1620921	A	G	rs1620921	pha002870	2.67E-14	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1620921-G	NA	C	NA	NA	NA
6	161197558	rs1740442	T	C	rs1740442	pha002870	1.63E-14	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1740442-C	NA	A	NA	NA	NA
6	161207892	rs2115869	G	A	rs2115869	pha002870	5.38E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2115869-A	NA	G	NA	NA	NA
6	161229578	rs783153	T	G	rs783153	pha002870	2.04E-15	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	NA	T	NA	NA	NA
6	161255544	rs1937479	C	T	rs1937479	pha002870	3.04E-14	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1937479-T	NA	T	NA	NA	NA
6	161287333	rs2465868	C	T	rs2465868	pha002870	1.54E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2465868-T	NA	NA	NA	NA	NA
6	161586840	rs729986	C	T	rs729986	pha002870	2.27E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs729986-T	NA	G	AGPAT4	intron	NM_020133
6	161863770	rs9458255	G	A	rs9458255	pha002870	9.49E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9458255-A	NA	G	PARK2	intron	NM_004562
6	161915982	rs992421	C	T	rs992421	pha002870	1.56E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs992421-T	NA	T	PARK2	intron	NM_004562
6	161916248	rs10755582	C	T	rs10755582	pha002870	2.69E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10755582-T	NA	T	PARK2	intron	NM_004562
6	161917337	rs6937817	T	C	rs6937817	pha002870	1.71E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6937817-C	NA	C	PARK2	intron	NM_004562
6	161919214	rs12191995	T	C	rs12191995	pha002870	7.53E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs12191995-C	NA	T	PARK2	intron	NM_004562
6	161960834	rs17651062	T	A,C	rs17651062	pha002870	1.03E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs17651062-A	NA	T	PARK2	intron	NM_004562
6	162170524	rs3019442	G	C	rs3019442	pha002870	7.57E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs3019442-G	NA	C	PARK2	intron	NM_004562
6	162192856	rs3016563	C	A	rs3016563	pha002870	5.39E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs3016563-A	NA	G	PARK2	intron	NM_004562
6	162192874	rs3016562	G	A	rs3016562	pha002870	5.39E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs3016562-A	NA	C	PARK2	intron	NM_004562
6	162192994	rs9458363	G	T	rs9458363	pha002870	1.15E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9458363-G	NA	T	PARK2	intron	NM_004562
6	162209898	rs3019433	A	G	rs3019433	pha002870	6.37E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs3019433-A	NA	T	PARK2	intron	NM_004562
6	162210934	rs3016557	T	C	rs3016557	pha002870	2.75E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs3016557-T	NA	G	PARK2	intron	NM_004562
6	162248169	rs2022991	C	T	rs2022991	pha002870	1.31E-22	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2022991-C	NA	A	PARK2	intron	NM_004562
6	162319145	rs9365344	A	G	rs9365344	pha002870	1.11E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9365344-A	NA	A	PARK2	intron	NM_004562
6	162453739	rs1105056	C	T	rs1105056	pha002870	3.72E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1105056-C	NA	G	PARK2	intron	NM_004562
6	162474893	rs9456734	A	G	rs9456734	pha002870	7.45E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9456734-A	NA	A	PARK2	intron	NM_004562
6	162609719	rs9295184	G	C	rs9295184	pha002870	3.26E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9295184-C	NA	G	PARK2	intron	NM_004562
6	162951587	rs2846494	G	C	rs2846494	pha002870	1.18E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2846494-G	NA	G	PARK2	intron	NM_004562
6	162964682	rs2846488	C	T	rs2846488	pha002870	3.07E-10	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2846488-C	NA	A	PARK2	intron	NM_004562
6	162979147	rs4636000	C	T	rs4636000	pha002870	3.41E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4636000-T	NA	T	PARK2	intron	NM_004562
6	162994639	rs2155510	T	C	rs2155510	pha002870	6.56E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2155510-C	NA	G,A	PARK2	intron	NM_004562
6	162994752	rs1012424	G	A	rs1012424	pha002870	1.22E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1012424-A	NA	T	PARK2	intron	NM_004562
6	162996263	rs9458611	C	T	rs9458611	pha002870	5.98E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9458611-T	NA	C	PARK2	intron	NM_004562
6	163012611	rs2803059	G	T	rs2803059	pha002870	9.79E-13	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2803059-G	NA	C	PARK2	intron	NM_004562
6	163636248	rs2206256	T	A	rs2206256	pha002870	1.04E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2206256-A	NA	A	PACRG	intron	NM_001080378
6	163639850	rs11966842	C	T	rs11966842	pha002870	2.88E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11966842-T	NA	T	PACRG	intron	NM_001080378
6	163640262	rs11966948	C	A	rs11966948	pha002870	1.12E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11966948-A	NA	A	PACRG	intron	NM_001080378
6	163664812	rs6904305	T	G	rs6904305	pha002870	2.32E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6904305-G	NA	T	PACRG	intron	NM_001080378
6	164193413	rs9356147	A	G	rs9356147	pha002870	3.45E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9356147-A	NA	A	NA	NA	NA
6	164393244	rs10428875	G	T	rs10428875	pha002870	8.47E-08	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10428875-T	NA	T	NA	NA	NA
6	164982150	rs2201806	C	T	rs2201806	pha002870	1.23E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2201806-T	NA	A	NA	NA	NA
6	165316048	rs6455970	A	G	rs6455970	pha002870	2.15E-07	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6455970-A	NA	A	NA	NA	NA
6	165590421	rs9459317	G	T	rs9459317	pha002870	6.76E-14	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9459317-G	NA	G	NA	NA	NA
6	165612858	rs1764053	T	C	rs1764053	pha002870	5.00E-16	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1764053-T	NA	T	NA	NA	NA
6	165621452	rs1923608	G	A	rs1923608	pha002870	7.61E-11	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1923608-G	NA	C	NA	NA	NA
6	165640017	rs16897566	C	T	rs16897566	pha002870	2.75E-09	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs16897566-C	NA	C	NA	NA	NA
7	14462937	rs12532234	A	C	rs12532234	23246012	0.00000418	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	A
7	14463577	rs196756	A	G	rs196756	23246012	0.00000591	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	T
7	20543838	rs12670982	G	A	rs12670982	23246012	0.00000653	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	G
7	24330162	rs16130	C	T	rs16130	21592478	9.50E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
7	24805240	rs10276782	C	T	rs10276782	21909108	1.00E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
7	33197515	rs4723264	A	G	rs4723264	23152477	0.0000394	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
7	62561484	rs17749368	T	C	rs17749368	pha002902	1.50E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs17749368-C	NA	T
7	78314549	rs321967	G	C	rs321967	17903303	6.00E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	MAGI2
7	90859617	rs10499903	A	C,G,T	rs10499903	17903303	4.10E-06	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	NA
7	94040133	rs389328	T	A	rs389328	19679847	7.70E-05	Carotid intima-media thickness (IMT)	NA	NA	328 South Asian samples; 302 Chinese samples; 268 European ancestry samples	South Asian(328)	European(268)	Chinese(302)	ALL(898)	ASN(302)	EUR(268)	SAN(328)	ALL(898)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis
7	106409452	rs17398575	G	A	rs17398575	21909108	2.00E-12	Plaque	0.16	[0.11-0.21] unit increase	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs17398575-A	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
7	106409452	rs17398575	G	A	rs17398575	21909108	3.00E-06	cIMT	0.01	[0.01-0.01] per unit increase	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs17398575-A	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
7	107244545	rs10953541	C	T	rs10953541	pha002902	9.98E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10953541-T	NA	C
7	131932485	rs6944400	T	C	rs6944400	17903303	8.20E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	PLXNA4
7	143739937	rs17164583	C	T	rs17164583	23152477	0.0000488	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	T,C
8	9183596	rs4841132	A	G	rs4841132	22916037	2.00E-09	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	NA
8	10671272	rs6601530	G	A	rs6601530	21909108	2.00E-08	cIMT	0.01	[0.01-0.01] unit increase	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs6601530-G	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
8	11668153	rs1534863	T	C	rs1534863	pha002902	4.78E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1534863-C	NA	T
8	11671041	rs1736058	G	A	rs1736058	pha002902	1.76E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1736058-A	NA	G
8	19844222	rs12678919	A	G	rs12678919	22916037	9.00E-13	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	A	NA
8	23547510	rs1866347	G	A	rs1866347	pha002902	9.82E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1866347-A	NA	G
8	32126374	rs17624670	G	A	rs17624670	23152477	0.00000562	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
8	40382816	rs2251671	T	C	rs2251671	17903303	4.90E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
8	59261869	rs2925663	T	C	rs2925663	23152477	0.0000107	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
8	93468175	rs2013056	T	C	rs2013056	23152477	0.0000163	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
8	95193235	rs2613235	T	A	rs2613235	23152477	0.0000655	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	T
8	106528030	rs16873291	C	T	rs16873291	21757650	2.99E-16	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
8	106556634	rs1349319	A	G	rs1349319	21757650	4.55E-11	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
8	106558235	rs16873365	C	T	rs16873365	21757650	5.17E-15	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
8	106581284	rs6993696	G	A	rs6993696	21757650	1.67E-15	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
8	106581528	rs6993770	A	T	rs6993770	21757650	5.00E-23	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	rs6993770-T	Research Support, N.I.H., Extramural
8	106589247	rs16873402	C	T	rs16873402	21757650	3.39E-20	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
8	106593558	rs7013321	G	A	rs7013321	21757650	2.48E-13	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
8	113268098	rs10505182	G	T	rs10505182	17903303	5.20E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	CSMD3
8	123408091	rs11781551	G	A	rs11781551	21909108	2.00E-11	cIMT	0.01	[0.01-0.01] unit decrease	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs11781551-A	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
8	124862503	rs6470192	C	T	rs6470192	pha002902	9.34E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6470192-T	NA	T
8	124864404	rs1897318	G	A	rs1897318	pha002902	3.87E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1897318-A	NA	G
8	126404148	rs4332153	C	T	rs4332153	pha002902	5.67E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4332153-T	NA	C
8	127661127	rs13260097	G	A	rs13260097	23152477	0.0000255	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
8	134686065	rs2945756	A	G	rs2945756	pha002902	4.51E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2945756-A	NA	C
8	137526323	rs2660664	G	A	rs2660664	pha002902	7.91E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2660664-G	NA	A
9	2668187	rs4741756	A	C	rs4741756	21757650	1.22E-32	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
9	2673933	rs6475920	C	A	rs6475920	21757650	1.94E-38	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
9	2675698	rs10967470	A	G	rs10967470	21757650	2.39E-21	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
9	2681175	rs10967492	T	A	rs10967492	21757650	9.22E-21	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
9	2691186	rs10738760	A	G	rs10738760	21757650	1.00E-39	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	rs10738760-A	Research Support, N.I.H., Extramural
9	2691951	rs10122587	C	T	rs10122587	21757650	2.56E-24	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
9	2692622	rs2375980	C	G	rs2375980	21757650	4.67E-34	NA	NA	NA	3,527 European ancestry individuals	European(3527)	ALL(3527)	EUR(3527)	ALL(3527)	Vascular endothelial growth factor levels	HPOID:0002621	HPOID:0002664	Atherosclerosis	Neoplasm	DOID:1936	atherosclerosis	D042461	Vascular Endothelial Growth Factor A	EFOID:0004762	vascular endothelial growth factor measurement	Atherosclerosis	NA	Research Support, N.I.H., Extramural
9	4100236	rs806031	C	T	rs806031	pha002902	9.39E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs806031-T	NA	A
9	4911930	rs10815111	T	C	rs10815111	21909108	7.10E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
9	22072264	rs10757269	A	G	rs10757269	23152477	0.0000941	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
9	22099568	rs1537371	C	A	rs1537371	17903303	1.70E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	CDKN2B-AS1
9	22100176	rs1556516	G	C	rs1556516	17903303	8.80E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	CDKN2B-AS1
9	22112599	rs10511701	T	C	rs10511701	17903303	1.10E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	CDKN2B-AS1
9	73736643	rs4620343	C	T	rs4620343	pha002902	4.85E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4620343-T	NA	C
9	89230779	rs9696070	C	T	rs9696070	pha002902	8.47E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9696070-T	NA	C
9	92873665	rs4744106	G	A	rs4744106	pha002902	7.68E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4744106-G	NA	G
9	107589134	rs4149310	A	T	rs4149310	22916037	2.00E-10	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	A	ABCA1
9	135861033	rs2773822	C	T	rs2773822	21909108	1.40E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
10	9296840	rs17145627	G	A	rs17145627	23152477	0.000022	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
10	9326101	rs11256141	T	C	rs11256141	23152477	0.00000321	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	T
10	20984907	rs4748699	G	A	rs4748699	pha002902	6.78E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4748699-A	NA	G
10	30079533	rs10763757	C	T	rs10763757	23152477	0.0000957	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
10	33236305	rs2488336	T	C	rs2488336	pha002902	5.92E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2488336-T	NA	C
10	33277782	rs10827167	C	T	rs10827167	pha002902	6.16E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10827167-T	NA	C
10	50109223	rs3849150	C	T	rs3849150	17903303	2.00E-06	NA	NA	NA	Up to 984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	WDFY4
10	63023314	rs4145320	A	G	rs4145320	23152477	0.0000236	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
10	63525288	rs117670064	G	C	rs117670064	23246012	0.00000191	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	G
10	89823147	rs945559	A	G	rs945559	pha002902	2.21E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs945559-A	NA	A
10	89849519	rs4933466	A	G	rs4933466	pha002902	8.74E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4933466-G	NA	A
10	96942283	rs601746	T	C	rs601746	17903303	1.60E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NA
10	114388316	rs1033922	A	G	rs1033922	pha002902	5.08E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1033922-A	NA	G
11	6340706	rs1051992	A	G	rs1051992	19679847	9.60E-05	Carotid intima-media thickness (IMT)	NA	NA	328 South Asian samples; 302 Chinese samples; 268 European ancestry samples	South Asian(328)	European(268)	Chinese(302)	ALL(898)	ASN(302)	EUR(268)	SAN(328)	ALL(898)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis
11	10302016	rs10500724	C	T	rs10500724	17903303	2.00E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	SBF2
11	10331664	rs4444073	A	C	rs4444073	17903303	5.00E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	NA
11	21820406	rs12225197	G	A	rs12225197	pha002902	8.72E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs12225197-A	NA	A
11	35163462	rs2785171	G	A	rs2785171	21592478	4.23E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
11	35201810	rs11033019	T	C	rs11033019	21592478	3.73E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
11	47277090	rs181556634	C	T	rs181556634	23152477	0.0000629	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
11	47277090	rs58304713	CTT	C	rs181556634	23152477	0.0000629	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
11	59681043	rs11230099	G	A	rs11230099	pha002902	8.92E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11230099-A	NA	G
11	60859791	rs175133	C	T	rs175133	22916037	1.38E-07	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	C	NA
11	61552680	rs174537	G	T	rs174537	pha002902	7.24E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs174537-G	NA	T
11	61557803	rs102275	T	C	rs102275	22916037	4.00E-264	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	C11orf10
11	61557803	rs102275	T	C	rs102275	pha002902	6.51E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs102275-C	NA	G
11	61569830	rs174546	C	T	rs174546	pha002902	6.38E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs174546-T	NA	T
11	61580635	rs174556	C	T	rs174556	pha002902	4.04E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs174556-T	NA	C
11	61597972	rs1535	A	G	rs1535	pha002902	1.16E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1535-T	NA	G
11	61605215	rs2072114	A	G	rs2072114	pha002902	9.58E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2072114-G	NA	G
11	61641542	rs174450	G	T	rs174450	pha002902	2.18E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs174450-T	NA	C
11	61830169	rs387137	G	C	rs387137	22916037	8.22E-06	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	NA
11	91952154	rs1350445	G	A	rs1350445	17903303	9.00E-06	NA	NA	NA	Up to 984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NA
11	91952544	rs10501784	A	G	rs10501784	17903303	1.60E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
11	96942393	rs4754011	G	A	rs4754011	pha002902	4.09E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4754011-A	NA	G
11	116648917	rs964184	G	C	rs964184	22916037	8.00E-20	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	C	NA
11	116713630	rs579163	C	G	rs579163	pha002902	7.67E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs579163-C	NA	C
11	116752163	rs482371	T	C	rs482371	pha002902	7.82E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs482371-A	NA	T
11	116772787	rs518181	C	A	rs518181	pha002902	2.49E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs518181-C	NA	G
11	116952392	rs11216267	C	T	rs11216267	pha002902	3.91E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11216267-C	NA	T
12	22626071	rs7296372	T	C	rs7296372	23152477	0.0000336	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	T
12	30503935	rs12579259	C	A	rs12579259	23152477	0.0000467	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
12	56861458	rs7302925	A	G	rs7302925	23246012	0.00000342	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	A
12	56863770	rs2657880	G	C	rs2657880	22916037	7.00E-30	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	SPRYD4
12	77341906	rs1037232	G	A	rs1037232	21909108	8.90E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
12	101736381	rs2270861	A	G	rs2270861	17903303	2.00E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	UTP20
12	108438922	rs933890	T	C	rs933890	17903303	6.60E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NA
12	126149641	rs2214959	T	G	rs2214959	17903303	1.50E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	NA
13	38523096	rs17210569	A	T	rs17210569	pha002870	3.59E-10	phs000184	NA	NA	NA	ALL(0)	ALL(0)	Lipoprotein a [lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs17210569-A	NA	A	NA	NA	NA
13	43814236	rs9285151	G	A	rs9285151	17903303	1.70E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	ENOX1
13	43853550	rs7995026	A	C	rs7995026	17903303	6.90E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	ENOX1
13	44437104	rs9567289	C	T	rs9567289	23246012	0.00000313	NA	NA	NA	3612 individuals	NOPOP(3612)	ALL(3612)	NOPOP(3612)	ALL(3612)	Inter-adventitial common carotid artery diameter	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Meta-Analysis	Research Support, Non-U.S. Gov't	C
13	74299830	rs17090381	T	C	rs17090381	21909108	7.90E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
13	95009262	rs9524457	G	A	rs9524457	pha002902	6.55E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9524457-A	NA	G
13	99551265	rs6491467	A	G	rs6491467	23152477	0.0000558	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
14	36422275	rs11850769	A	G	rs11850769	23152477	0.0000148	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
14	44641635	rs1040691	T	C	rs1040691	23152477	0.0000761	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
14	55200534	rs4901536	T	C	rs4901536	23152477	0.000000997	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
14	63568488	rs9323431	A	C	rs9323431	17903303	3.60E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	KCNH5
14	86358567	rs6574859	A	C	rs6574859	pha002902	3.73E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6574859-A	NA	A
14	88291305	rs2167239	G	A	rs2167239	pha002902	3.35E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2167239-A	NA	G
14	94844843	rs1303	T	G	rs1303	22916037	5.00E-48	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	T	SERPINA1
14	95640329	rs6575501	C	A	rs6575501	pha002902	4.50E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6575501-A	NA	C
15	31324531	rs2113945	G	A	rs2113945	17903303	7.20E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	TRPM1
15	38297066	rs8035530	C	T	rs8035530	19679847	1.50E-05	Carotid intima-media thickness (IMT)	NA	NA	328 South Asian samples; 302 Chinese samples; 268 European ancestry samples	South Asian(328)	European(268)	Chinese(302)	ALL(898)	ASN(302)	EUR(268)	SAN(328)	ALL(898)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis
15	58471979	rs16939881	G	C	rs16939881	22916037	3.00E-27	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	AQP9
15	58683366	rs1532085	A	G	rs1532085	22916037	9.00E-104	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	A	NA
15	59487930	rs2306786	C	G	rs2306786	22916037	1.00E-10	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	C	MYO1E
15	70552303	rs1655217	G	A	rs1655217	23152477	0.0000968	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
16	7125901	rs11863148	T	G	rs11863148	23152477	0.0000574	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
16	52911609	rs4461066	C	T	rs4461066	17903303	3.10E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
16	56988044	rs173539	C	T	rs173539	22916037	3.00E-70	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	T	NA
16	65259345	rs7195314	C	T	rs7195314	21909108	8.30E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
16	65261411	rs11864736	C	A	rs11864736	21909108	8.00E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
16	71634811	rs4788815	A	T	rs4788815	22916037	4.00E-13	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	T	NA
16	72114002	rs217181	C	T	rs217181	22916037	1.00E-36	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	NA
16	72756101	rs10500569	G	T	rs10500569	22916037	7.00E-12	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	NA
16	75306455	rs1001861	G	A	rs1001861	23152477	0.00000716	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
16	75332041	rs4888378	A	G	rs4888378	23152477	0.000000675	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
16	79280298	rs9922579	C	T	rs9922579	pha002902	5.02E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9922579-T	NA	C
17	3513719	rs465563	G	A	rs465563	19679847	3.70E-05	Carotid intima-media thickness (IMT)	NA	NA	328 South Asian samples; 302 Chinese samples; 268 European ancestry samples	South Asian(328)	European(268)	Chinese(302)	ALL(898)	ASN(302)	EUR(268)	SAN(328)	ALL(898)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis
17	4683035	rs12051548	G	C	rs12051548	22916037	1.00E-11	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	TM4SF5
17	6513329	rs2304977	G	A	rs2304977	23152477	0.000073	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
17	9795452	rs4791906	C	T	rs4791906	23152477	0.0000565	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	T
17	13129143	rs10521211	C	T	rs10521211	pha002902	2.00E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10521211-T	NA	C
17	17087880	rs4985741	T	G	rs4985741	17903303	6.60E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	MPRIP
17	27085564	rs2043031	A	G	rs2043031	pha002902	3.65E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2043031-G	NA	G
17	27087929	rs4795457	C	T	rs4795457	pha002902	3.28E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4795457-T	NA	T
17	27161138	rs9303621	A	G	rs9303621	pha002902	2.84E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9303621-G	NA	T
17	30102635	rs220457	C	T	rs220457	17903303	3.80E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NA
17	31239329	rs2470209	G	A	rs2470209	17903303	1.90E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	NA
17	39154663	rs8075776	C	T	rs8075776	17903303	9.80E-04	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NA
17	47529746	rs2584681	A	G	rs2584681	23152477	0.0000266	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
17	53390421	rs12453442	G	A	rs12453442	23152477	0.0000239	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
17	64234461	rs76773033	G	A,C	rs76773033	23152477	0.0000924	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
17	67258233	rs9895649	G	A	rs9895649	pha002902	7.97E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs9895649-A	NA	G
17	74211844	rs9302997	T	A	rs9302997	17903303	5.10E-06	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	RNF157
17	75009071	rs6501930	G	A	rs6501930	pha002902	9.80E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs6501930-G	NA	A
18	1106342	rs304409	C	T	rs304409	17903303	4.60E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NA
18	22193236	rs8085514	C	T	rs8085514	23152477	0.00009	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	T
18	27857785	rs2949535	A	G	rs2949535	17903303	2.00E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	A	NA
18	54219977	rs683366	A	G	rs683366	17903303	1.20E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	NA
18	57812145	rs145967119	C	T	rs145967119	23152477	0.0000138	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	C
18	60031489	rs7231887	G	A	rs7231887	21592478	4.15E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
18	61722900	rs8094641	A	G	rs8094641	17903303	2.00E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	NA
18	61787038	rs2850711	A	T	rs2850711	17903303	1.50E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	LINC00305
18	75938925	rs1587893	T	C	rs1587893	17903303	5.80E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	C	NA
18	75948807	rs1039610	G	A	rs1039610	17903303	4.90E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	T	NA
19	10332988	rs10409243	C	T	rs10409243	pha002902	6.23E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs10409243-T	NA	C
19	10909953	rs11881315	C	T	rs11881315	pha002902	3.05E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11881315-T	NA	C,T
19	10961273	rs11085749	G	A	rs11085749	pha002902	3.56E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11085749-A	NA	A
19	10987013	rs1541596	A	G	rs1541596	pha002902	8.97E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1541596-A	NA	G
19	11072610	rs11879293	G	A	rs11879293	pha002902	7.54E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11879293-A	NA	G
19	11195030	rs11668477	A	G	rs11668477	pha002902	1.51E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs11668477-G	NA	A
19	11202306	rs6511720	G	T	rs6511720	21909108	1.00E-07	Plaque	0.18	[0.11-0.25] unit decrease	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs6511720-T	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
19	11202306	rs6511720	G	T	rs6511720	22916037	4.00E-09	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	G	LDLR
19	11210912	rs2228671	C	T	rs2228671	pha002902	2.34E-06	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2228671-T	NA	T
19	44055726	rs25487	T	C	rs25487	19679847	4.40E-05	Carotid intima-media thickness (IMT)	NA	NA	328 South Asian samples; 302 Chinese samples; 268 European ancestry samples	South Asian(328)	European(268)	Chinese(302)	ALL(898)	ASN(302)	EUR(268)	SAN(328)	ALL(898)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis
19	45237812	rs2965101	T	C	rs2965101	pha002902	5.67E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2965101-C	NA	A
19	45247627	rs4803750	A	G	rs4803750	pha002902	3.36E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs4803750-G	NA	A
19	45395266	rs157580	G	A	rs157580	pha002902	4.96E-08	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs157580-G	NA	A
19	45395619	rs2075650	A	G	rs2075650	pha002902	1.05E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2075650-G	NA	G
19	45415640	rs445925	G	A	rs445925	21909108	2.00E-08	cIMT	0.02	[0.01-0.03] unit decrease	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs445925-A	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
19	45415640	rs445925	G	A	rs445925	21909108	4.00E-06	plaque	1.22	[1.12-1.32]	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	rs445925-G	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
19	45415640	rs445925	G	A	rs445925	22916037	6.00E-42	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	C	NA
19	47736216	rs2032809	T	C	rs2032809	pha002902	9.64E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2032809-T	NA	G
19	52127053	rs4801882	G	A	rs4801882	23152477	0.0000788	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	G
20	5815074	rs6053733	A	G	rs6053733	17903303	3.70E-06	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	C20orf196
20	15254689	rs367421	G	C	rs367421	17903303	3.60E-05	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	MACROD2
20	17357573	rs4814615	G	A	rs4814615	17903303	3.40E-06	NA	NA	NA	984 individuals depending on measure (Framingham)	Framingham(984)	ALL(984)	EUR(984)	ALL(984)	Subclinical atherosclerosis	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	D050197	Atherosclerosis	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	G	PCSK2
20	39670470	rs117756447	A	G	rs117756447	23152477	0.0000574	NA	NA	NA	3430 European ancestry individuals	European(3430)	ALL(3430)	EUR(3430)	ALL(3430)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, Non-U.S. Gov't	A
20	44545048	rs4810479	C	T	rs4810479	22916037	2.00E-42	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	C	NA
20	62661052	rs2275292	T	C	rs2275292	21909108	6.50E-06	NA	NA	NA	Up to 31,211 European ancestry individuals	European(31211)	ALL(31211)	EUR(31211)	ALL(31211)	Carotid intima media thickness	HPOID:0005344	Abnormality of the carotid arteries	DOID:1936	atherosclerosis	D059168	Carotid Intima-Media Thickness	EFOID:0003914	atherosclerosis	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Meta-Analysis	Research Support, Non-U.S. Gov't
21	41131945	rs2837175	T	C	rs2837175	pha002902	9.66E-07	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2837175-C	NA	T
21	41172166	rs2837227	C	T	rs2837227	pha002902	8.46E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2837227-T	NA	C
21	41192203	rs1984023	G	A	rs1984023	pha002902	6.44E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs1984023-A	NA	A,G
21	41221256	rs2837253	G	A	rs2837253	pha002902	4.21E-05	phs000276	phs000501	NA	NA	NA	ALL(0)	ALL(0)	LDL lipoproteins	HPOID:0003119	HPOID:0002621	Abnormality of lipid metabolism	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	rs2837253-A	NA	A
21	47571162	rs17004504	G	A	rs17004504	21592478	1.98E-05	Plasma lipoprotein A (Lp(a))	NA	NA	5059 European samples	European(5059)	ALL(5059)	EUR(5059)	ALL(5059)	Lipoprotein A [Lp(a)] levels in plasma	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	Atherosclerosis	NA	Research Support, N.I.H., Extramural	Research Support, U.S. Gov't, P.H.S.	Meta-Analysis
22	19156117	rs712964	T	C	rs712964	22916037	3.00E-11	NA	NA	NA	6,608 European ancestry individuals	European(6608)	ALL(6608)	EUR(6608)	ALL(6608)	Metabolite levels (atherosclerosis)	HPOID:0002621	Atherosclerosis	DOID:1936	atherosclerosis	NA	NA	NA	NA	NA	NA	Research Support, Non-U.S. Gov't	C	NA

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:42)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0003850	amlodipine	D017311	88150-42-9	atherosclerosis	MESH:D050197	therapeutic	11002857
C0003850	arsenic trioxide	C006632	1327-53-3	atherosclerosis	MESH:D050197	marker/mechanism	21851829
C0003850	azelaic acid	C010038	-	atherosclerosis	MESH:D050197	therapeutic	19880116
C0003850	benazepril	C044946	86541-75-5	atherosclerosis	MESH:D050197	therapeutic	10217360
C0003850	capsaicin	D002211	404-86-4	atherosclerosis	MESH:D050197	therapeutic	21908651
C0003850	cetirizine	D017332	83881-51-0	atherosclerosis	MESH:D050197	marker/mechanism	25020133
C0003850	cholic acid	D019826	81-25-4	atherosclerosis	MESH:D050197	marker/mechanism	223374
C0003850	clozapine	D003024	5786-21-0	atherosclerosis	MESH:D050197	marker/mechanism	19028422
C0003850	dronabinol	D013759	-	atherosclerosis	MESH:D050197	therapeutic	15815632
C0003850	enalapril	D004656	75847-73-3	atherosclerosis	MESH:D050197	therapeutic	15585195
C0003850	indinavir	D019469	150378-17-9	atherosclerosis	MESH:D050197	marker/mechanism	19429260
C0003850	isradipine	D017275	75695-93-1	atherosclerosis	MESH:D050197	therapeutic	1376828
C0003850	dextromethorphan	D003915	125-71-3	atherosclerosis	MESH:D050197	therapeutic	19189960
C0003850	metoprolol	D008790	37350-58-6	atherosclerosis	MESH:D050197	therapeutic	19356726
C0003850	nicotine	D009538	-	atherosclerosis	MESH:D050197	marker/mechanism	10509436
C0003850	nitric oxide	D009569	10102-43-9	atherosclerosis	MESH:D050197	therapeutic	12677255
C0003850	paclitaxel	D017239	-	atherosclerosis	MESH:D050197	therapeutic	17449502
C0003850	phenytoin	D010672	57-41-0	atherosclerosis	MESH:D050197	therapeutic	15136057
C0003850	pravastatin	D017035	81093-37-0	atherosclerosis	MESH:D050197	therapeutic	19330073
C0003850	propranolol	D011433	525-66-6	atherosclerosis	MESH:D050197	marker/mechanism	1893141
C0003850	propylthiouracil	D011441	51-52-5	atherosclerosis	MESH:D050197	marker/mechanism	19931584
C0003850	ramipril	D017257	87333-19-5	atherosclerosis	MESH:D050197	therapeutic	11835907
C0003850	rofecoxib	C116926	-	atherosclerosis	MESH:D050197	marker/mechanism	17612051
C0003850	rosiglitazone	C089730	-	atherosclerosis	MESH:D050197	therapeutic	16020748
C0003850	sirolimus	D020123	53123-88-9	atherosclerosis	MESH:D050197	therapeutic	17449502
C0003850	streptozocin	D013311	18883-66-4	atherosclerosis	MESH:D050197	marker/mechanism	16020748
C0003850	ticlopidine	D013988	55142-85-3	atherosclerosis	MESH:D050197	therapeutic	2651175
C0003850	troglitazone	C057693	97322-87-7	atherosclerosis	MESH:D050197	therapeutic	11231916
C0003850	cholecalciferol	D002762	67-97-0	atherosclerosis	MESH:D050197	marker/mechanism	19931584
C0003850	vitamin e	D014810	1406-18-4	atherosclerosis	MESH:D050197	therapeutic	12675867
C0003850	zidovudine	D015215	30516-87-1	atherosclerosis	MESH:D050197	marker/mechanism	19429260
C0003850	acetaminophen	D000082	103-90-2	arteriosclerosis	MESH:D001161	therapeutic	11724102
C0003850	cyclophosphamide	D003520	50-18-0	arteriosclerosis	MESH:D001161	marker/mechanism	15014928
C0003850	diltiazem	D004110	42399-41-7	arteriosclerosis	MESH:D001161	therapeutic	6332935
C0003850	folic acid	D005492	59-30-3	arteriosclerosis	MESH:D001161	therapeutic	17118406
C0003850	nicotine	D009538	-	arteriosclerosis	MESH:D001161	marker/mechanism	812508
C0003850	ramipril	D017257	87333-19-5	arteriosclerosis	MESH:D001161	therapeutic	10630734
C0003850	reserpine	D012110	50-55-5	arteriosclerosis	MESH:D001161	therapeutic	10729376
C0003850	ritonavir	D019438	-	arteriosclerosis	MESH:D001161	marker/mechanism	17879945
C0003850	rosiglitazone	C089730	-	arteriosclerosis	MESH:D001161	therapeutic	17713437
C0003850	cholecalciferol	D002762	67-97-0	arteriosclerosis	MESH:D001161	marker/mechanism	1648535
C0003850	vitamin e	D014810	1406-18-4	arteriosclerosis	MESH:D001161	therapeutic	10052017

FDA approved drug and dosage information(Total Drugs:8)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D001161	norvir	ritonavir	80MG/ML	SOLUTION;ORAL	Prescription	None	Yes	Yes
MESH:D001161	norvir	ritonavir	100MG	CAPSULE;ORAL	Discontinued	None	No	No
MESH:D001161	norvir	ritonavir	100MG	CAPSULE;ORAL	Prescription	None	Yes	Yes
MESH:D001161	norvir	ritonavir	100MG	TABLET;ORAL	Prescription	AB	Yes	Yes
MESH:D001161	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D001161	ofirmev	acetaminophen	1GM/100ML (10MG/ML)	SOLUTION;IV (INFUSION)	Prescription	AP	Yes	Yes
MESH:D001161	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes
MESH:D001161	acetaminophen	acetaminophen	650MG	SUPPOSITORY;RECTAL	Over-the-counter	None	Yes	Yes

FDA labeling changes(Total Drugs:8)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D001161	6/10/2005	norvir	ritonavir	Treatment of HIV-infection in combination with other antiretroviral agents	Extended age range from 2 years down to 1 month AE profile in the pediatric population was similar to that for adults Information on dose and PK parameters	Labeling	B	-	-	-	Abbott	06/14/2005	FALSE'
MESH:D001161	6/10/2005	norvir	ritonavir	Treatment of HIV-infection in combination with other antiretroviral agents	Extended age range from 2 years down to 1 month AE profile in the pediatric population was similar to that for adults Information on dose and PK parameters	Labeling	B	-	-	-	Abbott	06/14/2005	FALSE'
MESH:D001161	6/10/2005	norvir	ritonavir	Treatment of HIV-infection in combination with other antiretroviral agents	Extended age range from 2 years down to 1 month AE profile in the pediatric population was similar to that for adults Information on dose and PK parameters	Labeling	B	-	-	-	Abbott	06/14/2005	FALSE'
MESH:D001161	6/10/2005	norvir	ritonavir	Treatment of HIV-infection in combination with other antiretroviral agents	Extended age range from 2 years down to 1 month AE profile in the pediatric population was similar to that for adults Information on dose and PK parameters	Labeling	B	-	-	-	Abbott	06/14/2005	FALSE'
MESH:D001161	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D001161	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE
MESH:D001161	2/11/2010	ofirmev	acetaminophen	Management of mild-to-moderate pain, for the management of moderate-to-severe pain with adjunctive opioid analgesics, and for the reduction of fever	The safety and effectiveness of Ofirmev for the treatment of acute pain and fever in pediatric patients ages 2 years and older is supported by evidence from adequate and well-controlled studies of Ofirmev in adults. Additional safety and PK data was collected in 355 from premature neonates to adolescents. The effectiveness of Ofirmev for the treatment of acute pain and fever has not been studied in pediatric patients < 2 years of age.The PK exposure of Ofirmev observed in children and adolescents is similar to adults, but higher in neonates and infants. Dosing simulations from PK data in infants and neonates suggest that dose reductions of 33% in infants 1 month to < 2 years of age, and 50% in neonates up to 28 days, with a minimum dosing interval of 6 hours, will produce a PK exposure similar to that observed in children age 2 years and olderMost common adverse reactions in pediatric patients were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.Information on dosing, clinical studies, adverse reactions and PK parametersNew dosage form and route of administration	Labeling	-	P	-	-	Cadence	-	FALSE'
MESH:D001161	01/27/2017	ofirmev	acetaminophen	Treatmeny of pain and fever in pediatric patients birth to 2 years	Treatment of pain Efficacy was not demonstrated in pediatric patients younger than 2 years in a double-blind, placebo-controlled study of 198 pediatric patients younger than 2 years. Pediatric patients less than 2 years of age, including neonates from 28 to 40 weeks gestational age at birth, were randomized to receive opioid plus acetaminophen or opioid plus placebo. No difference in analgesic effect of intravenous acetaminophen, measured by assessment of reduced need for additional opioid treatment for pain control, was observed. Treatment of fever The safety and effectiveness for the treatment of fever in pediatric patients, including premature neonates born at 32 weeks or greater gestation is supported by adequate and well-controlled studies of Ofirmev in adults, clinical studies in 244 pediatric patients 2 years and older, and safety and pharmacokinetic data from 239 patients younger than 2 years including neonates 32 weeks or greater gestational age. Information on dosing, clinical trials. Postmarketing study.	Labeling	-	-	B,P	-	Mallinckrodt	11/7/2016	FALSE